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In 2005, a new peptide derived from the ghrelin 
peptide precursor, named obestatin, was discovered. 
One of the most important functions of obestatin is its 
mitogenic activity. Obestatin and the GPR39 receptor 
were reported to be involved in the control of 
mitogenesis of gastric cancer cell lines; this fact 
prompted us to investigate obestatin/GPR39 signalling 
and the relationship between the system and gastric 
cancer progression, and explored their potential 
functional roles.  
The main objective of this doctoral thesis is to 
establish the relationship between obestatin and 
GPR39 receptor in healthy and tumour-like 
surroundings, from structural to tissue level, to 
determinate the fundamental parameters of its 
mitogenic bioactivity. This issue will be accomplished 
with the following points:  
1. To determine the structural features of obestatin 
required for the interaction with its receptor. 
2. To elucidate the detailed activation/regulation 
mechanism of GPR39 receptor signalling triggered by 
obestatin.  
3. To analyse the role of obestatin/GPR39 system in 
the development and malignity of tumours. 
Our results demonstrated that: 
At structural level,  the amidation at the C-terminus is 
essential to adopt an α-helix structure and stabilize 
the GPR39 conformations necessary for the full range 
of receptor activities. Furthermore, human (11-23)-
obestatin is able to induce selective coupling to the β-
arrestin-dependent signalling, representing the first 
example of an endogenous biased ligand for GPR39. 
Meanwhile, mouse and human obestatin exhibit clear 
conformational differences beyond their primary 
structure. This evidence supports the species-specific 
activity of this peptide. Additionally,  obestatin-GPR39 
interaction might involve an E/Z isomerization of the 
peptide and the posibility that GPR39 could be acting 
as a prolyl cis-trans isomerase.  
Regarding the activation/regulation mechanism of 
GPR39 signalling triggered by obestatin, our results 
show that obestatin increases GPR39 phosphorylation 
and induces receptor endocytosis. In this signalling 
network, the transactivation process induced by 
obestatin GPR39-EGFR is a key mechanism, regulated 
by MMPs. The RTKs and proteases expression profiles 
confirm the implication of EGFR and MMPs in the 
obestatin signalling pathway, and introduce other 
proteases and RTKs in this cross-talk. 
 In human tissues, we observe that the 
obestatin/GPR39 system regulates pepsinogen 
secretion. This result provide the first biological 
function for the obestatin/GPR39 system in healthy 
stomach. This system also regulates proliferation, 
motility, EMT, and invasion of gastric cancer cells. 
More importantly, the GPR39 expression levels found 
in human gastric adenocarcinomas provide the 
rationale for including GPR39 as a prognostic marker 
of these tumours. The ubiquitous expression of GPR39 
and its cancer-associated overexpression, together 
with obestatin, provokes the proliferation and cell 
motillity of diverse human cancer cell lines. Moreover, 
these effects depend not only on GPR39, but also on 
the expression of key components of its signalling 
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In 2005, using a bioinformatics approach, Zhang et al 
discovered a new peptide derived from the ghrelin 
peptide precursor, called obestatin. The word 
obestatin is a contraction of obese, from Latin 
‘obedere’ meaning ‘to devour’, and ‘statin’, denoting 
suppression. It was firstly isolated from stomach and 
was identified as a physiological opponent of ghrelin 
on food intake, body weight, and gastric emptying.1 
Obestatin has been a controversial peptide since its 
discovery, and many questions have made on it. In 
recent years, some issues have been clarified but 
many of them are still unrevealed.  
GHRELIN 
Several years ago, ghrelin had already been 
characterized as one of the most important gut 
peptides for their ability to regulate food intake and 
energy homeostasis.2,3 It was discovered using 
“reverse pharmacology” in gastric extracts as the 
natural ligand of the orphan growth hormone 
secretagogue receptor type 1a (GHSR1a).4 Ghrelin is a 
28 amino acid peptide hormone with a unique post-
translational modification of O-n‐octanoylation at 
Ser3,5 which is mainly produced in the stomach by the 
                                                          
1 Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide 
encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. 
Science. 2005;310:996-9. 
2 Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J 
Clin Invest. 2007;117:13-23. 
3 Van der Lely AJ, Tschöp M, Heiman ML, et al. Biological, physiological, 
pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 
2004;25:426-57. 
4 Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing 
peptide from stomach. Nature. 1999;402:656-60. 
5 Kojima M, Hosoda H, Matsuo H, et al. Ghrelin: discovery of the natural 
endogenous ligand for the growth hormone secretagogue receptor. Trends 
Endocrinol Metab. 2001;12:118-22. 
enteroendocrine X/A-like cells of the oxyntic mucosa, 
although it is also synthesized in other organs and 
tissues, as some sections of the gastrointestinal tract, 
pancreas, kidney, pituitary and hypothalamus.6,7 The 
acylation modification is essential for the binding to 
the GHSR1a, for the release of growth hormone (GH) 
both in vivo and in vitro and for most of its other 
endocrine actions.4 This octanoyl modification is 
catalysed by the ghrelin O-acyl transferase (GOAT) 
enzyme, which has been discovered by using 
bioinformatics predictions.8,9 Ghrelin possess other no 
endocrine activities such as the control of body 
energy, gastric motility, acid-gastric secretion, 
influence on pancreatic activity and glucose 
metabolism, cardiovascular effects and mitogenic 
effects on different cell lines. Furthermore, the non-
acylated peptide, commonly named des-acyl ghrelin 
or unacylated ghrelin (UAG), which circulates in a 
greater amount respect to acylated ghrelin, possess its 
own biological functions. UAG has different no 
endocrine functions like cardiovascular and 
antiproliferative effects10,11 and numerous reports 
6 Horvath TL, Diano S, Sotonyi P, et al. Minireview: ghrelin and the 
regulation of energy balance: a hypothalamic perspective. Endocrinology. 
2001;142:4163-9. 
7 Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. 
Nat Rev Neurosci. 2001;2:551-60. 
8 Yang J, Brown MS, Liang G, et al. Identification of the acyltransferase that 
octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell. 
2008;132:387-96. 
9 Gutierrez JA, Solenberg PJ, Perkins DR, et al. Ghrelin octanoylation 
mediated by an orphan lipid transferase. Proc Natl Acad Sci USA. 
2008;105:6320-5. 
10 Korbonits M, Goldstone AP, Gueorguiev M, et al. Ghrelin: a hormone 
with multiple functions. Front Neuroendocrinol. 2004;25:27-68. 
11 Bowers CY. Unnatural growth hormone-releasing peptide begets natural 




point to the possibility that its actions were mediated 
by other receptor distinct from the GHSR1a.12 
OBESTATIN BIOSYNTHESIS 
Obestatin is a 23-amino acid peptide hormone derived 
from the post-translational cleavage of the ghrelin 
gene with a Leu residue on the carboxyterminal 
domain that can be amidated. The human ghrelin gene 
is located on the chromosome position 3p25-26 and 
comprises five exons and three introns,13,14 being the 
short first exon which encodes part of the 5’ 
untranslated region.15,16 Mature ghrelin is encoded by 
exons 2 and 3 with the remaining proghrelin peptide 
sequence contained in exons 4 and 5.17 Different 
transcriptional initiation sites have been described in 
the ghrelin gene originating distinct messenger 
ribonucleic acid (mRNA) transcripts: an alternative 
splicing product from exon 2 to exon 4 that is the main 
form of human ghrelin,16 and some mRNA splicing 
variants that generate peptides with small changes in 
their sequences compared with native ghrelin. These 
are  the cases of des-Gln14-ghrelin, a spliced variant 
without the codon for Gln in position 14;18 the Ex3-
deleted ghrelin that lacks the coding region for 
obestatin;19 and a novel ghrelin variant generated by 
                                                          
12 Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin 
inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 
and PI 3-kinase/AKT. J Cell Biol. 2002;159:1029-37. 
13 Camina JP. Cell biology of the ghrelin receptor. J Neuroendocrinol. 
2006;18:65-76. 
14 McKee KK, Palyha OC, Feighner SD, et al. Molecular analysis of rat 
pituitary and hypothalamic growth hormone secretagogue receptors. Mol 
Endocrinol. 1997;11:415-23. 
15 Kishimoto M, Okimura Y, Nakata H, et al. Cloning and characterization of 
the 50- flanking region of the human ghrelin gene. Biochem Biophys Res 
Commun. 2003;305:186-92. 
16 Kanamoto N, Akamizu T, Tagami T, et al. Genomic structure and 
characterization of the 50-flanking region of the human ghrelin gene. 
Endocrinology. 2004;145:4144-53. 
17 Jeffery PL, Duncan RP, Yeh AH, et al. Expression of the ghrelin axis in the 
mouse: an exon 4-deleted mouse proghrelin variant encodes a novel C 
terminal peptide. Endocrinology. 2005;146:432-40. 
retention of intron 1 (In1), named In1-ghrelin.20 It has 
also been identified multiple ghrelin-derived 
molecules produced by post-translational processing, 
on the basis of amino acid length and by type of 
acylation at Ser3.18 Human ghrelin mRNA codes for a 
117 amino acid long peptide called preproghrelin. 
Preproghrelin contains 23 amino acids conforming the 
signal peptide and a 94 amino acid fragment called 
proghrelin (1-94). Proghrelin includes the mature 
ghrelin (1-28) and a 66 amino acid tail (29-94)4,17 and 
it is cleaved by the proprotein convertase (PC) 1/3.21 
The signal sequence is eliminated subsequently in the 
endoplasmic reticulum (ER) and then a proteolytic 
processing occurs giving the mature ghrelin and a 66 
amino acids C-terminal fragment named C-ghrelin.22 
C-ghrelin is able to circulate as a full-length peptide or 
be processed into smaller peptides, mainly obestatin 
[proghrelin (53-75)]. Obestatin results from 
proteolysis of proghrelin at two cleavage sites of the 
preproghrelin molecule, between Arg75 and Phe76, 
and between Lys100 and Phe101 (Figure 1). It is 
proposed that Arg75 and Lys100 predict the 
monobasic recognition sites for an unknown protease 
besides the known PCs. 
18 Hosoda H, Kojima M, Mizushima T, et al. Structural divergence of human 
ghrelin. Identification of multiple ghrelin-derived molecules produced by 
post-translational processing. J Biol Chem. 2003;278:64-70. 
19 Yeh AH, Jeffery PL, Duncan RP, et al. Ghrelin and a novel preproghrelin 
isoform are highly expressed in prostate cancer and ghrelin activates 
mitogen-activated protein kinase in prostate cancer. Clinical Cancer 
Research. 2005;11:8295-03.  
20 Gahete MD, Cordoba-Chacon J, Hergueta-Redondo M, et al. a A novel 
human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are 
overexpressed in breast cancer: potential pathophysiological relevance. 
PLoS ONE. 2011;6:e23302.  
21 Romero A, Kirchner H, Heppner K, et al. GOAT: the master switch for the 
ghrelin system? Eur J Endocrinol. 2010;163:1-8. 
22 Gualillo O, Lago F, Casanueva FF, et al. One ancestor, several peptides 
post-translational modifications of preproghrelin generate several 





Figure 1. Proposed post-translational processing of human 
ghrelin/obestatin prepropetide to mature ghrelin and mature 
obestatin. Modified from: J Clin Endocrinol Metab. 
2007;92:3396-8. 
After the cleavage, the Lys residue at the carboxy 
terminal of the obestatin precursor is cleaved by 
carboxypeptidase E, and the next Gly residue donates 
the amide group to the carboxy-terminal Leu residue. 
The amidation is likely catalysed by the bifunctional 
enzyme peptidyl glycine α-amidating monooxygenase 
(PAM, Figure 1).23 However, the proteolytic cleavage 
of preproghrelin is an intriguing feature. Studies of 
animals lacking diverse PCs suggest that PC1 is 
involved in processing of proghrelin to ghrelin as well 
as to obestatin, although the direct processing of 
proghrelin to obestatin was not evaluated.24 Other 
report suggests that PC7 and furin might also be 
involved in ghrelin processing.25 But what happens to 
                                                          
23 Garg A. The ongoing saga of obestatin: is it a hormone? J Clin Endocrinol 
Metab. 2007;92:3396-8. 
24 Zhu X, Cao Y, Voogd K, et al. On the processing of proghrelin to ghrelin. J 
Biol Chem. 2006;281:38867-70. 
25 Ozawa A, Cai Y, Lindberg I. Production of bioactive peptides in an in vitro 
system. Anal Biochem. 2007;366:182-9. 
obestatin? These proteases recognize di-basic 
residues Lys-Arg or Arg-Arg and cleave the peptide 
bond carboxyterminal to the dibasic pair.26 They may 
also recognize monobasic residue cleavage sites, but 
the cleavage is not efficient. The release of ghrelin 
after signal peptide elimination involves a single 
cleavage (C-terminus), but obestatin release requires 
the cleavage at the amino- and carboxy-terminus. The 
efficiency of these two cleavages for obestatin is 
unclear because the proposed cleavage sites lack the 
more efficient dibasic residues. Furthermore, in vitro 
digestion of proghrelin using several convertases 
failed to yield obestatin.25 So, does obestatin 
production require other proteases or even work in a 
different microenvironment? The answer remains 
unclear. 
Obestatin amidation. The structure of obestatin was 
deduced by amino acid sequencing of a purified 20-
residue peptide, combined with mass spectrometry 
data, to generate a 23 amino acid sequence. On the 
basis of a C-terminal Gly-Lys motif, amidation of 
obestatin was assumed and verified as a prerequisite 
for biological activity.1 Amidation is a quite common 
post-translational modification. Hydroxylation at the 
methylene carbon of a C-terminal Gly residue is the 
first step in the conversion of Gly-extended 
prohormones into the physiologically active α-
amidated peptide hormones. A bifunctional enzyme, 
the PAM enzyme, catalyses peptide α-amidation. The 
first step is brought about the copper-dependent N-
terminal peptidyl Gly α-hydroxylating monooxygenase 
domain (PHM) and followed by the zinc-containing 
peptidylamido-glycolate lyase (PAL) domain.27 
26 Steiner DF. The proprotein convertases. Curr Opin Chem Biol. 1998;2:31-
9. 
27 Owen TC, Merkler, DJ. A new proposal for the mechanism of glycine 
hydroxylation as catalyzed by peptidylglycine alphahydroxylating 
monooxygenase (PHM). Med Hypoth. 2004;62:392-400. 
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Although the enzyme/s responsible for obestatin 
amidation has not yet been identified it is likely that 
PHM might be involved in this process.22  
Other biological obestatin fragments. The mass 
spectrometric data of Zhang’s work indicated that in 
addition to obestatin, this peptide may be processed 
in stomach extracts to a 13-amino acid residue 
peptide: (11-23)-obestatin.1 It has not been 
determined whether (11-23)-obestatin occurs 
physiologically and the details of the obestatin peptide 
processing have yet to be elucidated, however, 
searching of enzyme databases reveals that trypsin, 
endopeptidase LysC and α-secretase might, in theory, 
perform the enzymatic cleavage from full obestatin to 
(11-23)-obestatin. Furthermore, the fact that trypsin 
were native to the intestine would enable the 
participation of this enzyme in the process, but further 
information is required to establish exactly how (11-
23)-obestatin is formed, and if the process occurs 
either during biosynthesis, intracellular processing or 
upon secretion. Regarding the biological properties of 
(11-23)-obestatin, several reports indicate that this 
isoform is biologically active. Green et al reported that 
mouse (1-23)-obestatin and (11-23)-obestatin were 
both to be equally effective in reducing glucose 
excursions and insulin responses to feeding in normal 
mice, and reduced food intake by approximately 50% 
compared with control mice, but their results indicate 
no direct actions on glucose homeostasis or insulin 
secretion.28 Nagaraj et al demonstrated, in rodents, 
that (11-23)-obestatin was more effective than full 
                                                          
28 Green BD, Irwin N, Flatt PR. Direct and indirect effects of obestatin 
peptides on food intake and the regulation of glucose homeostasis and 
insulin secretion in mice. Peptides. 2007;28:981-7.  
29 Nagaraj S, Peddha MS, Manjappara UV. Fragments of obestatin as 
modulators of feed intake, circulating lipids, and stored fat. Biochem 
Biophys Res Commun. 2008;366:731-7. 
30 Subasinghage AP, Green BD, Flatt PR, et al. Metabolic and structural 
properties of human obestatin (1-23) and two fragments peptides. 
Peptides. 2010;31:1697-705. 
length obestatin in lowering plasma cholesterol and 
triglycerides, equally as effective in reducing perirenal 
fat, and less effective in decreasing epididymal fat.29 
Later, Subasinghage et al showed that in high-fat fed 
mice administration of either the full length peptide or 
the (11-23)-fragment led to significantly reduced food 
intake and post-meal glucose responses. In this study 
human obestatin and (11-23)-obestatin similarly 
affected food intake in high-fat fed mice, however, the 
glucose responses to feeding were smaller and insulin 
responses were not affected.30 
In addition to (11-23)-obestatin, a diverse range of 
degradatory fragments appears to be formed when 
obestatin is incubated in vitro in mouse plasma and 
kidney or liver homogenate.31 This study had reported 
the formation of an N-terminal fragment: (1-10)-
obestatin. A later published work from Nagaraj’s 
group indicated that this (1-10)-fragment showed 
improved bio-active features when some residues 
were modified,32 however, several studies so far 
suggested that this peptide is an inactive 
metabolite.29,30  
OBESTATIN EXPRESSION 
The main producer of obestatin is the stomach, and 
most of the obestatin-producing cells are distributed 
in the basal end of the gastric oxyntic mucosa. 
Furthermore, it was found that the removal of the 
stomach by gastrectomy reduces obestatin-circulating 
levels around 50-80%.33 Nevertheless, obestatin- and 
31 Vergote V, Van Dorpe S, Peremans K, et al. In vitro metabolic stability of 
obestatin: kinetics and identification of cleavage products. Peptides. 
2008;29:1740-8. 
32 Nagaraj S, Peddha MS, Manjappara UV. Fragment analogs as better 
mimics of obestatin. Regul Pept. 2009;158:143-8. 
33 Furnes MW, Stenstrom B, Tømmerås K, et al. Feeding behavior in rats 





ghrelin-immunoreactive (IR) cells were found 
throughout the entire gastrointestinal tract. 34  
Grönberg et al showed that obestatin and ghrelin 
peptides were expressed in the whole human stomach 
including cardia, fundus, corpus, and antrum. The IR 
cells were more abundant in the stomach region, less 
in duodenum, occasional in jejunum, and rare in 
ileum. The vast majority of the obestatin and ghrelin-
IR cells were located in the deeper third of the glands, 
whereas few cells were found in the superficial 
mucosa regions of the cardia, fundus, duodenum, and 
ileum. No IR cells were detected in the colonic mucosa 
or caudally. A substantial number of obestatin-IR cells 
and ghrelin-IR cells were found in the crypts of 
Lieberkühn, whereas only a few scattered IR cells were 
seen in the Brunner’s glands (Figure 2). 
Grönberg’s work also showed a limited number of 
both obestatin and ghrelin-IR cells in the periphery of 
the pancreatic islets and a few scattered cells detected 
in connection to the exocrine pancreatic ducts. 
Likewise, ghrelin and obestatin were expressed in 
human mammary glands with similar patterns. 
Cytoplasmic IR was seen in ductal epithelial cells, 
whereas the myoepithelial cells were non-IR. Pituitary, 
prostate, testis, placenta, ovaries, thyroid, and 
parathyroid human tissues showed a weak expression 
for obestatin. By double immunofluorescence 
microscopy, it was showed that all cells detected were 
IR for both peptides. Furthermore, the subcellular 
localization of ghrelin and obestatin was essentially 
identical, indicating that obestatin and ghrelin are 
stored in the same secretory vesicles. Interestingly, 
                                                          
34 Grönberg M, Tsolakis AV, Magnusson L, et al. Distribution of obestatin 
and ghrelin in human tissues: inmunoreactive cells in the gastrointestinal 
tract, pancreas, and mammary glands. J Histochem Cytochem. 
2008;56:793‐801. 
epithelial cells of the ducts of the mammary glands 
showed different IR for both peptides.  
One year later, Volante et al published a work showing 
that obestatin is produced in the same cells that 
express endocrine ghrelin in the human foetal 
pancreas and stomach, adult stomach and small 
intestine tissues.35 In foetal tissues, obestatin was 
detected diffusely in the endocrine cells and thyroid, 
and in single or small clusters of cells in the pituitary, 
lung, gastrointestinal tract and pancreas. Other 
endocrine (adrenal) and non-endocrine (spleen, 
thymus, liver, kidney and heart) tissues did not show 
obestatin expression. 
 
Figure 2. Ghrelin and obestatin immunohistochemical staining in 
human stomach tissue. The sections show the immunoreactivity 
for ghrelin (A, C) and obestatin (B, D). Cardia (A, B): obestatin and 
ghrelin IR cells are localised in the deeper regions of the mucosa 
including the cardiac glands. Corpus (C, D): scattered obestatin and 
ghrelin IR cells are seen throughout the whole mucosa. Bar=50 µm. 
Modified from: J Histochem Cytochem. 2008;56:793-801.
35 Volante M, Rosas R, Ceppi P, et al. Obestatin in human neuroendocrine 














Figure 3. Geographic mapping of the ghrelin/obestatin cell lineage of the human stomach. A. On the left panel are shown the quantitated 
cell lineage numbers per core mapped onto three-dimensional stomach maps to demonstrate the distribution of ghrelin/obestatin IR-cells 
in the gastric mucosa. The scale bars represent the range of positive IR-cells in a core. B. Two representative cores from the body and antrum 
showing the ghrelin/obestatin cell-staining pattern are shown on the right panel. Modified from: Gut. 2014;63:1711-20. 
In adult tissues, obestatin-positive cells were 
identified in the pituitary and in pancreatic islets and, 
to a lower extent, in the bronchial tree and 
gastrointestinal tract. Thyroid parenchyma, as well as 
all other tissues tested (parathyroid, adrenal, liver, 
thymus, lymph node, kidney, testis and ovary) did not 
show any IR. In both foetal and adult tissues, they 
showed the neuroendocrine nature of obestatin-
expressing cells by double immunofluorescence with 
chromogranin A. Furthermore, they observed that 
obestatin colocalized with GH in the adenohypophysis. 
Tsolakis et al also demonstrated that in human 
mucosa cells obestatin/ghrelin rarely co-express with 
the vesicular monoamine transporter-2 (VMAT-2), a 
marker for enterochromaffin-like cells (ECL).36  
In 2014, Goldenring’s group published a cell lineage 
distribution atlas of the human stomach. They 
reported that enteroendocrine cells showed distinct 
patterns of localisation in the gastric mucosa, and that 
                                                          
36 Tsolakis AV, Grimelius L, Stridsberg M, et al. Obestatin/ghrelin cells in 
normal mucosa and endocrine tumours of the stomach. Eur J Endocrinol. 
2009;160‐941‐9. 
the existence of antral glands with mixed cell lineages 
indicated that human antral glands might be 
functionally chimeric with glands assembled from 
multiple distinct stem cell populations. Regarding 
ghrelin-expressing cells, they were essentially 
excluded from the distal stomach and were abundant 
in the body regions with a relatively even distribution 
throughout the body mucosa and a similar staining 
pattern was also observed for obestatin (Figure 3). An 
inverse relationship between gastrin and ghrelin 
expression was observed and these findings suggested 
that gastrin and ghrelin/obestatin cells define the 
anatomical division between the human stomach 
body and antrum, respectively.37 
In rats, the expression of obestatin was found in 
gastric mucosa, pancreas, and Leydig and myenteric 
ganglion cells showing that the peptide is bioactive on 
central neurons.38 Additionally, rat pancreas 
immunoreactivity correlates positively with insulin 
37 Choi E, Roland JT, Barlow BJ, et al. Cell lineage distribution atlas of the 
human stomach reveals heterogeneous gland populations in the gastric 
antrum. Gut. 2014;63:1711-20.  









secretion, suggesting that obestatin could contribute 
to pancreatic β cell function.39  
OBESTATIN STRUCTURE AND BIOACTIVITY 
FEATURES 
Regarding obestatin structure, the primary structure is 
formed by 23 amino acids with a post-translational 
amide modification on the Leu of the C-terminus.1  
Since its discovery, a few reports were published 
about obestatin structure and conformation. Scrima et 
al performed circular dichroism (CD) and nuclear 
magnetic resonance (NMR) studies to determine the 
possible secondary structure of mouse obestatin and 
its (11-23)-obestatin truncated biological isoform in 
the presence of dodecyl-phosphocholine 
(DPC)/sodium dodecy sulphate (SDS) micelles.40 
The results showed the preference of both peptides to 
assume regular secondary structures at the C-
terminus rather than in its N-terminal portion, and 
that carboxy-amidation is a prerequisite for the 
biological activity because it is necessary to induce and 
to stabilize the regular conformations. Their data 
showed that a regular backbone arrangement might 
be required to provide the conformational 
prerequisites of important residues for receptor 
binding. Furthermore, investigating the occurrence of 
the sequence Gln15-Tyr-Gln-Gln-His-Gly-Arg-Ala-
Leu23 in protein databanks, they found that the 
sequence Gln-Tyr-Gln-Gln-His-Gly-Arg results 
exclusively present among the different obestatin 
species. Moreover, Gln15-Tyr16, Gln18-His19, and 
Ala22-Leu23 pairs were completely conserved, 
indicating a possible participation of these residues to 
the biological specificity of obestatin (Table 1). 
                                                          
obestatin in the rat. J Endocrinol. 2006;191:481-9. 
39 Chanoine JP, Wong AC, Barrios V. Obestatin, acylated and total ghrelin 
concentrations in the perinatal rat pancreas. Horm Res. 2006;66:81-8. 
Human obestatin FNAPFDVGIKLSGVQYQQHSQAL-NH2 
Human (11-23)-obestatin LSGVQYQQHSQAL-NH2 
Mouse obestatin FNAPFDVGIKLSGAQYQQHGRAL-NH2 
Mouse (11-23)-obestatin LSGAQYQQHGRAL-NH2 
Table 1. Amino acid sequence comparison between human and 
mouse obestatin and its active biological fragments 
In 2008, Nagaraj et al published a work about the 
relationship between the primary structure and the 
bioactivity of mouse obestatin. They synthesized 
mouse obestatin and the three overlapping fragments 
on the C-terminus: N-terminal, (11-23)-obestatin; 
middle (6-18)-obestatin, and the C- terminal (11-23)-
obestatin fragment. Their results showed that the N-
terminal peptide harboured the ability to reduce the 
feed intake and gain in body weight and was as 
effective as obestatin in reducing the epididymal and 
perirenal fat; whereas the middle fragment, less 
effective in altering the feed intake and gain in body 
weight, did very effectively reduce the amount of 
stored fat. They concluded that residues 1-18 in 
obestatin with a C-terminal amidation seem to be vital 
for appetite suppression, body weight loss, and 
reduction in total fat.29  
Later, Subasinghage et al performed a structure-
bioactivity study in rodents using human obestatin.30 
They evaluated the acute metabolic effects of human 
obestatin and the fragments (1-10) and (11-23)-
obestatin in high-fat fed mice, and investigated their 
solution structure by NMR spectroscopy. Structure 
results showed that in aqueous solution none of the 
obestatin peptides possessed secondary structural 
features. However, in a 2,2,2-trifluoroethanol (TFE)-
d3:H2O solvent mixture, the structure of human 
40 Scrima M, Campiglia P, Esposito C, et al. Obestatin conformational 
features: a strategy to unveil obestatin´s biological role? Biochem Biophys 




obestatin was characterized by an alpha-helix 
followed by a single turn helix conformation between 
residues Pro4 and Gln15 and His19 and Ala22 
respectively. (1-10)-obestatin showed no structural 
components whereas (11-23) fragment contained an 
alpha-helix between residues Val14 and Ser20 in a 
mixed solvent (Figure 4). Regarding bioactivity study, 
they observed that full lenght and (11-23)-obestatin 
significantly reduced food intake (86% and 90%, 
respectively) and lowered glucose responses to 
feeding, whilst leaving insulin responses unchanged. 
They did not find metabolic changes following the 
administration of (1-10)-obestatin, correlating the 
presence of secondary conformations with biological 
actions.  
 
Figure 4. Three-dimensional structure of human (11-23)-
obestatin (A) and full-length human obestatin (B) in TFE solution 
showing the ribbon representation and backbone 
conformations. Helical segments showing best-fit residues are 
represented for both peptides. (11-23)-obestatin shows an helical 
conformation between residues 14 and 20 (A). Full-length 
obestatin suggests an α-helical arrangement between residues 4 
and 15 and 19 and 22 (B). Modified from: Peptides. 2010;31:1697-
705. 
                                                          
41 Krishnarjuna B, Ganjiwale AD, Manjappara UV, et al. NMR Structure 
implications of enhanced efficacy of obestatin fragment analogs. Int J Pept 
Res Ther. 2011;17:259-70.  
42 Martín-Pastor M, De Capua A, Álvarez CJ, et al. Interaction between 
ghrelin and the ghrelin receptor (GHS-R1a), a NMR study using living cells. 
More recently, Raghothama’s group published a NMR 
analysis on synthetic mice obestatin and six analogue 
peptides: three overlapping 13 residue fragments (1-
13), (6-18) and (11-23)-obestatin; and three mutant 
analogues Nt8U, NtCha and MF38dU incorporating 
helix-inducing residues. They demonstrated the 
formation of helical secondary structure in all the 
peptide analogues and found that these unusual 
amino acids could provide protection from immediate 
degradation and aid structure stabilization, enhancing 
efficacy of obestatin for better drug development.41 
Taken together, obestatin structure have been already 
established; however, the fact that all published 
reports have been performed in mice using even 
human obestatin,30 and the use of solutions that 
favours helical conformations like TFE or methanol 
puts these results into question. A proper study of the 
structure-activity should be based on knowledge of 
the bioactive conformation when obestatin binds to 
its receptor. NMR techniques using living cells 
enriched with receptor could be suitable for this 
purpose. Since the system has adequate kinetic facts, 
these experiments with living cells, would avoid the 




When it was discovered, obestatin was characterized 
to bind selectively to the orphan G-protein 39-coupled 
receptor (GPR39), a G-protein-coupled receptor 
(GPCR) that was first characterized in 1997 from a 
foetal brain cDNA library by hybridization.43 GPR39 
Bioorg Med Chem. 2010;18:1583-90. 
43 McKee KK , Tan CP, Palyha OC, et al. Cloning and characterization of two 
human G protein-coupled receptor genes (GPR38 and GPR39) related to 





belongs to the same family as ghrelin (GHSR1a), 
motilin (GPR38) and neurotensin receptor (NTR)1 
(Figure 5, upper panel), and it was speculated to have 
a gut peptide ligand, since all the other receptors 
homologous to GHSR have such ligands.44 In this 
context, GPR39 was considered an orphan GPCR until 
2005, when Zhang et al based on the data of 
radiolabelled ligand binding assays proposed 
obestatin as its selective ligand.1 
GPR39 structure. The human GPR39 is a 435-amino 
acid seven transmembrane GPCR (Figure 5, bottom 
panel). It is encoded by a single copy gene located in 
chromosome 2, band q21–q2243 and spans about 200 
kb. Two different transcripts called sbGPR39-1a and 
sbGPR39-1b were identified derived through a process 
of alternative splicing.45 The gene has two exons, the 
first one encodes residues 1 to 285, corresponding to 
the N-terminal region and the first five 
transmembrane helices; and the second exon encodes 
residues 286 to 435, corresponding to the last two 
transmembrane helices and the C-terminal region. 
Between the two exons there is an intron of 200 kb, 
whose analogue appears in the genes of the ghrelin 
receptor and the motilin receptor. The second exon 
also shares a segment of DNA with LYPD1 gene; GPR39 
is encoded by the forward strand of DNA, while LYPD1 
is transcribed from the reverse strand. The two-exon 
structure and LYPD1 gene-overlapping pattern are 
conserved among several species.46 GPR39-1a is 
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2005;85:495-522. 
45 Zhang Y, Zhao H, Peng H, et al. Two alternatively spliced GPR39 
transcripts in seabream: molecular cloning, genomic organization, and 
regulation of gene expression by metabolic signals. J Endocrinol. 
2008;199:457-70. 
46 Egerold KL, Holst B, Petersen PS, et al. GPR39 splice variants versus 
antisense gene LYPD1: expression and regulation in gastrointestinal tract, 
endocrine pancreas, liver, and white adipose tissue. Mol Endocrinol. 
2007;21:1685-98. 
considered the canonical form. The splice variant, 
GPR39-1b, is encoded by the first exon and it is 
truncated after the fifth transmembrane helix. GPR39-
1b was believed to have no functionality until very 
recently.47 Novel reports found that GPR39-1b could 
be implied in anxiety-related behaviours and appetite 
disorders48 and in a novel regulatory mechanism in 
NTR1 signalling.49 GPR39 has a relatively high 
constitutive activity independent from its ligand like 
GHSR1a and the neurotensin receptor.50 But, whereas 
GHSR1a and NTR2 have more efficiency than GPR39 in 
signalling through the inositol triphosphate and cAMP 
element pathways, GPR39 is mainly constitutively 
active through the serum response element (SRE)-
dependent pathway. The structural basis for the 
unusually high degree of constitutive activity is 
determined in the three ghrelin-like receptors 
(GHSR1a, NTR2, GPR39) by an aromatic cluster on the 
inner face of the extracellular ends of transmembrane 
domains VI and VII; nevertheless, receptors also 
display major differences in their internalization 
properties. Holliday et al found that GHSR1a 
internalization was regulated by its C-terminus, and 
that constitutive activity is required but not enough 
for receptor endocytosis. They observed that β-
arrestin-independent mechanisms contributed to 
GHSR internalization. Furthermore, GPR39 displayed 
constitutive signalling, but only ghrelin receptor 
undergo basal internalization, and GPR39 
47 Zhang JV, Li L, Huang Q, et al. Obestatin receptor in energy homeostasis 
and obesity pathogenesis. Prog Mol Biol Transl Sci. 2013;114:89-107. 
48 Ishitobi Y, Akiyoshi J, Honda S, et al. Administration of antisense DNA for 
GPR39-1b causes anxiolytic-like responses and appetite loss in rats. 
Neurosci Res. 2012;72:257-62.  
49 Yasuda S, Ishida J. GPR39-1b, the 5-transmembrane isoform of GPR39 
interacts with neurotensin receptor NTSR1 and modifies its function. J 
Recept Signal Transduct Res. 2014;34:307-12. 
50 Holst B, Holliday ND, Bach A, et al. Common structural basis for 





phosphorylation were not sufficient for β-arrestin 2 
recruitment.51  
 
Figure 5. The GPR39 receptor family. Upper panel. Schematic 
phylogenic tree of the GPR39 receptor family. Red dots indicate 
the three receptors that display a high degree of constitutive 
signalling activity. Bottom panel. Serpentine model of GPR39 
receptor. Residues that are identical among GPR39, GHSR1a, and 
NTR2 are highlighted in white on black circles. Modified from: J 
Biol Chem. 2004;279:53806‐17. 
                                                          
51 Holliday ND, Holst B, Rodionova EA, et al. Importance of constitutive 
activity and arrestin-independent mechanisms for intracellular trafficking 
of the ghrelin receptor. Mol Endocrinol. 2007;21:3100-12. 
52 Depoortere I. GI functions of GPR39: novel biology. Curr Opin Pharmacol. 
2012;12:647-52. 
53 Moechars D, Depoortere I, Moreaux B, et al. Altered gastrointestinal and 
metabolic function in the GPR39-obestatin receptor-knockout mouse. 
Gastroenterology. 2006;131:1131-41. 
54 Jackson VR, Nothacker HP, Civelli O. GPR39 receptor expression in the 
mouse brain. Neuroreport. 2006;17:813‐6. 
55 Holst B, Egerod KL, Schild E, et al. GPR39 signaling is stimulated by zinc 
GPR39 expression. GPR39 is widely expressed 
throughout the body, both human and rat, but the 
highest expression levels are localized in the 
gastrointestinal mucosa (stomach, duodenum, 
jejunum, ileum…), white adipose tissue, kidney,43 
pancreas (β-cells, duct epithelium), liver, spleen, lung, 
heart, and reproductive tissues.52 In the brain, high 
expression levels are observed in the septum and in 
discrete cells in the amygdala and hippocampus.43,53,54 
In contrast to the original study of Zhang et al, several 
groups failed to detect GPR39 expression in the 
hypothalamus.53,54,55,56.  
GPR39 relevant physiological functions 
Digestive system. The GPR39 receptor family is 
involved in the regulation of gastrointestinal 
motility.57,58,59 In addition, GPR39 is expressed mostly 
in stomach and intestine. Therefore it is reasonable to 
think that GPR39 receptor exerts functions in the 
gastrointestinal tract. Moechars et al published a work 
showing that in GPR39 null mice gastric emptying was 
accelerated and that transit and expulsion of faecal 
pellets was more effective.53 Furthermore, gastric 
secretion was increased. These studies suggest that 
GPR39 agonists may inhibit gastric and colonic motility 
and could have an important role in energetic 
homeostasis.  
 
ions but not by obestatin. Endocrinology. 2007;148:13‐20. 
56 Nogueiras R , Pfluger P, Tovar S, et al. Effects of obestatin on energy 
balance and growth hormone secretion in rodents. Endocrinology. 
2007;148:21‐6. 
57 Zhao D, Pothoulakis C. Effects of NT on gastrointestinal motility and 
secretion, and role in intestinal inflammation. Peptides. 2006;27:2434-44. 
58 Brighton PJ, Szekeres PG, Willars GB. Neuromedin U and its receptors: 
structure, function, and physiological roles. Pharmacol Rev. 2004;56:231-
48. 
59 De Smet B, Mitselos A, Depoortere I. Motilin and ghrelin as prokinetic 
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Metabolic functions. Published reports showing a 
GPR39 role on metabolism exhibited conflicting 
results. Gastric emptying acceleration observed in 
GPR39 null mice in Moechars’ work were expected to 
enhance appetite signalling and contributed to body 
weight gain. GPR39 null mice, really showed higher 
mature body weights and body fat compositions, 
reduced hyperphagia after fasting, and increased 
cholesterol levels.53 Tremblay et al reported similar 
observations with respect to food intake but the 
increase in body weight was not observed, probably 
because mice were a few weeks age.60  
Contradictory results related to body weight were also 
reported when GPR39 null mice were put on a high-fat 
diet (HFD) after weaning. Authors found no 
difference61 or an increase62 in body weight  between 
both genotypes. Verthulst et al also suggested that 
GPR39, through intracellular crosstalk with the β-
adrenergic receptors signalling pathways, could 
modulate lipolysis. Furthermore, they observed an 
increase in octanoyl ghrelin levels in GPR39 null mice 
with HFD.61 Petersen's work reported that whereas 
food intake was normal, energy storage was increased 
with an almost complete elimination of diet-induced 
thermogenesis. This increase in fat accumulation was 
due to impaired lipolysis since expression levels and 
activity of lipolytic enzymes was downregulated in 
adipocytes.62 Others reports in GPR39 null mice fed 
either with a low-fat/high-sucrose or a high-fat/high-
sucrose diet, showed no changes in energy intake and 
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Endocrinology. 2007;148:501-6. 
61 Verhulst PJ, Lintermans A, Janssen S, et al. GPR39, a receptor of the 
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62 Petersen PS, Jin C, Madsen AN, et al. Deficiency of the GPR39 receptor is 
associated with obesity and altered adipocyte metabolism. FASEB J. 
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body weight.63 But the age of initial exposure to the 
diet and the type of diet can be essential to reveal 
differences in body weight. In obese patients with type 
2 diabetes and in mice fed a HFD, expression of GPR39 
in white adipose tissue was decreased and did not 
correlate with changes in body mass index (BMI) or 
body weight but correlated negatively to fasting 
glucose levels.64 All these studies suggest a more 
important role of GPR39 in the regulation of glucose 
homeostasis than in changes of body weight.  
Role of GPR39 in glucose homeostasis. GPR39 is 
expressed in pancreatic beta cells.53,55 In a pancreatic 
islets model, glucose-induced insulin secretion was 
impaired in female but not male GPR39 null mice. Islet 
architecture was normal but the expression of the 
master regulator of islet development, pancreatic and 
duodenal homeobox-1 (Pdx-1), was down-regulated.55 
In the Verhults’ study mentioned above, mice on a 
HFD after weaning displayed a less overt diabetic 
phenotype, with lower glucose levels in the fed state 
despite reduced insulin levels suggesting changes in 
insulin sensitivity.61 Mice preferentially used 
carbohydrates as an energy source instead of fat 
which could reduced blood glucose levels. However, 
glucose tolerance tests revealed an impaired insulin 
response, which did not result in changes in glucose 
levels. Similar results were observed in mice fed a low-
fat/high-sucrose or a high-fat/high-sucrose diet.63 
These studies suggested a direct effect of GPR39 on 
insulin secretion and that GPR39 null mice are less 
63 Tremblay F, Richard AM, Will S, et al. Disruption of G protein-coupled 
receptor 39 impairs insulin secretion in vivo. Endocrinology. 
2009;150:2586-95. 
64 Catalán V, Gómez-Ambrosi J, Rotellar F, et al. The obestatin receptor 
(GPR39) is expressed in human adipose tissue and is down-regulated in 





prone to develop diabetes. In contrast, in the same 
model of HFD-induced obese GPR39 null mice in 
Petersen’s work, increased blood glucose levels and 
impaired insulin sensitivity did not implied effects on 
insulin secretion.62 GPR39 could also have a role on 
type 1 diabetes. GPR39 overexpression in a β-cell 
model, affected cell mass and slightly impaired the 
glucose tolerance, but nevertheless totally protected 
against the gradual hyperglycaemia in a model of type 
1 streptozotocin-induced diabetes.65  
Figure 6. Relevant physiological actions of GPR39. The data are provided by studies with Zn+2 and obestatin agonists, mice overexpressing 
GPR39, GPR39 knockout mice and in vitro assays. Modified from: Curr Opin Pharmacol. 2012;12:647-52.
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Taken together, the type and treatment period of diet, 
and the age and gender of the mice seem to influence 
the role of GPR39 in the regulation of glucose 
homeostasis. However the overall finding of these 
studies is that GPR39 has an important role on insulin 
secretion. 
Other functions. In these years, other physiological 
functions were reported for GPR39. GPR39 protects to 
oxidative stress, endoplasmic reticulum stress and 
apoptosis in a hippocampal cell line overexpressing 
GPR39.66 In this way, GPR39 was proposed to be a 
novel inhibitor of cell death through its constitutive 
activity. In human keratinocytes, GPR39 also mediates 
the epithelial injury repairing wound effects.67 In 
brain, Cornu Ammonis 3 (CA3) hippocampal region 
showed neurons and dendrites immunoreactive for 
GPR39.68 Small interfering RNA (siRNA) GPR39 in a 
neuronal cell line and hippocampal slices studies of 
GPR39 null mice showed that endogenous GPR39 
mediates Zn+2-dependent signalling in neurons.68,69 
These studies suggest that GPR39 has a role in 
memory formation. Very recently, GPR39 was 
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72 Gurriarán-Rodríguez U, Santos-Zas I, Al-Massadi O, et al. The 
involved with adipocite metabolism70 and insulin 
action on adipogenesis,71 as well as myogenesis72 and 
skeletal muscle repair.73 
Is GPR39 the obestatin receptor?  
Obestatin was described as the selective ligand of 
GPR39,1 however, there are several studies that 
indicate that obestatin is not its natural ligand, since 
there is not specific binding on GPR39-transfected 
cells, display any effect such as cAMP production or 
activation of signal transduction pathways.60,74,75 The 
authors of the discovery of obestatin, unable to 
reproduce their original trials of binding and activation 
of GPR39, observed that the absence of binding could 
be due to loss of obestatin bioactivity after its poly-
iodization. Moreover, De Spiegeleer’s group found 
that the quality of the peptides was insufficient for in 
vitro and in vivo experiments.76 In this way, Zhang et al 
found that mono-iodinated obestatin was able to bind 
human embrionyc kidney (HEK)293T cells transfected 
with plasmids encoding the GPR39.77 The same 
authors also found that treating stomach cells with 
obestatin induced the expression of c-fos (a 
obestatin/GPR39 system is up-regulated by muscle injury and functions as 
an autocrine regenerative system. J Biol Chem. 2012;287:38379-89. 
73 Gurriarán-Rodríguez U, Santos-Zas I, González-Sánchez J, et al. Action of 
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and microenvironment remodeling. Mol Ther. 2015;23:1003-21. 
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transcription factor marker of gastrointestinal activity) 
in wyld type (WT) mice, but not in GPR39 null mice; 
and, in cultured 3T3-L1 cells, treatment with 
obestatin, but not motilin, induced c-fos expression 
and also stimulated ERK1/2 phosphorylation. 
Immunohistochemistry analysis using antibodies 
against the third extracellular loop of GPR39 also 
indicated a colocalization for GPR39 and c-fos in 
different obestatin-targeted cells.77 Previously, other 
group had constructed a GPR39-knockout mice model, 
and partially confirmed the in vivo effects of obestatin 
depending on GPR39.53 GPR39 null mice showed 
accelerated gastric emptying; increased gastric 
secretion, higher mature body weights and body fat 
compositions; reduced hyperphagia after fasting; and 
increased cholesterol levels. Furthermore, studies on 
bone metabolism78 and term pregnancy79 have shown 
the correlation of expression levels of both receptor 
and ligand. Other studies tested the influence of the 
acute GPR39 deficiency by siRNA showing that the 
observed obestatin effects were mediated by the 
GPR39 receptor in several cell lines (healthy and 
pathological).71,72 Very recently, Camiña’s group 
demonstrated that obestatin coimmunoprecipitated 
specifically with GPR39, validating the binding of 
obestatin to this receptor  in cultured C2C12 myoblast 
cells.73 All these data points clearly in the direction that 
obestatin is able to bind GPR39 receptor to perform 
their functions. 
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GPR39 as the Zn+2-Sensing Receptor 
After the first published works on the inability of 
obestatin to activate the GPR39,75 some groups 
started to work about the possibility that Zn+2 were an 
effective activator of this receptor, which could 
indicate its validity as an agonist or physiological 
modulator of GPR39.55 Specially, Hershfinkel’s group 
considered GPR39 as Zn+2-sensing receptor (ZnR), 68 
and not as the obestatin receptor. Their results found 
that GPR39 is implied in neuronal function68 and 
synapsis,69 is activated in injury and promoted 
signalling leading to epithelial repair.67 In addition, 
ZnR/GPR39 was tuned to sense physiologically 
relevant changes in extracellular pH that thus regulate 
ZnR-dependent signalling and ion transport activity.80 
They also showed that the receptor, activated by Zn+2, 
had a dual role in promoting proliferation of 
colonocytes and in controlling their differentiation 
and might be a therapeutic target for promoting 
epithelial function and tight junction barrier integrity 
during ulcerative colon diseases.81 In cancer cell lines, 
they found that GPR39 enhanced survival of HT-29 
colonocytes.82 In addition, in human prostate cancer 
PC3 cells, they found that endogenous ZnR/GPR39 
activity was regulated by the expression and activity of 
another cation sensing GPCR, the Ca+2-sensing 
receptor (CaSR). ZnR/GPR39 was required for 
mediating the Zn+2-dependent activation of mitogen-
activated protein kinase (MAPK) and 
phosphatidlyinositol 3-kinase (PI3K) pathways leading 
to enhanced cell growth; and also enhanced the 
81 Cohen L, Sekler I, Hershfinkel M. The zinc sensing receptor, ZnR/GPR39, 
controls proliferation and differentiation of colonocytes and thereby tight 
junction formation in the colon. Cell Death Dis. 2014;5:e1307. 
82 Cohen L, Azriel-Tamir H, Arotsker N, et al. Zinc sensing receptor signaling, 
mediated by GPR39, reduces butyrate-induced cell death in HT29 




expression of the Ca+2-binding protein S100A4 that is 
linked to invasion of prostate cancer cells.83  
Nowak et al, also support the possibility that GPR39 
were the ZnR. Their results showed that the receptor 
is an important target for zinc "transmission" (its 
activation modulates/induces diverse biochemical 
pathways involved in neuroprotection) and plays a 
pivotal role in antidepressant action being a new 
target for depression drug development. 84,85,86,87,88 
Other authors reported other actions for GPR39 
activated by Zn+2 like an important transducer of 
autocrine and paracrine Zn+2 signals, impacting upon 
cellular processes such as insulin secretion, gastric 
emptying, neurotransmission and epithelial repair;89 
or a role in signalling pathways in sperm capacitation 
and acrosome reaction.90 
COULD OBESTATIN EXERT ITS ACTION THROUGH 
GLP1R? 
Granata et al published in 2008 that obestatin action 
might be mediated partially by the glucagon-like 
peptide-1 (GLP-1) receptor (GLP1R) in pancreatic β-
cells, which would explain its insulinotropic and 
survival effects.91,92 They observed that obestatin 
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bound to GLP1R and promoted β-cells and islet cell 
survival. The interaction among them was proposed 
based on binding displacement assays of radiolabelled 
GLP-1 by obestatin. Obestatin inhibited dose-
dependently binding of GLP-1 to cell membrane, thus, 
obestatin and GLP-1 recognized the same binding 
sites. In addition, obestatin did not influence GLP1 
secretion so that promotion of cell survival was 
independent of GLP-1. However, these results were 
questioned based on results obtained from INS-1β and 
HEK cells overexpressing GLP1R in which obestatin 
was not able to displace radiolabelled GLP-1 binding93 
and the fact that this work is prior to the report about 
quality of obestatin peptides.76 Furthermore, there is 
no report showing a specific binding between 
obestatin and GLP1R. In this sense, although it might 
be possible for obestatin to activate GLP1R by 
transactivation, the role of GLP1R in obestatin 
signalling still needs to be unravelled.  
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OBESTATIN BIOACTIVITY. FUNTIONS AND 
SIGNALLING 
Ruling out the role of obestatin in food intake, 
numerous biological functions have been described 
for it in both central and peripheral tissues (Figure 7). 
Role of obestatin in adipose tissue 
Regarding the abilities of obestatin in adipose tissue, 
several works by different groups go in the same 
direction and showed that this peptide regulates two 
key enzymes of cell metabolism: Akt and AMP-
activated protein kinase (AMPK) in preadipocytes and 
adipocytes.70,71,94,95 Obestatin inhibits AMPK and 
activates Akt and their targets, glycogen synthase 
kinase 3 (GSK3) (regulator of the synthesis of 
glycogen), AS160 (regulator of glucose transporters), 
mammalian target of rapamycin (mTOR) and S6K 
(regulator of protein synthesis), in preadipocytes and 
adipocytes 3T3-L1. This fact was confirmed in vivo in 
white adipose tissue obtained from rats under chronic 
sc administration of obestatin. The relevance of the 
role of obestatin on the metabolism of preadipocytes 
and adipocytes is supported by glucose transporter 
type 4 (GLUT4) translocation to the plasma membrane 
with the consequent increase in glucose uptake. On 
the contrary, obestatin did not modify the 
translocation of fatty acid carriers fatty acid transport 
(FAT) protein 4 (FATP4) and FAT/CD36 to the plasma 
membrane. Surprisingly, obestatin regulated the 
expression of transcription factors involved in 
adipogenesis: CCAAT/enhancer binding protein 
(C/EBP)α, C/EBPβ, C/EBPδ and peroxisome 
proliferator-activated receptor y (PPARy) promoting 
the differentiation. 
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Figure 7. Functions of obestatin. Obestatin may act by endocrine, 
paracrine, or autocrine mechanisms. These biological effects have 
been described in central and peripheral tissues, and might be 
direct or indirect. Modified from: Mol Cell Endocrinol. 
2011;340:111-7.  
Remarkably, preproghrelin expression, and therefore 
obestatin expression, showed an increase during 
adipogenesis being sustained in late differentiation.71 
Furthermore, the neutralization of endogenous 
obestatin secreted during differentiation of 3T3-L1 
preadipocytes decreased significantly in adipogenesis, 
and GPR39 siRNA studies reduced obestatin action 
involving this receptor as an extracellular target for 
obestatin.55 From these results, it might be concluded 
that obestatin promotes adipogenesis as an 
autocrine/paracrine factor. Interestingly, obestatin 
also regulates lipid metabolism by inhibiting lipolysis, 
as observed in 3T3-L1 and human subcutaneous (sc) 
and omental adipocytes isolated from both lean and 
95 Gargantini E, Grande C, Trovato L, et al. The role of obestatin in glucose 




obese individuals, and from HFD-treated mice.94,96 
Moreover, AMPK phosphorylation, whose increase 
has been associated with inhibition of lipolysis, was 
found enhanced by obestatin in both 3T3-L1 and 
human adipocytes.94 In vivo studies also showed that 
in rat, plasma triglyceride levels were significantly 
reduced by a chronic treatment with a stable 
obestatin analogue,97 suggesting a possible role for 
obestatin in lipid homeostasis. Furthermore, in cow 
white adipose tissue (WAT), obestatin infusion 
decreased the expression levels of ATP-binding 
cassette A1 (ABCA1), a key cholesterol transporter.98 
In addition, and in agreement with the results 
obtained in cultured adipocytes, mice treated with 
obestatin showed increased plasma adiponectin and 
reduced leptin levels, in both epididymal and sc 
adipose tissue of HFD mice. In these mice, obestatin 
even reduced inflammation, a hallmark of insulin 
resistance and diabetes, by inhibiting 
proinflammatory cytokine release in fat, muscle and 
liver, through activation of signalling pathways 
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Obestatin bioactivity in pancreas 
Obestatin expression has been demonstrated in the 
endocrine pancreas, suggesting that may act together 
as local regulator of β-cell fate and 
function.34,35,91,99,100,101 Obestatin was also secreted by 
pancreatic β-cell lines and human pancreatic islets, 
and has been shown to reduce apoptosis and to 
promote proliferation of β-cells and human pancreatic 
islets upregulating the expression of genes which play 
a key role in insulin signalling, glucose homeostasis 
and β-cell survival and differentiation, such as insulin 
receptor substrate 2 (IRS-2), cAMP response element-
binding protein (CREB), Pdx-1 and glucokinase. These 
obestatin effects in β-cells involve multiple molecular 
mechanisms, suggesting an intercom with ghrelin and 
GLP1R.102,92 It have also been investigated the ability 
of obestatin to promote in vitro β-cell generation from 
mouse pancreatic islet derived precursors. Obestatin 
induced the generation of islet-like cell clusters and 
showed increased levels of insuline gene expression 
and C-peptide secretion.103 However, the role of 
obestatin in glucose metabolism in humans is in 
contradiction with the results  demonstrated in mice 
100 Walia P, Asadi A, Kieffer TJ, et al. Ontogeny of ghrelin, obestatin, 
preproghrelin, and prohormone convertases in rat pancreas and stomach. 
Pediatr Res. 2009;65:39-44. 
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2012;114:349-57. 
102 Granata R, Volante M, Settanni F, et al. Unacylated ghrelin and obestatin 
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regarding insulin levels104,105,106 and insulin 
release.107,108 Another study indicated that obestatin 
may have dual effects on insulin release in response to 
glucose high levels in perfused rodent islets.109 Taken 
together, all these findings suggest an important role 
of obestatin in pancreas formation and regeneration 
and its potential application for treating metabolic 
disorders such as insulin resistance, diabetes mellitus 
and in the pathogenesis of the metabolic syndrome. 
Myogenic effect of obestatin 
Recent publications of Camiña’s group revealed the 
role of obestatin in muscle. Results showed that this 
peptide activated Akt and its downstream targets, 
GSK3α/β, and S6K1, in L6E9 myotube cells. 
Simultaneously, obestatin inactivated AMPK in this 
cell model. In keeping with this, acetyl-CoA-
carboxilase (ACC) phosphorylation was also 
decreased. This fact was confirmed in vivo in rat 
skeletal muscle, gastrocnemius and soleus, obtained 
from male rats under continuous sc infusion of 
obestatin.72 In differentiating L6E9 cells, preproghrelin 
expression and correspondingly obestatin, increased 
during myogenesis being sustained throughout 
terminal differentiation. Autocrine action was 
demonstrated by neutralization and knock-down 
experiments confirming the contribution of obestatin 
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to the myogenic program. Furthermore, the 
overexpression of the obestatin/GPR39 system in 
skeletal muscle enhanced muscle regeneration after 
muscle injury by stimulating satellite stem cell 
expansion as well as myofiber hypertrophy through a 
kinase hierarchy. The effective action was due to the 
specific regulation of this peptide on different stages 
affecting myogenesis: proliferation, fusion and 
myofiber growth. Added to the myogenic action, 
obestatin administration resulted in increased 
expression of vascular endothelial growt factor 
(VEGF)/VEGF receptor 2 (VEGFR2) and the consequent 
microvascularization, with no significant effect on 
collagen deposition in developing skeletal muscle.73 
Obestatin in the cardiovascular system 
Different groups have investigated the cardiovascular 
effects of obestatin. Changes in obestatin levels have 
been reported in patients with heart failure110 or 
ischaemic heart disease.111 Moreover, binding sites for 
obestatin have been identified in the heart; and 
obestatin might be playing a role in protecting 
myocardial function following reperfusion injury of 
cardiac muscle cells, reducing infarct size and 
contractile dysfunction in a concentration-dependent 
manner. Obestatin also reduced cardiomyocyte 
apoptosis and reduced caspase-3 activation.112 
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However, obestatin was also found unable to prevent 
apoptosis or to have effect on cell cycle or viability of 
HL-1 cardiomyocytes.113  
Other work showed that an increase in the contraction 
force of ex vivo frog hearts stimulated by obestatin 
was blocked by β-blockers and a protein kinase A  
(PKA) inhibitor, indicating that obestatin influenced 
beta-adrenergic receptors of cardiac muscle cells.114 
Obestatin also preserved papillary muscle 
contractility, β-adrenergic response, as well as β1-
adrenoreceptors and α-myosin heavy chain (α-MHC) 
levels in rat diabetic myocardial tissue.115 
Furthermore, obestatin may also have a role in 
regulating blood pressure. The ghrelin:obestatin ratio 
and obestatin levels were reduced in patients with 
high blood pressure,116 and fasting plasma obestatin 
levels had also been shown to have a negative 
correlation with systolic blood pressure in humans.117 
In pregnant women with pregnancy-induced 
hypertension, obestatin levels were elevated 
compared to normotensive pregnant women.118 In 
contrast, in hipertensive rats, obestatin levels were 
increased,106 or did not alter blood pressure.119  
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Mitogenic capabilities 
Camiña’s group were the first to show the proliferative 
capabilities of obestatin in human retinal pigment 
epithelium (RPE) cells. They evaluated the effect of 
obestatin in primary cultures of RPE cells. The results 
showed that this peptide induces cell proliferation in a 
dose-dependent manner with the phosphorylation of 
MEK/ERK1/2. The signalling pathway towards ERK1/2 
activation involves consecutive Gi, PI3K, Src and 
protein kinase C (PKC)ε novel.120 Peripheral 
administration of obestatin also induced an early 
response gene that undergoes rapid transcriptional 
activation by growth factors and mitogens, in white 
adipose tissue and cultured mouse adipocytes.77 
Nevertheless, obestatin did not modify the cell cycle 
or viability in HL-1 murine cardiomyocytes113 and 
inhibited proliferation in a human chondrocyte cell 
line.121 Other group showed the role of this peptide in 
proliferation, apoptosis and secretion in pig ovarian 
granulosa cells. In these cells, obestatin increased 
proliferation, apoptosis and secretion of progesterone 
and might regulate turnover and remodelling of 
ovarian follicles.122 It was also described that obestatin 
promoted cell growth and cell survival in β cells and 
human pancreatic islets.91,102 The same mitogenic 
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Peptides. 2009;30:1928-30. 
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result through ERK signalling pathway was discovered 
in the human gastric carcinoma cell line KATO III.123  
Other functions 
In addition to all the capabilities mentioned above, 
obestatin has a role in many other physiological 
functions. Obestatin suppresses thirst,124 decreases 
anxiety and improves memory,125,126 decreases the 
secretion of GH in vivo127 but stimulates GH release in 
GC cells,128 regulates sleep,129 increases vasopressin 
secretion,130 and actives cortical neurons.38 In chronic 
obstructive pulmonary disease obestatin levels are 
elevated.131 In addition, obestatin might play a role in 
kidney diseases. Obestatin levels are elevated in 
plasma of patients with chronic kidney disease132,133 
and kidney failure (end stage renal of disease),134 and 
patients undergoing haemodialysis resulted in lower 
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plasma levels.135 Other works showed antagonic 
results about the physiological significance of plasma 
obestatin levels136 but seems to be that this peptide 
could be an useful biomarker for some disease states 
like inflammatory bowel disease,137 atrophic 
gastritis138 or anorexia nervosa.139,140,141  
Obestatin signalling 
Pazos’ group dilucidated the transmembrane 
signalling pathway responsible for obestatin induced-
Akt activation in human gastric carcinoma cells, KATO 
III and AGS.142 They carried out an analysis of the 
sequential transmembrane signalling pathway of 
obestatin to characterize the intracellular mechanisms 
responsible for the activation of Akt, a 
serine/threonine kinase that acts as a key molecule of 
apoptosis, transcription and cell cycle, in addition to 
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his role on the regulation of metabolism.143 Results 
showed that Akt activation requires the 
phosphorylation of T308 in the A-loop by the 
phosphoinositide-dependent kinase 1 (PDK1) and 
S473 within the HM by the mTOR kinase complex 2 
(mTORC2: RICTOR, mLST8, mSin1, mTOR kinase) with 
participation neither of Gi/o-protein nor Gβ dimers. 
Obestatin induces the association of the GPR39/β-
arrestin1/Src signalling complex leading to the 
transactivation of the epidermal growth factor (EGF) 
receptor (EGFR) and subsequently to the activation of 
Akt (Scheme 1). After administration of obestatin, 
phosphorylation of both mTOR (S2448) as p70S6K1 
(T389) increases with a time course in parallel to the 
activation of Akt. Apart from the obvious complexity 
and specificity of cellular signalling pathways of EGFR 
transactivation, in KATO III cells they found that the 
signalling routes of ERK1/2 and Akt act in parallel. It is 
clear that the specificity of signalling routes not only 
depends on the presence of an ErbB specific receptor 
of EGFR family, but also on the biochemical 
characteristics of every EGF-like ligands.144 These 
ligands are bivalent, a property that determines which 
combinations homo- or heterodimeric are formed and 
the active signalling cascade.144 In addition, β-arrestin-
scaffolding complex presumably located different 
members for ensuring the substrate specificity and 
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metalloproteinases (MMPs) activity. Such complexity 
reflects the importance of this process in obestatin 
transactivation signalling. Some studies show that Zn+2 
induces phosphorylation of EGFR through the release 
of EGF-like ligands, process mediated by MMPs.145,146 
Treatment with Zn+2 triggers the activation of MAPK 
and PI3K/Akt signalling pathways through EGFR 
activation in several cell types.147,148,149 These findings 
also suggest that there are specific marked differences 
to each cell type in the EGFR activation mechanism 
induced by Zn+2. All these data could imply that the 
stimulatory effects of Zn+2 in GPR39 signalling might be 
due to the activation of MMP-EGFR pathways, since 
obestatin needs EGFR transactivation and MMPs 
activity.  
It would be necessary to determine the exact function 
of Zn+2 on the GPR39 signalling in the absence of MMP 
and/or EGFR to clearly define its function as a ligand 
or ago-allosteric modulator of this receptor.150 This 
signalling pathway adds a new component to the 
intracellular signalling targets regulated by obestatin. 
In this sense, obestatin is added to the group of MMPs 
regulator factors, which have been implicated in 
diverse human diseases, such as inflammatory 
diseases and cancer.151,152 It would be possible that 
EGFR transactivation induced by obestatin implied a 
key mechanism by which MMPs regulate these 
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diseases. Supporting this hypothesis, numerous 
studies have shown that the alteration in the 
expression and/or mutations in genes of members of 
the EGFR/ErbB receptor family are present in tumours 
and cell lines derived, and these changes may 
contribute to cancer progression.153,154,155 However, it 
seems to be necessary a detailed elucidation of the 
mechanism of activation/regulation of EGFR 
transactivation stimulated by obestatin and the 




Scheme 1. Proposed model of signalling pathway for Akt and ERK1/2 activation in response to obestatin. Traslocation of β-arrestins 1 to 
obestatin receptor (GPR39) allows its association with Src. β-arrestin 1 activates Src (phosphorylation at Y416) triggering the transactivation 
of EGFR and the subsequent downstream Akt signalling. Modified from: Endocr-Relat Cancer. 2009;16:599-611. 
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OBESTATIN/GPR39 SYSTEM IN CANCER 
Since 2009, several papers were published about the 
obestatin role in various types of cancer. It has been 
reported that low EGFR expression in a rat pituitary 
adenoma cell line (GC) blocked obestatin induced cell 
proliferation, showing that EGFR expression is the key 
to its proliferative activity.128 In humans, Volante35 and 
Tsolakis’36 groups reported that obestatin was 
expressed in gastric well-differentiated (WD) 
neuroendocrine tumours (NETs). Interestingly, 
immunohistochemical studies suggested that 
obestatin expression is reduced in thyroid and 
pancreatic tumour tissue and obestatin may be 
specifically downregulated by these tumours types in 
order to circumvent the inhibition of the proliferation 
demonstrated in vitro.35 Immunoassay-based studies 
have reported that obestatin levels are higher in the 
blood of patients with ovarian cancer than in normal 
controls,156 but there was no correlation between 
plasma levels of obestatin and the disease status, 
however, in prostate cancer157 and uterine leiomyoma 
patients.158 In serous ovarian tumours, severe 
expression of ghrelin and obestatin correlated with an 
increase in malignancy, suggesting that ghrelin and 
obestatin may be effective in the malignant 
transformation.159 Furthermore, obestatin 
immunoreactivity was observed in benign nodular 
goiter, as well as in cancer thyroid cells. The 
differences between ghrelin and obestatin 
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immunoreactivity in benign and malignant thyroid 
tumours could support the theory of alternative 
transcription of the pre-proghrelin gene and thus of 
the independent production of ghrelin and 
obestatin.160 However, the possible usefulness of the 
modulation of the ghrelin/obestatin axis in neoplastic 
conditions using either synthetic agonists or 
antagonists, though interesting in perspective, is still 
far from clinical applicability, and probably more 
related to the regulation of specific metabolic 
pathways in tumour cells, including lipid and 
carbohydrate use, than to the specific modulation of 
cell proliferation.161 Taken together, the available 
evidence shows that obestatin is an 
autocrine/paracrine growth factor in peripheral 
tissues and may play a role in cancer progression.162 
On the other hand, it has been reported that GPR39 
was an inhibitor of cell death in hippocampal cells and 
GPR39 overexpression led to increased secretion of 
the cytoprotective pigment epithelium-derived factor 
(PEDF), which might represent a therapeutic target 
with implications for processes involving apoptosis 
and endoplasmic reticulum stress like cancer, 
ischemia/reperfusion injury, and neurodegenerative 
disease.66 Additionally, GPR39 reduced butyrate-
induced cell death in HT-29 colonocytes;82 and in 
human prostate cancer PC3 cells, GPR39 signalling 
enhanced cell growth and might be linked to invasion 
of these cells.83  Furthermore, GPR39 receptor was 
found to be frequently overexpressed in primary 
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oesophageal squamous cell carcinomas (ESCCs) in 
both mRNA level and protein level, which was 
significantly associated with the lymph node 
metastasis and advanced TNM stage suggesting that 
GPR39 played an important tumorigenic role in the 
development and progression of ESCC.163 Introduction 
of GPR39 gene into ESCC cell line KYSE30 promotes cell 
proliferation, increases foci formation, colony 
formation in soft agar, and tumour formation in nude 
mice. The mechanism by which amplified GPR39 
induces tumorigenesis was associated with its role in 
promoting G1/S transition via up-regulation of cyclin 
D1 and CDK6. GPR39 also enhanced cell motility and 
invasiveness by inducing epithelial-mesenchymal 
transition (EMT) and remodelling cytoskeleton. 
Moreover, depletion of endogenous GPR39 by siRNA 
could effectively decrease the oncogenicity of ESCC 
cells. Finally, a recent published article, using a 
phenotypic screening approach, postulates GPR39 as 
the unknown GPCR able to inhibit Hedgehog (Hh) 
signalling, which determinates cell fate during 
development and can drive tumorigenesis.164 The 
GPR39 is necessary for compound activity and the 
proposed model of activation involved the cyclohexyl-
methyl aminopyrimidine chemotype compounds 
(CMAPs), driving the signalling to the Gli transcription 
factors in crosstalk with MAPK pathway. This 
mechanism may involve Gi pathway activation, Gβγ 
signalling or β-arrestin recruitment blocking the Hh 
signalling. 
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GASTRIC CANCER 
Gastric cancer is a cancer disease emerging from the 
stomach epithelium. It is often diagnosed at an 
advanced stage because there are no clear early signs 
or symptoms. The cancer may spread from the 
stomach to other parts of the body, particularly the 
liver, lungs, bones, lining of the abdomen and lymph 
nodes.165  
AETIOLOGY 
Signs and Symptoms. Gastric cancer is often either 
asymptomatic or it may cause nonspecific symptoms 
in early stages like indigestion, a bloated sensation 
after eating, and heartburn. As it progresses, 
symptoms may include dyspepsia, nausea, diarrhoea 
or constipation, bloody stools, vomiting blood, loss of 
appetite, weight loss, anaemia, and sensations of full-
ness or pressure in the stomach. By the time 
symptoms occur, the cancer has often reached an 
advanced stage and may have also metastasized, 
which is one of the main reasons for its relatively poor 
prognosis.166  
Risk factors and causes. Chronic infection with 
Helicobacter pylori is the strongest identified risk 
factor for stomach cancer, with more than 60% of new 
stomach cancer cases worldwide attributed to this 
bacterium.167 It is not known with certainty how H. 
pylori is spread, but the most likely route of 
transmission is from person to person through faecal-
oral or oral-oral routes. Possible environmental 
sources include water contaminated with human 
165 Ruddon RW. Cancer biology. 4th ed. Oxford: Oxford University Press. 
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waste. Prevalence of H. pylori infection is higher in 
developing countries (74%) than in developed 
countries (58%). Notably, less than 5% of the 
chronically infected individuals will develop stomach 
cancer.167 The mechanism by which H. pylori induces 
stomach cancer potentially involves chronic 
inflammation, or the action of H. pylori virulence 
factors such as CagA.168  It was estimated that Epstein–
Barr virus is also responsible for 84,000 cases per 
year.167  
Dietary risk factors for stomach cancer include a diet 
rich in smoked foods, salted meat or fish, and pickled 
vegetables;169 fresh fruits and vegetables appear to 
lower risk.170 Smoking also increases risk of stomach 
cancer.171 Smokers have a 50% to 60% increased risk 
for stomach cancer compared with non-smokers. 
Some studies show increased risk with alcohol 
consumption as well.172 Obesity is associated with 
increased risk of adenocarcinoma of the gastric cardia, 
possibly due to gastroesophageal reflux disease or 
chronic inflammation.173 
Gastric cancer shows a male predominance in its 
incidence as up to two males are affected for every 
female. Oestrogen may protect women against the 
development of this cancer type.174  
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Approximately 10% of cases show a genetic 
component.175 A genetic risk factor for gastric cancer 
is a genetic defect of the CDH1 gene known as 
hereditary diffuse gastric cancer (HDGC). The CDH1 
gene, which codes for E-cadherin, lies on the 16th 
chromosome. When the gene experiences a particular 
mutation, gastric cancer develops through a 
mechanism that is not fully understood. 176 
Other factors associated with increased risk are 
diabetes,177 pernicious anaemia, acquired immune 
deficiency syndrome (AIDS), Menetrier's disease,178 
chronic atrophic gastritis and intestinal metaplasia.179 
Treatment. The main treatments for stomach cancer 
are surgery, chemotherapy, targeted therapy, and 
radiation therapy. Often the best approach uses two 
or more of these treatment methods. Treatment for 
advanced stage cancer is often aimed at relieving 
symptoms.  
Biology of gastric cancer. H. pylori infection is 
considered as the single most important risk factor 
leading to gastric cancer,180 through chronic 
inflammatory changes in the gastric mucosa, followed 
by pre-neoplastic changes such as atrophy and 
metaplasia, as in the Correa cascade (Figure 8).181  
Over 20 years ago, Correa delineated the association 
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of intestinal metaplasia with the development of 
intestinal-type gastric cancer. In Correa’s model of 
gastric carcinogenesis, H. pylori infection triggers the 
progressive sequence of gastric lesions from chronic 
gastritis, gastric atrophy, intestinal metaplasia, 
dysplasia, and finally, gastric adenocarcinoma. 
However, the details of how metaplasia is initiated 
and how it can progress towards cancer have 
remained elusive until recently. 
Figure 8. Correa’s gastric carcinogenesis model. Carcinogenesis 
model for the Laurén intestinal type gastric carcinomas, according 
to the proposed by Pelayo Correa in 1992. Modified from: Gastritis 
and Gastric Cancer. New Insights in Gastroprotection, Diagnosis 
and Treatments. 2011. 
This initiating event in gastric pre-neoplasia in humans 
with chronic infection with H. pylori,182 initiates both 
parietal cell loss (and oxyntic atrophy) and prominent 
inflammation. Loss of parietal cells appears to 
represent a key fulcrum in the process of pre-
neoplasia due to the role of the acid secreting cells as 
the coordinate source of a number of critical growth 
                                                          
182 Blaser M, Parsonnet J. Parasitism by the 'slow' bacterium Helicobacter 
pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest. 
1994;94:4-8. 
183 Jain RN, Brunkan CS, Chew CS, et al. Gene expression profiling of gastrin 
target genes in parietal cells. Physiol Genomics. 2006;24:124-32. 
184 Li Q, Karam SM, Gordon JI. Diphtheria toxin-mediated ablation of 
parietal cells in the stomach of transgenic mice. J Biol Chem. 
1996;271:3671-6.  
185 Bredemeyer AJ, Geahlen JH, Weis VG, et al. The gastric epithelial 
progenitor cell niche and differentiation of the zymogenic (chief) cell 
lineage. Dev Biol. 2009;325:211-24. 
186 El-Zimaity HMT, Ota H, Graham DY, et al. Patterns of gastric atrophy in 
intestinal type gastric carcinoma. Cancer. 2002;94:1428-36. 
factors.183 Loss of parietal cell-derived signalling 
molecules disrupts the proper differentiation of other 
lineages most notably the zymogen-secreting chief 
cells.184,185 The chronic Helicobacter infection also 
elicits prominent inflammation throughout the 
mucosa. Thus, the combination of oxyntic atrophy 
along with prominent inflammation is a prerequisite 
for progression of metaplasia to gastric 
adenocarcinoma.186 Oxyntic atrophy triggers a series 
of changes in the cells lining the gastric mucosa. In 
humans, two types of metaplasia arise in the milieu of 
oxyntic atrophy and inflammation: intestinal 
metaplasia (IM) and spasmolytic polypeptide 
expressing metaplasia (SPEM). Both IM and SPEM 
have been associated with the progression to 
intestinal type gastric cancer.187,188,189,190,191  Mouse 
models of both chronic Helicobacter infection and 
acute pharmacological oxyntic atrophy have led to the 
recognition that SPEM arises from transdifferentiation 
of mature chief cells. The presence of inflammation 
promotes the expansion of SPEM in mice. 
Furthermore, human studies indicates that SPEM 
likely represents a precursor for development of IM 
(Figure 9).  
These findings indicate that the loss of parietal cells, 
augmented by chronic inflammation, leads to a 
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cascade of metaplastic events. Thus, oxyntic atrophy 
in association with prominent inflammation incites 
the induction of gastric lineages that predispose to the 
development of gastric cancer.192 Nevertheless, the 
factors mediating progression from oxyntic atrophy to 
gastric cancer remain unclear. 
 
 
 Figure 9. Proposed model for the origin and progression of 
different gastric metaplasias in humans by Goldenring and Nam. 
The oxyntic atrophy and subsequent loss of parietal cells would 
lead to chief cell transdifferentiation and the SPEM-type 
metaplasia emergence. In the presence of chronic inflammation 
from H. pylori infection, SPEM would progress into intestinal 
metaplasia and gastric neoplasia. Modified from: Prog Mol Biol 
Transl Sci. 2010;96:117-31. 
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EPIDEMIOLOGY   
Gastric cancer was the fourth most common malig-
nancy in the world in 2012, with an estimated 951,600 
new cases; and is the third and fifth leading cause of 
cancer death in men and women, respectively.193 
About 723,100 people worldwide died from gastric 
cancer in 2012.194 Its incidence rates vary widely 
across countries, but, in general, the highest incidence 
rates are in Asia (particularly in Korea, Mongolia, 
Japan, and China) and many parts of South America 
and the lowest rates are in Northern America and 
most parts of Africa. Generally, gastric cancer rates are 
about twice as high in men as in women. These data 
suggest that environmental and lifestyle factors are 
strongly implicated in the carcinogenesis of this 
tumour. 
Gastric cancer is a disease with a poor prognosis. A low 
rate of cases is diagnosed at an early stage, with a wide 
variation between countries and, in developing 
countries, survival rates are generally below 20%.195 
However, a steady decline in gastric cancer incidence 
and mortality rates has been observed in most 
developed countries of Northern America and Europe 
since the mid-20th century.196,197 Similar decreasing 
trends have been noted in more recent years in areas 
with historically high rates, including several countries 
in Asia, Latin America and Europe.198 The factors to 
have contributed to these declines include a trend to 
a healthier diet, and a reduction in chronic H. pylori 
infection due to improvements in sanitation and 
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antibiotics.199 In developed countries, decreases in 
smoking prevalence may also account.200 Although 
gastric cancer is declining overall, adenocarcinoma of 
the gastric cardia is increasing in Northern America 
and Europe and is thought to be due to increased 
obesity and metabolic diseases.  
In Spain, gastric cancer average rate is 31/100,000 and 
is the third cause of death, only lung and colon cancer 
have higher rates. The areas that still retain a high risk 
of death from gastric cancer are large areas of Castilla 
and León, and the Atlantic coast of Galicia, specially 
Pontevedra.201,202  Over an 8,000 new cancers and 
6,000 cancers deaths were predicted in Spain in 2020. 
 
 
Figure 10. Prediction of number of new gastric cancers and cancer deaths in Spain in 2020. Population forecasts were extracted from the 
United Nations, World Population prospects, the 2012 revision. Numbers are computed using age-specific rates and corresponding 
populations for 10 age-groups. Source: GLOBOCAN. Over an 8,000 new cancers and 6,000 cancers deaths were predicted in Spain in 2020. 
However, a steady decline in gastric cancer incidence and mortality rates were observed.
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Gastric cancer classification has necessitated the use 
of histological features of tumour cells together with 
information about their respective tissues-of-origin, 
differentiation states, and biological behaviours; 
together these characteristics make possible to 
develop a taxonomy of tumours that has proven useful 
for the diagnosis and clinical management of most of 
them. Numerous pathohistological and clinical 
classification systems have been established for 
gastric cancer thus far, but there is still controversy as 
to which classifications unify a prognostic correlation 
with a high validity and practicability in diagnosis and 
clinical routine. 
Almost all gastric cancers are adenocarcinomas. Other 
types are gastrointestinal carcinoid tumours, 
gastrointestinal stromal tumours, and lymphomas.203 
Gastric adenocarcinoma is a malignant epithelial 
tumour, originating from glandular epithelium of the 
gastric mucosa. 90% of gastric carcinomas are 
adenocarcinomas  and tend to invade gastric wall, 
infiltrating the muscularis mucosae, submucosa and 
muscularis propia. Lymphomas [mucosa-associated 
lymphoid tissue (MALT) lymphomas or MALTomas] 
are around 5% of gastric malignancies.  
Grades of gastric cancer. The grade of stomach cancer 
is based on the degree of differentiation of the cells 
and their rate of growth. 
G1. Well differentiated (WD) or low grade. Slow 
growing, less likely to spread. 
G2. Moderately differentiated (MD) or moderate 
grade. 
                                                          
203 Kumar V, Abbas AK, Aster JC. Pathologic Basis of Disease. 8th ed. 
Saunders Elsevier. 2010. 
204 Laurén P. The two histological main types of gastric carcinoma: Diffuse 
and so-called intestinal-type carcinoma an attempt at a histo-clinical 
classification. Acta Pathol Microbiol Scand. 1965;64:31-49. 
G3. Poorly differentiated (PD) or high grade. 
G4. Undifferentiated. Tend to grow quickly and are 
more likely to spread. 
HISTOPATHOLOGICAL CLASSIFICATIONS 
Laurén classification. Since its establishment in 1965, 
the Laurén classification of gastric cancer has been the 
most commonly used and the most studied 
classification for gastric adenocarcinoma among all of 
the classification systems. Laurén divided the 
histology of gastric cancer into two groups the 
intestinal type and the diffuse type. Later, the 
indeterminate type was included to describe an 
uncommon histology.204,205 
Intestinal type adenocarcinoma. Characterized by 
tumour cells that describe irregular tubular structures, 
harbouring pluristratification, multiple lumen and 
reduced stroma. Often, it associates intestinal 
metaplasia in neighbouring mucosa and with the 
presence of H. pylori. Depending on glandular 
architecture, cellular pleomorphism and 
mucosecretion, the adenocarcinoma may present 3 
degrees of differentiation: well, moderate and poorly 
differentiated. 
Diffuse type adenocarcinoma. Characterized by 
tumour cells that are discohesive and secrete mucus, 
which is delivered in the interstitium, producing large 
pools of mucus/colloid. It is poorly differentiated. If 
the mucus remains inside the tumour cell, it pushes 
the nucleus to the periphery and forms the type 
signet‐ring cell.  It metastasizes much quicker than 
intestinal type tumours. 
Mixed type adenocarcinomas. They have both 
intestinal and diffuse type growth patterns. 
205 Leocata P, Ventura L, Giunta M, et al. Gastric carcinoma: a 





WHO classification. The World Health Organization 
(WHO) classification issued in 2010 appears to be the 
most detailed among all pathohistological 
classification systems. This classification includes not 
only adenocarcinoma of the stomach but also all other 
types of gastric tumours of lower frequency.  
Epithelial tumours 
Premalignant lesions 
8140/0. Adenoma, NOS 
8148/0. Glandular intraepithelial neoplasia, low grade 
8148/2. Glandular intraepithelial neoplasia, high 
grade 
Carcinoma 
8140/3. Adenocarcinoma, NOS 
8260/3. Papillary adenocarcinoma, NOS 
8211/3. Tubular adenocarcinoma 
8480/3. Mucinous adenocarcinoma 
8490/3. Poorly cohesive carcinoma, including signet 
ring cell carcinoma and other variants 
8255/3. Adenocarcinoma with mixed subtypes 
8560/3. Adenosquamous carcinoma 
8512/3. Medullary carcinoma with lymphoid stroma 
8576/3. Hepatic carcinoma 
8070/3. Squamous cell carcinoma, NOS 
8020/3. Undifferentiated carcinoma 
Neuroendocrine neoplasms 
8240/3. NET G1 /Carcinoid 
8249/3. NET G2  
8246/3. Neuroendocrine carcinoma, NOS 
8013/3. Large cell neuroendocrine carcinoma 
8041/3. Small cell neuroendocrine carcinoma 
8244/3. Mixed adenoneuroendocrine carcinoma 
8241/3. Enterochromaffin cell (EC), serotonin-
producing NET 
8153/3. Gastrinoma, malignant 
 
                                                          
206 The Cancer Genome Atlas Research Network. Comprehensive molecular 
characterization of gastric adenocarcinoma. Nature. 2014;513:202-9.  
Lymphomas 
9680/3. Diffuse large B-cell lymphoma (DLBCL), NOS 
9699/3. Extranodal marginal zone MALT lymphoma  
9673/3. Mantle cell lymphoma 
9687/3. Burkitt lymphoma 
9827/3. Adult T-cell leukaemia/lymphoma 
9650/3. Classical Hodgkin lymphoma 
Mesenchymal tumours 
8711/0. Glomus tumour, NOS 
9580/0. Granular cell tumour, NOS 
8890/0. Leiomyoma, NOS 
8811/0. Plexiform fibromyxoma 
9560/0. Schwannoma, NOS 
8825/1. Inflammatory myofibroblastic tumour 
8936/0. Gastrointestinal stromal tumour, benign 
8936/1. Gastrointestinal stromal tumour, NOS 
8936/3. Gastrointestinal stromal tumour, malignant 
9140/3. Kaposi sarcoma 
8890/3. Leiomyosarcoma, NOS 
9040/3. Synovial sarcoma, NOS 
Secondary tumours 
MOLECULAR CLASSIFICATION 
Gastric cancer is a multifaceted disease with different 
aetiologies, genetic changes and phenotypes. Recent 
data based on genetic alterations suggested that it 
could be classified into four subclasses (Figure 11).206 
This schematic lists some of the salient features 






Figure 11. Molecular subtypes of gastric cancer. Insert charts 
represent the distribution of molecular subtypes in tumours 
obtained from distinct regions of the stomach. CIN: chromosomal 
instability. EBV: Epstein-Barr virus-positive. GS: genomically 
stable. MSI: microsatellite instability. CIMP: CpG island methylator 
phenotype. Modified from: Nature. 2014;513:202-9. 
 
MOST RELEVANT CLINICAL CLASSIFICATIONS 
Borrmann classification 
The Borrmann classification describes the 
macroscopic appearance and growth patterns of 
advanced gastric cancer: 
Type I: polypoid. Tumours grow outward from the 
stomach wall and stick out into the stomach. The 
tumours have no ulcers or areas of erosion. 
Type II: fungating. Tumours grow outward from the 
stomach wall in irregular patterns. The tumours may 
have ulcers or areas of erosion. 
Type III: ulcerated. Tumours have ulcers with irregular, 
hard, stiff margins of raised tissue. There are areas of 
dead or dying tissue (necrosis) within the ulcer.  
                                                          
207 Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th 
ed. New York: Springer-Verlag. 2009.  
Type IV: infiltrated. Tumours spread along the mucosa 
or submucosa of the stomach wall, producing flat 
tumours. These tumours may eventually cause the 
stomach wall to become hard and rigid. 
Type V: unclassifiable. Tumours do not fit into any of 
the other 4 categories. 
TNM classification 
TNM stands for Tumour, Node and Metastasis. The 
system describes the size and spread of the stomach 
tumour (T), whether cancer cells have spread to lymph 
nodes (N); and whether the cancer has spread to a 
different part of the body (M).207 
Primary tumour (T) 
Tx. Primary tumour cannot be assessed 
T0. No evidence of primary tumour 
Tis. Carcinoma in situ: intraepithelial tumour without 
invasion of the lamina propria 
T1a. Tumour invades lamina propria or muscularis 
mucosae 
T1b. Tumour invades submucosa 
T2. Tumour invades muscularis propria 
T3. Tumour penetrates subserosal connective tissue 
without invasion of visceral peritoneum or adjacent 
structures*,**,*** 
T4. Tumour invades serosa (visceral peritoneum) or 
adjacent structures**,** 
T4a. Tumour invades serosa (visceral peritoneum) 
T4b. Tumour invades adjacent structures 
* A tumour may penetrate the muscularis propria with extension into the 
gastrocolic or gastrohepatic ligaments, or into the greater or lesser 
omentum, without perforation of the visceral peritoneum covering the 
gastric ligaments or the omentum, the tumour should be classified T4. 
** The adjacent structures of the stomach include the spleen, transverse 
colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, 
























*** Intramural extension to the duodenum or oesophagus is classified by 
the depth of the greatest invasion in any of these sites, including the 
stomach. 
Regional lymph nodes (N) 
Nx. Regional lymph nodes cannot be assessed 
N0. No regional lymph nodes metastasis 
N1. Metastasis in 1 to 2 regional lymph nodes 
N2. Metastasis in 3 to 6 regional lymph nodes 
N3. Metastasis in 7 or more regional lymph nodes 
N3a. Metastasis in 7 to 15 regional lymph nodes 
N3b. Metastasis in 16 or more regional lymph nodes 
* A designation of pN0 should be used is all examined lymph nodes are 
negative, regardless of the total number removed and examined. 
Distant metastasis (M) 
M0. No distant metastasis (no pathologic M0; use 
clinical M to complete stage group) 














































The main objective of this doctoral thesis is to 
establish the relationship between obestatin and 
the GPR39 receptor in healthy and tumour-like 
surroundings, from structural to tissue level, to 
determinate the fundamental parameters of its 
mitogenic bioactivity.  
This issue will be accomplished with the following 
points:  
1. To determine the structural features of 
obestatin required for the interaction with its 
receptor. 
2. To elucidate the detailed activation/regulation 
mechanism of GPR39 receptor signalling triggered 
by obestatin.  
3. To analyse the role of obestatin/GPR39 system 










































































Materials Code Manufacturer 
Human obestatin (1) 471-97 
California Peptide Research 
Inc (Napa, CA, US) 
Human non-amidated 
obestatin (2) 
SE-4764 Biomedal (Sevilla, ES) 
Human 6-23 obestatin (3) SE-4764 Biomedal (Sevilla, ES) 
Human 11-23 obestatin (4) SE-4764 Biomedal (Sevilla, ES) 
Human 16-23 obestatin (5) SE-4764 Biomedal (Sevilla, ES) 
Human 1-10 obestatin (7) SE-4764 Biomedal (Sevilla, ES) 
Mouse obestatin (6) 475-97 
California Peptide Research 
Inc (Napa, CA, US) 
Table 1. Peptides. Relation of the peptides used in the different 
analyses performed in this work.  
HUMAN SAMPLES 
The study protocol of human samples was approved 
by the local ethical committee (CAEI Galicia, 
2009/118) and carried according to the Declaration of 
Helsinki. One human healthy sample and 28 gastric 
adenocarcinomas were used. Histological 
classification of the gastric adenocarcinomas was 
performed according to the Laurén system:204 22 were 
intestinal type adenocarcinomas (with signet ring 
cells, n=1), 3 diffuse type adenocarcinomas (with 
signet ring cells, n=2), and 3 mixed (with signet ring 
cells, n=2). Three levels of differentiation were used to 
classify grading as: well in 9, moderately in 10 and 
poorly differentiated in 9 patients. Pathological 
tumour staging was assessed according to the 7th 
edition of American Joint Committee on Cancer TNM 
classification.207 The pathological tissue samples were 
from gastric adenocarcinomas located in antrum and 
corpus. The surgical control specimens were located 
at least 3 cm from the adenocarcinoma. All the 
examined control tissues originated from macro- and 
microscopically normal gastric mucosa. 
CELLS 
Cell culture  
All of the cell lines used in this work were cultured as 
described by the supplier (ATCC, Manassas, VA, US) 
with 100 U/mL penicillin G, 100 mg/mL streptomycin 
sulphate and 2.5 mM L-glutamine with 5% CO2 at 37 
°C. Cells have been used always with passages lower 
than 15 in all the experiments.  
Cell line Growth medium (v/v) 
ARPE-19. Retinal pigment epithelium cells DMEM:F12 + 10% FBS 
HEK293. Embryonic kidney cells EMEM + 10% FBS 
AGS. Gastric adenocarcinoma HAM´s F12 + 10% FBS 
KATO III. Gastric carcinoma RPMI-1640 + 10% FBS 
PANC-1. Pancreatic carcinoma DMEM + 10% FBS FBS 
MCF7. Breast adenocarcinoma EMEM + 10% FBS 
HT-29. Colorectal adenocarcinoma McCoy´s  5A + 10% FBS 
PC3. Prostate adenocarcinoma HAM´S F12K + 10% FBS 
A549 . Lung carcinoma HAM´S F12K + 10% FBS 
SW872. Liposarcoma Leivobitz L15 + 10% FBS 
BeWo. Choriocarcinoma HAM´S F12K + 10% FBS 
A431. Epidermoid carcinoma DMEM + 10% FBS 
Table 2. Cells. Relation of human cell lines and its growth medium 
used in this work. FBS: foetal bovine serum.       




Antibodies Use Dilution Code Manufacturer 





GPR392-A Alpha Diagnostic International 
Anti-Human GPR39 (C-terminal region) Antibody IH 1:500 SAB4200185 Sigma Chemical 
Anti-GPCR GPR39 Antibody WB 1:1000 ab39227 Abcam 





OBSN11-A Alpha Diagnostic International 
Obestatin (Human, Monkey) Antibody NA 10 μg/mL G-031-92 Phoenix Pharmaceuticals 
Anti-Human Ki67 Antigen Clone MIB-1 IC, IH Ready to use M724001 Dako Agilent 
Anti-Ki67 Antibody WB 1:1000 ab15580 Abcam 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) Antibody WB 1:2000 9101S Cell Signaling Technology 
P44/42MAPK Antibody WB 1:2000 9102S Cell Signaling Technology 
Phospho-Akt (Ser473) Antibody WB 1:2000 9271S Cell Signaling Technology 
Akt Antibody WB 1:1000 9272S Cell Signaling Technology 
Anti-Actin Antibody - Loading Control WB 1:4000 ab1801 Abcam 
Anti-Active beta-Catenin Antibody WB 1:1000 05-665 Millipore 
Anti-E-Cadherin Antibody WB 1:1000 ab76055 Abcam 
Anti-N-Cadherin Antibody WB 1:1000 ab76011 Abcam 
Anti-Vimentin Antibody WB 1:1000 ab92547 Abcam 
Anti-Flk1 (C-1158) Antibody WB 1:500 sc-504 Santa Cruz 
Anti-VEGF (A-20) Antibody WB 1:500 sc-152 Santa Cruz 
Anti-PEDF (H-25)  Antibody WB 1:500 sc-25594 Santa Cruz 
Anti-EGFR Antibody WB 1:1000 2232 Cell Signaling Technology 
Anti-Pepsinogen I Antibody WB 1:1000 ab135403 Abcam 
Anti-Pepsinogen I Antibody IH 1:2000 ab50123 Abcam 
Anti-GAPDH Antibody WB 1:1000 ab9485 Abcam 
Anti-GFP Antibody WB 1:1000 ab111258 Abcam 
Anti-Phospho-Tyrosine-HRP Detection Antibody PA 1:5000 ARY100B R&D Systems 
Phalloidin CruzFluor™-594 IF 1:1000 sc-363795 Santa Cruz Biotechnology 
Peroxidase-AffiniPure Goat Anti-Rabbit IgG (H+L) WB 1:10000 111-035-003 Jackson ImmunoResearch Europe 
Peroxidase-AffiniPure Goat Anti-Mouse IgG (H+L) WB 1:10000 115-035-003 Jackson ImmunoResearch Europe 
Peroxidase-AffiniPure Rabbit Anti-Goat IgG (H+L) WB 1:10000 305-035-003 Jackson ImmunoResearch Europe 
Alexa Fluor 594 Antibody IF 1:1000 A-11012 ThermoFisher 
Alexa Fluor 488 Antibody IF 1:1000 ab150089 Abcam 
DAPI IF   Invitrogen 
Human GPR39 Control Antigen Peptide IC 1:5* GPR392-P Alpha Diagnostic International 
Human GPR39 Control Antigen Peptide WB 1:5 ab39283 Abcam 
Mouse/Rat/Human Obestatin Control Peptide IC 1:5* OBSN11-P Alpha Diagnostic International 
Table 3. Antibodies. Relation of the antibodies used in the different analyses performed in this work. Abbreviations: IC: immunocytochemistry; IEM: 
immunoelectron microscopy; IH: immunohistochemistry; WB: western blot; NA: neutralization assay; IF: immunofluorescence; PA: protein array. *10 nmol/mL. 




Human phospho-Receptor Tyrosine Kinase Array  
Coordinate Receptor family RTK/Control Coordinate Receptor family RTK/Control 
A1, A2 Reference Spots  D1, D2 Tie Tie2 
A23, A24 Reference Spots  D3, D4 NGFR TrkA 
B1, B2 EGFR EGFR D5, D6 NGFR TrkB 
B3, B4 EGFR ErbB2 D7, D8 NGFR TrkC 
B5, B6 EGFR ErbB3 D9, D10 VEGFR VEGFR1 
B7, B8 EGFR ErbB4 D11, D12 VEGFR VEGFR2 
B9, B10 FGFR FGFR1 D13, D14 VEGFR  VEGFR3 
B11, B12 FGFR FGFR2α D15, D16 MuSK MuSK 
B13, B14 FGFR FGFR3 D17, D18 EphR EphA1 
B15, B16 FGFR FGFR4 D19, D20 EphR EphA2 
B17, B18 Insulin R Insulin R D21, D22 EphR EphA3 
B19, B20 Insulin R IGF1R D23, D24 EphR EphA4 
B21, B22 Axl Axl E1, E2 EphR EphA6 
B23, B24 Axl Dtk E3, E4 EphR EphA7 
C1, C2 Axl Mer E5, E6 EphR EphB1 
C3, C4 HGFR HGFR E7, E8 EphR EphB2 
C5, C6 HGFR MSPR E9, D10 EphR EphB4 
C7, C8 PDGFR PDGFRα E11, E12 EphR EphB6 
C9, C10 PDGFR PDGFRβ E13, E14 Insulin R ALK 
C11, C12 PDGFR SCFR E15, E16  DDR1 
C13, C14 PDGFR Flt-3 E17, E18  DDR2 
C15, C16 PDGFR M-CSFR E19, E20 EphR EphA5 
C17, C18 RET c-Ret E21, E22 EphR EphA10 
C19, C20 ROR ROR1 F1, F2 Reference Spots  
C21, C22 ROR ROR2 F5, F6 EphR EphB3 
C23, C24 Tie Tie1 F7, F8  RYK 
   F23, F24 Control (-) PBS 
Table 4. RTKs. Human phospho-receptor tyrosine kinase (RTKs)  included in the array and the correspondent coordinates. R&D Systems 
(Minneapolis, MN, US). 
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A1,A2 Reference spots  RS C5, C6 Kallikrein 7 Proform & Active KLK7, SCCE, PRSS6, 
hK7 
A3,A4 ADAM8 Ectodomain MS2, CD156a C7, C8 Kallikrein 10 Proform & Active KLK10, NES1, 
PRSSL1 
A5,A6 ADAM9 Ectodomain MDC9, meltrin g C9,C10 Kallikrein 11 Proform & Active KLK11, TLSP, 
PRSS20 
A7, A8 ADAMTS1 Proform METH1 C11,C12 Kallikrein 13 Proform & Active KLK13, KLKL4 
A9, A10 ADAMTS13 Active von Willebrand factor-
cleaving protease 
C13,C14 MMP1 Proform & Active Collagenase 1, 
Interstitial 
Collagenase 
A11, A12 Cathepsin A Proform & Active CTSA, Lysosomal 
Carboxypeptidase A 
C15,C16 MMP2 Proform & Active Gelatinase A 
A13, A14 Cathepsin B Proform CTSB, APPS, CPSB C17,C18 MMP3 Proform & Active Stromelysin-1 
A15, A16 Cathepsin C Proform & Active CTSC D3,D4 MMP7 Proform & Active Matrilysin, PUMP1 
A17, A18 Cathepsin D Proform & Active CTSD, CPSD D5,D6 MMP8 Proform & Active Collagenase 2, 
Neutrophil 
Collagenase 
A19, A20 Reference Spots  RS D7, D8 MMP9 Proform & Active Gelatinase B, 
CLG4B, GELB 
B3, B4 Cathepsin E Proform & Active CTSE, CATE D9, D10 MMP12 Proform & Active Macrophague 
Elastase 
B5, B6 Cathepsin L Proform & Active CTSL, CATL, MEP, 
Cathepsin L1 
D11, D12 MMP13 Proform Collagenase 3 
B7, B8 Cathepsin S Proform & Active CTSS D13, D14 Neprilysin/CD10 Ectodomain MME, NEP, CALLA 
B9, B10 Cathepsin V Proform & Active CTSV, CTSL2, CTSU, 
Cathepsin L2 
D15,D16 Presenilin-1 N-terminal 
fragment 
PSEN1, AD3, PS-1 
B11, B12 Cathepsin X/Z/P Proform & Active CTSX, CTSZ D17,D18 Proprotein 
Convertase 9 
Active PC9, NARC1 
B13, B14 DPPIV/CD26 Ectodomain ADABP, ADCP2 E1, E2 Reference spots  RS 
B15, B16 Kallikrein 3/PSA Proform & Active KLK3, hK3, KLK2A1 E3, E4 Proteinase 3 Active PRTN3, 
Myeloblastin 
B17, B18 Kallikrein 5 Proform & Active KLK4, SCTE, KLKL2 E5, E6 uPA/Urokinase Proform & Active Urokinase-type 
Plasminogen 
Activator, PLAU 
C3, C4 Kallikrein 6 Proform & Active KLK6 E7,E8 Negative Control  Control (-) 
Table 5. Proteases. Human proteases included in the array and the correspondent coordinates. R&D Systems (Minneapolis, MN, US).
  





NMR spectroscopy in SDS micelles. Samples for the 
NMR experiments were prepared by dissolving 
peptides in 500 μL of a perdeuterated SDS (SDS-d25) 
aqueous solution [9:1 H2O:deuterated water (D2O), 
phosphate buffer saline (PBS) at pH 6.5] to make a 
final concentration of approximately 0.8-1.0 mM and 
a peptide/SDS ratio of approximately 1/70. The NMR 
spectra were recorded at 298 K using Bruker 600 and 
700 MHz spectrometers equipped with a triple-
resonance Z gradient probe and processed using 
XWIN-NMR software (Bruker Inc.; Billerica, MA, US). 
The resonance of 2,2,3,3-tetradeutero-3-
trimethylsilylpropionic acid (TSP) was used as a 
chemical shift reference in the 1H NMR experiments (δ 
TSP=0 ppm). The one-dimensional (1D) 1H 
homonuclear spectra were recorded in the Fourier 
mode using quadrature detection. The two-
dimensional (2D) 1H homonuclear total correlation 
spectroscopy (TOCSY) and nuclear Overhauser effect 
(NOE) spectroscopy (NOESY) spectra were collected in 
the phase-sensitive mode using time-proportional 
phase increments in t1. For each of these experiments, 
512 t1 increments were used. The free induction 
decay in t2 consisted of 2048 data points over a 
spectral width of 6009.615 Hz. In general, 4096x1024 
data points were collected for each block, and 96 
transients were collected for the 2D experiments. The 
TOCSY spectra were recorded using the MLEV-17 
pulse sequence with mixing times (spin-lock) of 60-80 
ms. The NOESY experiments were acquired with 
mixing times of 250-400 ms. The experimental data 
were acquired and processed using the TopSpin™ 
(Bruker Inc; Billerica, MA, US) program on a PC station. 
The data matrices were multiplied by a qsine function 
in both dimensions and then zero-filled to 1024 data 
points in F1 prior to the Fourier transformation. The 
peptide resonance assignments were obtained using 
standard strategies based on the 2D NMR 
experiments.  
NMR spectroscopy in living cells. NMR samples of the 
pure peptides were prepared by dissolving 400 μg of 
each peptide in 0.5 mL of water or of a mixture PBS 
buffer (pH 7.2):D2O (95:5, v/v). To perform the NMR 
experiments with living cells, 4 × 106 cells were 
counted, washed, and dissolved in PBS, pH 7.2. 
Samples were prepared by placing 400 μg of each 
peptide in 0.5 mL of a suspension of the cells in a 
mixture PBS (pH 7.2):D2O (95:5, v/v). Different 
samples of peptides were prepared as a suspension 
with the following cell lines: HEK293 and HEK293-
GPR39. The exact amount of receptors on the cell 
surface is unknown. NMR spectra were acquired on a 
Varian INOVA spectrometer operating at 750 MHz and 
processed with NMRPipe software using a standard 
inverse detection triple-resonance and triple-axis 
gradient probe. A soft-watergate solvent suppression 
scheme was used to suppress the H2O solvent signal in 
all the experiments. All the spectra were acquired with 
an external reference of TSP (0.0 ppm). 2D 1H TOCSY 
was acquired for each NMR sample. NMR samples 
were prepared as previously described for each 
peptide using 4 × 106 cells. For each sample, three 2D 
1H TOCSY experiments were acquired at different 
times after preparation to check sample stability. The 
1H NOESY and rotating-frame nuclear Overhauser 
effect spectroscopy (ROESY) experiments were 
acquired with mixing times of 250-400 ms.  The 
experiments were acquired at time 0, 7 and 24 h after 
sample preparation. Each spectrum was acquired in 
ca. 2.5 h with 24 scans and 128 complex points in the 
t1 dimension using the states phase sensitive mode. 
The spectra were processed with a 90° shifted sinebell 
apodization function and Fourier transformed to 2048 
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× 512 real points in dimensions F2 and F1, respectively. 
The peptide resonance assignments were obtained 
using standard strategies based on the 2D NMR 
experiments. 
Structure calculation. The peak lists for the NOESY and 
ROESY spectra recorded with a 0.25 s mixing time 
were generated by interactive peak picking using the 
CARA software.208 The NOESY cross-peak volumes 
were determined using the automated peak 
integration routine implemented in CARA. The three-
dimensional (3D) structures of human obestatin (1) 
and its derivatives were determined using the 
standard protocol of combined automated NOE 
assignment and the structure calculation 
implemented in the CYANA 2.1 program.209 Seven 
cycles of combined automated NOESY assignment and 
structure calculations were followed by a final 
structure calculation. The structure calculation started 
in each cycle from 100 randomized conformers, and 
the standard simulated annealing schedule was used. 
The 20 conformers with the lowest final CYANA target 
function values were retained for analysis and passed 
to the next cycle. Weak restraints on the φ/ψ torsion-
angle pairs and on the side-chain torsion angles 
between tetrahedral carbon atoms were applied 
temporarily during the high-temperature and cooling 
phases of the simulated annealing schedule to favour 
the permitted regions of the Ramachandran plot and 
the staggered rotamer positions, respectively. The list 
of upper-distance bonds for the final structural 
calculation consists of unambiguously assigned upper-
distance bonds and does not require the possible 
swapping of diastereotopic pairs. The 20 conformers 
                                                          
208 Keller RLJ.  The Computer Aided Resonance Assignment tutorial.2004. 
Goldau: CANTINA Verlag. Available: http://cara.nmr-software.org/portal/ 
209 Güntert P. Automated NMR structure calculation with CYANA. Methods 
Mol Biol. 2004;278:353-78. 
210 Case DA, Cheatham TE 3rd, Darden T, et al. The Amber biomolecular 
simulation programs. J Comput Chem. 2005;26:1668-88. 
with the lowest final CYANA target function values 
were subjected to restrained energy-minimization in a 
water shell using the AMBER 8.0 program.210 The 
resulting 20 energy-minimized CYANA conformers 
represent the solution structures of human obestatin 
(1) and its derivatives. The MOLMOL program was 
used to visualize the 3D structures.211 CYANA was used 
to obtain statistics on the target function values, 
restraint violations and Ramachandran plots 
according to the PROCHECK-NMR conventions.212 The 
root mean square deviation (RMSD) values were 
calculated using CYANA for the superpositions of the 
backbone N, Cα and C’ atoms and the heavy atoms 
throughout the protein. To obtain the RMSD value of 
a structure represented by a bundle of conformers, all 
of the conformers were superimposed on the average 
structure, and the average of the RMSD values 
between the individual conformers and their average 
coordinates was calculated.  
CD spectroscopy. CD experiments of the peptides 
were performed using a 720-Jasco spectropolarimeter 
(Tokyo, JP) and a 1-mm-path-length quartz cuvette. 
The CD spectra of the peptides in the SDS micellar 
solution were recorded using a H2O solution 
containing 40 μM peptide and SDS micelle at a 
concentration of 2.8 mM (25 °C). In all cases, 25 mM 
NaH2PO4/Na2HPO4 buffer was used to maintain the pH 
at 6.5. The CD spectra presented are the average of 5 
accumulations from 190 to 250 nm, which were 
recorded with a bandwidth of 1 nm and a scanning 
speed of 20 nm/min. During all of the measurements, 
the trace of the high-tension voltage remained less 
than 700 V, which should ensure the reliability of the 
211 Koradi R, Billeter M, Wüthrich K. MOLMOL: a program for display and 
analysis of macromolecular structures. J Mol Graph. 1996;14:51-4. 
212 Laskowski RA, Rullmannn JA, MacArthur MW, et al. AQUA and 
PROCHECK-NMR: programs for checking the quality of protein structures 
solved by NMR. J Biomol NMR. 1996;8:477-86. 
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obtained data.213 Baselines of either solvent or 
micellar solutions without peptide were subtracted 
from each respective sample to yield the contribution 
of the sample. The secondary structure composition 
was estimated using the DICHROWEB web 
server,214,215 with the following algorithms: CONTINLL, 
involving 2 different reference data sets, and K2d.216 
[32P]ORTOPHOSPHATE LABELLING AND GPR39 
IMMUNOPRECIPITATION 
HEK293 cells were transfected with the green 
fluorescent protein (GFP)-tagged human GPR39 and 
plated in 6-well plates at 200,000 cells/well 24 h 
before experimentation and serum starved overnight 
(O/N). For phosphorylation experiments, cells were 
washed three times with Krebs/hydroxyethyl 
piperazineethanesulfonic acid (HEPES) buffer without 
phosphate [containing in mM: 10 HEPES (pH 7.4), 118 
NaCl, 1.3 CaCl2, 4.3 KCl, 1.17 MgSO4, 4.17 NaHCO3, 
11.7 glucose] and incubated in this buffer containing 
100 μCi/mL [32P]orthophosphate for 1 h at 37 °C and 
5% CO2. Cells were then stimulated with obestatin 
(200 nM, 5 min) and immediately lysed by addition of 
lysis buffer [containing in mM: 20 Tris/HCl (pH 7.4), 
150 NaCl, and 3 ethylenediaminetetraacetic acid 
(EDTA); and supplemented with 1% (v/v) NP-40, and 
0.5% (w/v) sodium deoxycholate]. GPR39 was 
immunoprecipitated from the cleared lysates using 
GFP-trap (Chromotek, DE) following manufacturer’s 
instructions. The washed immunoprecipitates were 
separated on two 10% SDS/polyacrylamide gels. The 
first gel was dried, and radioactive bands were 
revealed using autoradiography film. The second gel 
was transferred to nitrocellulose membrane (Bio-Rad, 
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Hercules, CA, US) as loading control. The blots were 
incubated with 5% non-fat milk in a Tris buffer solution 
(TBS) containing Tween-20 (TBST) [20 mM Tris-HCl (pH 
8.0), 150 mM NaCl, 0.1% (v/v) Tween-20, solution 
used for all incubation and washing steps] for 1 h. The 
blots were then incubated with GFP and GPR39 
antibodies, according to the manufacturer's 
instructions, and were subsequently incubated with 
the corresponding peroxidase-conjugated IgG 
antibody. After washing, the signals were visualized 
using an ECL plus Western Blotting Detection System 
(Pierce ECL Western Blotting Substrate; Thermo Fisher 
Scientific, Pierce, Rockford, IL). Blots shown are 
representative of three experiments. The image 
processing was performed using the NIH Image 
Sofware ImageJ 1.49 (National Institutes of Health, 
Bethesda, MD, US). 
GPR39 INTERNALIZATION  
For analysis of the endocytosis time course, HEK293 
cells on poly-D-lysine-coated coverslips were 
transfected with the GFP-tagged human GPR39. The 
cells were grown O/N in a humidified atmosphere of 
95% air and 5% CO2 at 37 °C. The cells were 
preincubated for 120 min at 37 °C with 90 μM 
cycloheximide in all experiments to prevent de novo 
protein synthesis. The cells were preincubated for 30 
min at 4 °C in ice-cold Earle’s buffer [containing in mM: 
140 NaCl, 5 KCl, 1.8 CaCl2, and 3.6 MgCl2 (pH 7.4); and, 
complemented with 0.2% bovine serum albumin 
(BSA), 0.01% glucose, 90 μM cycloheximide, and 0.8 
mM 1-10 phenanthrolene] in the presence/absence of 
obestatin (200 nM). Internalization was promoted by 
placing the cells at 37 °C for the indicated times. The 
215 Whitmore L, Wallace BA. Protein secondary structure analyses from 
circular dichroism spectroscopy: methods and reference databases. 
Biopolymers. 2008;89:392-400. 
216 Greenfield NJ. Using circular dichroism spectra to estimate protein 
secondary structure. Nat Protoc. 2006;1:2876-90. 
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cells were then rinsed three times with ice-cold Earle’s 
buffer and subsequently fixed for 10 min with 4% 
paraformaldehyde (PFA) dissolved in 0.1 mM PBS (pH 
7.4). The cells were rinsed again in cold Earle’s buffer, 
mounted using Vectashield (Vector Laboratories, 
Compiègne, France). DAPI was used to counterstain 
the cell nuclei. Digital images of cell cultures were 
acquired with a Leica TCS-SP5 spectral confocal 
microscope (Leica Microsystems; Heidelberg, DE). 
IMMUNOBLOT ANALYSIS 
Immunoblot analysis in cells. Serum-starved cells 
were stimulated with obestatin and/or truncates for 
the indicated time period and doses at 37 °C. The 
medium was then aspirated, and cells were lysed in 
ice-cold lysis buffer [RIPA buffer: 50 mM Tris-HCl pH 
7.2, 150 mM NaCl, 1 mM EDTA, 1% (v/v) NP-40, 0.25% 
(w/v) Na-deoxycholate, protease inhibitor cocktail 
(1:100, Sigma Chemical Co., St. Luis, MO, US), 
phosphatase inhibitor cocktail (1:100, Sigma Chemical 
Co., St. Luis, MO, US)]. The soluble cell lysates were 
pre-cleared by centrifuging at 14,000 rpm for 15 min. 
The protein concentration was evaluated with the 
QuantiPro™ BCA Assay kit (Sigma Chemical Co., St. 
Luis, MO, US). The same amount of protein for each 
sample was separated on 10% SDS/polyacrylamide 
gels and transferred to nitrocellulose membranes 
(Bio-Rad, Hercules, CA, US). The blots were then  
incubated with the corresponding antibodies and 
processed as described above. The blots shown are 
representative of six experiments. The image 
processing was performed using the NIH Image 
Sofware ImageJ 1.49 (National Institutes of Health, 
Bethesda, MD, US). 
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Inmunoblot analysis in human tissue samples. For 
each extraction, six series of 15 µm sections from fixed 
in formalin and embedded in paraffin (FFPE) samples, 
with an area of approximately 150 mm2, were 
collected in an Eppendorf tube. Samples were 
deparaffinised using 600 µL of mineral oil (Sigma-
Aldrich, US). After vortexing, samples were incubated 
to dissolve the wax (95 ˚C, 2 min), and finally the 
supernatants were removed after pelleting at 14,000 
xg [room temperature, (RT); 3 min]. These incubation 
and centrifugation steps were repeated again by 
adding 350 µL of mineral oil. The pellets were 
resuspended in 200 µL of lysis buffer (200 mM TrisHCl 
pH 7.5, 200 mM NaCl, 5% SDS, and 100 mM sodium 
citrate) and were incubated with this buffer for 20 
minutes at 100°C and then for 2 h at 80°C, both with 
shaking.217 After centrifugation at 14,000 xg for 5 min 
at RT, supernatants were recovered and the protein 
was quantified with the QuantiProTM BCA Assay kit 
(Sigma Chemical Co., St. Luis, MO, USA). The same 
amount of protein for each sample was separated on 
10% SDS/polyacrylamide gels and transferred to 
nitrocellulose membranes (Bio-Rad, Hercules, CA, US). 
The blots were then incubated with the corresponding 
antibodies and processed as described above. The 
image processing was performed using the NIH Image 
Sofware ImageJ 1.49 (National Institutes of Health, 
Bethesda, MD, US). 
CELL PROLIFERATION ASSAYS 
For the adherent cell lines the cell proliferation was 
measured using a bromodeoxiuridine (BrdU) cell 
proliferation enzyme-linked immunosorbent assay 
(ELISA) kit (Roche Diagnostics, Mannheim, DE). The 
BrdU assay was performed according to the 
manufacturer's protocol. Cells were cultured in a 96-
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well multiplate at a density of 2-5 x 103 cells per well 
in the culture medium described above for 24 h. The 
procedure comprised the following steps: 1) 0% FBS 
for 24 h; 2) stimulation with obestatin and/or 
truncates for the indicated time period and doses; 3) 
incubation with BrdU-labeling solution (10 μL, 3 h, 37 
°C); 4) removal of labeling solution and fixing with 
FixDenat solution (200 μL, 30 min, 25 °C); 5) incubation 
with anti-BrdU-peroxidase (POD) antibody solution 
(100 μL, 90 min, 25 °C); and, 6) washing followed by 
the addition of substrate solution (100 μL, 30 min). 
The BrdU incorporation was quantified using the 
spectrophotometric absorbance (370 nm) measured 
with a VersaMaxPLUS Reader (Molecular Devices, 
Sunnyvale, CA, US). The mean absorbance of the 
control cells represented 100% cell proliferation, and 
the mean absorbance of the treated cells was related 
to the control values to determine sensitivity. In all 
cases, each experiment point was replicated eight 
times. For the non-adherent cell line KATO III, a Trypan 
Blue protocol was used for viable cell counting. To 
ensure the reliability of the experimental procedure, 
the adherent HT-29 cell line was also subjected to the 
same protocol. In brief, the cells were cultured in a 96-
well multiplate at a density of 5 x 103 cells per well in 
the serum-free medium described in Table 2 for 24 h. 
The cells were then treated with 100 nM human 
obestatin, 10% FBS (positive control), 40 µM ZnCl2, 
and 100 nM obestatin plus 40 µM ZnCl2 for 48 h. For 
cell counting, a cell suspension in PBS was prepared. 
Sequentially, 0.5 mL of 0.4% Trypan Blue solution 
(w/v), 0.3 mL PBS and 0.2 mL of the cell suspension 
were added to a test tube, mixed thoroughly, and 
allowed to stand for 5-15 min. A hemacytometer was 
used to count viable cells as non-viable cells stained 
blue. Total cells were calculated using the following 
equations: Cells per mL = the average count per square 
× dilution factor × 104 (count 10 squares). Total Cells = 
cells per ml × the original volume of fluid from which 
cell sample was removed. Cell Viability (%) = total 
viable cells (unstained) ÷ total cells (stained and 
unstained) × 100. In all cases, each experiment point 
was replicated eight times. 
SMALL INTERFERING RNA ASSAYS 
siRNA silencing of gene expression in ARPE-19, AGS 
and PANC-1 cells. The following double-stranded 
siRNA duplexes of GPR39 were used (Thermo Fisher 
Scientific, Dharmacon, Lafayette, CO, US; ON-




AACCAGAUUCGGAGGAUCA-5’. A non-silencing RNA 
duplex was used as a control for all siRNA 
experiments. The cells were transfected using 
Lipofectamine 2000 (Invitrogen; CA, US). Silencing was 
quantified by immunoblotting. Only experiments with 
verified silencing were used.  
IMMUNOCYTOCHEMISTRY AND 
IMMUNOHISTOCHEMISTRY 
Immunocytochemistry detection of GPR39, obestatin 
and Ki67 in cells. Cells were cultured at a density of 4-
8 x 103 cells per well in the culture medium described 
above on 8-well Lab-Tek II chamber slides covered 
with cell conditioning solution 2 (CC2) glass slide 
coverslips. After 2 days, the medium was renewed, 
and the cells were cultured in a serum-free medium 
(300 μL) for 24 h. The cells were then treated with 
obestatin and/or its truncates for the indicated time 
period and doses. After indicated time, the intact cells 
were fixed in 96% ethanol for 1 h. The 
immunocytochemical technique was automatically 
performed using an AutostainerLink 48 instrument 
(Dako Agilent Technologies, Glostrup, DK). 
Correspondent primary antibodies was used. 
EnVision™ peroxidase FLEX/HRP (Dako Agilent 
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Technologies, Glostrup, DK) was employed as a 
detection system. Briefly, the procedure comprised 
the following steps: 1) epitope retrieval in 10 mM 
citrate buffer (pH 6.0) using a microwave (750 W, 10 
min); 2) incubation with peroxidase-blocking agent (5 
min); 3) incubation with primary antibody (30 min); 4) 
incubation with labeled polymer-horseradish 
peroxidase (HRP, dextran polymer conjugated with 
HRP and affinity-isolated immunoglobulins); 30 min); 
5) incubation with 3,3’-diaminobenzidine (DAB)-
tetrahydrochloride (Dako Liquid DAB + Substrate-
chromogen system)  (10 min); and 6) counterstaining 
with Harris hematoxylin solution (HHS) (9 min). In all 
cases, triplicate dishes were used for each 
experimental point. The preadsorption control for 
obestatin and GPR39 was performed applying the 
primary antibody plus obestatin or the GPR39 control 
peptide to positive samples. 
Immunocytochemistry detection of Ki67 in GPR39-
siRNA depleted AGS cells. The AGS cells were cultured 
at a density of 8 x 103 cells per well in the culture 
medium described above on 8-well Nunc® Lab-Tek® II 
chamber slides covered with CC2 glass slide coverslips. 
After 2 days, the medium was renewed, and the cells 
were cultured in a serum-free medium (300 μL) for 24 
h. The AGS cells were transfected using Lipofectamine 
2000 (Invitrogen; CA, US). Serum-starved cells were 
stimulated or not with obestatin (100 nM, 24 h) at 37 
°C. After 24 h, the intact cells were fixed in 96% 
ethanol for 1h. The immunocytochemical technique 
was performed as described above. In all cases, 
triplicate dishes were used for each experimental 
point. 
Immunoelectron microscopy of GPR39 and obestatin 
in AGS cells. For the immunoelectron microscopic 
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techniques, AGS cells were fixed (2-4 h) in a solution 
of 2% PFA and 0.2% glutaraldehyde in 0.1 M PBS (pH 
7.4). After washing with PBS, the specimens were 
dehydrated in graded ethanol series and embedded in 
LR White (The London Resin Co, Basingstoke, UK). 
Polymerization was done at 60°C for 18 h, avoiding 
contact between resin and oxygen. Ultrathin sections 
(60 nm thick) were collected on uncoated 700-mesh 
nickel grids. Labeling procedures were performed at 
RT. The procedure comprised the following steps: 1) 
0.5% ovalbumin (v/v) and 0.05% Tween 20 (v/v) in PBS 
(Solution A; 2x5 min); 2) anti-GPR39 or anti-obestatin 
antibody in the same buffer as used in step 1 (O/N, 
RT); 3) solution A (1x10 min); 4) 0.5% ovalbumin (v/v) 
and 0.05% Tween 20 (v/v) in TBS (0.02 M Tris-HCl, 0.65 
M NaCl) (Solution B; 2 x 10 min); 5) goat anti-rabbit 
labeled with 10 nm (GPR39) or 20 nm (obestatin) 
colloidal gold (BBInternational, Cardiff, UK), both 
diluted at 1:20 in solution B (1x1 h); 6) standard saline 
citrate (SSC; SSC: 0.15 M NaCl, 0.015 M sodium citrate, 
pH 7.0; 1x5 min); 7) distilled water (1x5 min); 8) 2% 
neutral uranyl acetate (1x2 min); and 9) distilled water 
(2x5 min). Controls were performed by replacing the 
primary antibody by either normal rabbit serum or 
PBS, or by omitting any essential step of the 
reaction.218 All ultrathin sections were observed and 
photographed using a JEM-1011 electron microscope 
(JEOL, JAPAN) equipped with a slow-scan digital 
camera at an accelerating voltage of 80 kV. 
Immunohistochemistry detection of GPR39, 
obestatin, Ki67 and pepsinogen I in human gastric 
mucosa samples. Immunohistochemistry was 
performed according to the protocol used by Raghay 
et al.219 In brief, the samples were immersion-fixed in 
10% buffered formalin for 24 h, dehydrated and 
219 Raghay K, Garcia-Caballero T, Bravo S, et al. Ghrelin localization in the 
medulla of rat and human adrenal gland and in pheochromocytomas. 
Histol Histopathol. 2008;23:57-65. 
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embedded in paraffin by a standard procedure. The 5 
μm-thick sections were mounted on Histobond 
adhesion microslides (Marienfeld, Lauda-Königshofen, 
DE), dewaxed and rehydrated. Antigen retrieval was 
carried out by heating in a microwave oven for 20 min 
at 750 W in 10 mM sodium citrate buffer (pH 6.0). For 
detection of obestatin, GPR39 and pepsinogen I (PGI) 
the corresponding antibodies were used. Detection of 
Ki67 was performed using the same technique as 
described for immunocytochemistry. All sections were 
counterstained with HHS for 1 min. Pre-adsorption 
controls of the obestatin and GPR39 
immunohistochemical technique were performed in 
gastric tissue. Negative controls (n=3) were performed 
by substituting the primary antibody with PBS or pre-
adsorption of the antibody with the homologous 
antigen. Ten different fields for each section were 
analyzed twice. A scale from 0 to 3+ was used to 
express the incidence of positive immunoreaction in a 
semi-quantitative assay. Photographs were taken 
using a Zeiss Observer Z1 microscope and the 
Axiovision software (Carl Zeiss, Göttingen, GE). Two 
different observers performed evaluation 
independently.  
IMMUNOFLUORESCENCE ANALYSIS 
Immunofluorescence detection of F-actin in AGS, 
PANC-1, A431 and KATO III cells. Cells were cultured 
at a density of 8-10 x 103 cells per well in the culture 
mediums described above on 8-well Nunc® Lab-Tek® II 
chamber slides covered with CC2 glass slide coverslips. 
After 2 days, the medium was renewed, and the cells 
were cultured in a serum-free medium (300 μL) for 24 
h. Serum-starved cells were stimulated or not with 
obestatin (200 nM, 24 h) at 37 °C. After 24 h, intact 
cells were fixed with 4% buffered PFA-PBS for 30 min, 
washed, permeabilized with 0,25% Triton X-100 in PBS 
for 45 min, and blocked with PBS containing Tween-20 
(PBST, 1% Triton X-100, 1% Tween 20, 5% heat-
inactivated normal goat serum, 1% BSA in PBS) for 30 
min. After three washes with PBS, cells were 
incubated with Phalloidin CruzFluor 594 in 1% BSA in 
PBST (1:1000) for 1 hour at RT. DAPI was used to 
counterstain the cell nuclei. Digital images of cells 
were acquired with a Zeiss Axio Vert.A1 fluoresecence 
microscope (Carl Zeiss AG, Oberkochen, Germany). 
Immunofluorescence detection of F-actin in GPR39-
siRNA depleted AGS and PANC-1 cells.  Cells were 
cultured at a density of 10 x 103 cells per well in the 
culture medium described above on 8-well Nunc® Lab-
Tek® II chamber slides covered with CC2 glass slide 
coverslips. After 2 days, the medium was renewed, 
and the cells were cultured in a serum-free medium 
(300 μL) for 24 h. Cells were transfected using 
Lipofectamine 2000 (Invitrogen; CA, US). Serum-
starved cells were stimulated or not with obestatin 
(200 nM, 24 h) at 37 °C. After 24 h, intact cells were 
fixed with 4% buffered PFA-PBS for 30 min, washed, 
permeabilized with 0,25% Triton X-100 in PBS for 45 
min, and blocked with PBST for 30 min and then 
incubated with anti-GPR39 rabbit antibody diluted in 
1% BSA in PBST (1:500) for 1 hour at RT. After three 
washes with PBS, cells were incubated with the 
secondary antibody (Alexa 488 anti-rabbit antibody) 
and Phalloidin CruzFluor 594 in 1% BSA in PBST 
(1:1000) for 1 hour at RT. DAPI was used to 
counterstain the cell nuclei. Digital images of cells 
were acquired with a Zeiss Axio Vert.A1 fluorescence 
microscope (Carl Zeiss AG, Oberkochen, Germany). 
PLASMID CELL TRANSIENT TRANSFECTION IN HEK293 
AND A431 CELLS 
The cDNA encoding GPR39 fused at its C terminus to 
GFP in p-CMV6-AC plasmid (Origene, Rockville, MD, 
US) was transfected into subconfluent HEK293 and 
A431 cells using Lipofectamine 2000 (Life 
Technologies, Invitrogen; Gran Island, NY, US), 
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according to the manufacturer’s instructions. Cells 
were transiently transfected.  Cell lines expressing the 
GPR39-GFP were cultured as described above. The 
GPR39 incorporation was confirmed by GFP 
visualization in transfected cells before and after 
treatment with a Zeiss Axio Vert.A1 fluorescence 
microscope (Carl Zeiss AG, Oberkochen, Germany). 
ARRAY PROTEIN ASSAYS 
Human Phospho-RTK Array and analysis 
To analyze the activation profiles of RTKs the 
Proteome Profiler™ Human Phospho-RTK Array Kit 
(R&D Systems, Minneapolis, MN, USA) was used 
according to the manufacturer’s instructions. This 
method allows simultaneous detection of the relative 
tyrosine phosphorylation levels of 49 different 
phospho-RTKs. Each array contained duplicate 
validated control and capture antibodies for specific 
RTKs. Serum-starved cells were stimulated with 
obestatin 200 nM for the indicated time period at 
37 °C. The medium was then aspirated, and cells were 
lysed in ice-cold array lysis buffer with protease 
inhibitor cocktail and phosphatase inhibitor cocktail 
(1:100, Sigma Chemical Co., St. Louis, MO, US). After 
30 min in ice-cold, samples were centrifuged at 14,000 
xg for 5 min at 4 °C and the supernatant was 
transferred into a clean tube. FFPE samples, were 
deparaffinised using 600 µL of mineral oil (Sigma-
Aldrich, US). After vortexing, samples were incubated 
to dissolve the wax (95 ˚C, 2 min), and finally the 
supernatants were removed after pelleting at 14,000 
xg (RT; 3 min). These incubation and centrifugation 
steps were repeated again by adding 350 µL of mineral 
oil. The pellets were resuspended in 200 µL of lysis 
buffer (200 mM TrisHCl pH 7.5, 200 mM NaCl, 5% SDS, 
and 100 mM sodium citrate) and were incubated with 
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induces human corpus cavernosum relaxation by inhibiting receptor 
this buffer for 20 minutes at 100 °C and then for 2 h at 
80 °C, both with shaking.  After centrifugation at 
14,000 xg for 5 min at RT, supernatants were 
recovered. Total protein concentration was quantified 
using the QuantiPro™ BCA Assay kit (Sigma Chemical 
Co., St. Luis, MO, US).  The membranes were incubated 
with 200 or 300 µg of protein. Briefly, phospho-RTK 
array membranes were blocked with Block Buffer (1 h) 
and incubated O/N with 1.5 mL of cell and tissue lysate 
after normalization for equal amounts of protein. 
After extensive washing with Wash Buffer the 
membranes were incubated with Anti–Phospho-
Tyrosine-HRP detection antibody (RT, 2h). The 
unbound HRP antibody was washed with Wash Buffer. 
Each array was then incubated with Chemi Reagent 
Mix, and exposed to X-ray film (1-10 min). Dot blot 
densitometric analysis of the immunoblots was 
performed in duplicate, using NIH ImageJ software 
1.49 (National Institutes of Health, Bethesda, MD, US). 
The relative phosphorylation profiles in 2 groups were 
normalized by using mean of positive control spots 
that are located in all 4 corners of the array. Fold 
changes were calculated by dividing untreated 
phosphorylation profile to treated profile 
accordingly.220 
Human Protease Array and analysis  
To analyze the expression profiles of protease proteins 
we used the Proteome Profiler™ Human Antibody 
Array Kit (R&D Systems, Minneapolis, MN, USA), 
according to the manufacturer’s instructions. This 
method allows for simultaneous detection of the 
relative expression levels of 34 different proteases. 
Each array contained duplicate validated control and 
capture antibodies for specific proteases. Serum-
starved cells were stimulated with obestatin 200 nM 
tyrosine kinases (RTKs): identification of new RTK targets. Urology. 
2013;82:745. 
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for the indicated time period at 37 °C. For the 
metalloproteases experiments, it was necessary to 
obtain the cellular secretome. The stimulation 
medium was recollected and filtered with a 3 kDa filter 
(Merck Millipore, Billerica, MA, US). Cells were lysed in 
ice-cold array lysis buffer with protease inhibitor 
cocktail and phosphatase inhibitor cocktail (1:100, 
Sigma Chemical Co., St. Louis, MO, US). After 30 min in 
ice-cold, samples were centrifuged at 14,000 xg for 5 
min at 4 °C and the supernatant was transferred into 
a clean tube. FFPE samples were processed as 
described above. Total protein concentration was 
quantified using the QuantiPro™ BCA Assay kit (Sigma 
Chemical Co., St. Luis, MO, US). The membranes were 
incubated with 200 or 300 µg of protein. Briefly, 
protease array membranes were blocked with Block 
Buffer for 1 hour. Supernatants and lysates of treated 
and untreated cells were centrifuged and mixed with 
15 µl of Detection Antibody Cocktail for 1 h at RT. 
Then, the membranes were incubated with the 
sample/antibody mixtures O/N at 4 °C on a rocking 
platform. Following a washing step to remove 
unbound material, membranes were incubated with 
Streptavidin-HRP reagent for 30 minutes.  The 
unbound Streptavidin-HRP reagent was washed with 
Wash Buffer. Each array was then incubated with 
Chemi Reagent Mix, and exposed to X-ray film for 1-
10 minutes. Dot blot densitometric analysis of the 
immunoblots was performed in duplicate, using NIH 
ImageJ software 1.49 (National Institutes of Health, 
Bethesda, MD, US). The relative expression profiles in 
2 groups were normalized by using mean of positive 
control spots that are located in all 4 corners of the 
array. Fold changes were calculated by dividing 
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untreated expression profile to treated profile 
accordingly.221 
MIGRATION AND INVASION ASSAYS 
Wound healing assay (migration assay). AGS cells 
were seeded on 6-well plates, grown to 100% 
confluence and then wounded with a sterile pipette 
tip to remove cells by linear scratches. The cells were 
washed and maintained in culture medium or culture 
medium with 200 nM obestatin. The progress of 
migration was photographed immediately after injury 
and at 24 h after wounding, near the crossing point. 
The wound was calculated by tracing along the border 
of the scratch using the ImageJ64 analysis software 
and using the following equation: %wound 
closure=[[wound area (0 h)-wound area (x h)]/ wound 
area (0 h)] x 100.72 
Cell-inverted invasion assay. Gastric adenocarcinoma 
AGS cells were cultured as described above. The 
invasion assay was conducted as previously 
described.222 Obestatin (200 nM) was used as 
chemoattractant. Cells were allowed to migrate and 
invade into growth factor-reduced Matrigel for 24 h, 
pretreated with 50 μM cytarabine (to avoid 
proliferation), stained with 4 μmol/L calcein-
acetoxymethyl ester (Invitrogen), and visualized by 
confocal microscopy (Leica TCS SP2 confocal 
microscope) using a ×10 objective. Optical sections 
were scanned at 5 μm intervals moving up from the 
underside of the membrane into the Matrigel. The 
fluorescence from each optical section was quantified 
with LCS Lite software (Leica Microsystems, 
Heidelberg, DE). 
 
222 Muinelo-Romay L, Colas E, Barbazan J, et al. High-risk endometrial 
carcinoma profiling identifies TGF-β1 as a key factor in the initiation of 
tumor invasion. Mol Cancer Ther. 2011;10:1357-66.  
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PEPSINOGEN SECRETION ASSAYS  
Haemoglobin-substrate pepsinogen secretion. 
Pepsinogen secretion was measured by the 
conversion of pepsinogen to pepsin using 
haemoglobin as a substrate as was described by 
Hersey et al.223 In brief, serum-starved cells were 
stimulated with obestatin 200 nM for 30, 40, 50 and 
60 minutes at 37 °C. The stimulated secreted medium 
was recollected, filtered with a 30 kDa filter (Merck 
Millipore, Billerica, MA, US) and concentrated by 
centrifugation. This concentrated solution was then 
mixed with haemoglobin solution and incubated for 
50 min at 37°C. 10%  trichloroacetic acid (TCA) was 
added to stop the reaction. After spinning to pellet 
proteins, the resulting supernatant was incubated 
with  0.5 M NaOH and quantified using the 
QuantiPro™ BCA Assay kit (Sigma Chemical Co., St. 
Luis, MO, US). The absorbance was measured at 280 
nm by use of DU730 Life Science UV/Vis 
spectrophotometer (Beckman Coulter, Indianapolis, 
IN, US) and the concentration of pepsinogen in each 
sample was calculated from a pepsin standard curve. 
Pepsinogen secretion by immunoblot analysis. 
Serum-starved cells were stimulated with obestatin 
(200nM) for 40 minutes at 37 °C. The secreted 
medium was collected and incubated with 20% TCA 
for 2 hours at 4 °C. Medium was then centrifuged 
(14,000 rpm, 10 min) and washed twice with ice-cold 
acetone (14,000 rpm, 5 min).224 Once the pellet is 
collected, precipitated secretome protein was diluted 
in blue loading sample buffer [62.5 mM Tris-HCl, 2% 
SDS, 25% glycerol, 50 mM dithiothreitol (DTT) and 
0,01% bromophenol blue]. Each sample was 
separated on 10% SDS/polyacrylamide gels and 
                                                          
223 Hersey SJ, Tang L, Pohl J, et al. Pepsinogen secretion in vitro. Methods 
Enzymol. 1990;192:124-39. 
transferred to nitrocellulose membranes (Bio-Rad, 
Hercules, CA, US). Before blocking, blots were stained 
with Ponceau S [1% (v/v) acetic acid] for 5 min and 
scanned as loading control.  Blots were then incubated 
with 5% non-fat milk in TBST (solution used for all 
incubation and washing steps) for 1 h. After blocking, 
blots were incubated with pepsinogen I antibody, 
according to the manufacturer's instructions, and 
were subsequently incubated with the corresponding 
peroxidase-conjugated IgG antibody. After washing, 
the signals were visualized using an ECL plus Western 
Blotting Detection System (Pierce ECL Western 
Blotting Substrate; Thermo Fisher Scientific, Pierce, 
Rockford, IL). The blots shown are representative of 
three experiments. The image processing was 
performed using the NIH Image Sofware ImageJ 1.49. 
Cell lysates were treated as described above in 
immunoblot analysis in cells.  
DATA ANALYSIS 
Data analysis. All of the data are reported as the 
mean±SEM. A Shapiro-Wilk normality test was 
performed for each data set. T-tests were carried out 
for comparisons between two samples. Unpaired t-
test was used to assess the statistical significance of 
one-way or two-way analysis when the test statistic 
followed a normal distribution. Mann-Whitney test 
was employed to assess the statistical significance of 
one-way or two-way analysis when the test statistic 
did not follow a normal distribution. For multiple 
comparisons, a statistical ANOVA analysis was 
performed using an analysis of variance with the 
Bonferroni post hoc test. Values of P<0.05 were 
considered to be statistically significant and are 
marked with an asterisk (*) or a dagger (#). Asterisk 
224 Méchin V, Damerval C, Zivy M. Total Protein Extraction with TCA-
Acetone. Methods Mol Biol. 2007;355:1-8.  
 
Materials and Methods 
 
79 
(**, ***) denotes P<0.01 and P<0.001, respectively. 
The strength of the relationship between the different 
parameters for GPR39 expression quantization was 
estimated by a Pearson correlation coefficient after a 
Shapiro-Wilk normallity test. 
Scoring systems of gastric adenocarcinomas. For 
assessment of the patterns of expression of GPR39 in 
gastric adenocarcinomas, staining intensity was 
scored as 0 (absent), 1 (weak), 2 (moderate), or 3 
(strong) by three independent observers. For 
assessment of cell proliferation in tumour tissue, 
percentage of Ki67 positivity was obtained by ACIS® 
Assisted Quantitative Image Analysis (Dako Agilent 












































CHAPTER 1: THE NMR STRUCTURE OF HUMAN OBESTATIN IN MEMBRANE-LIKE 
ENVIRONMENTS. STRUCTURE-BIOACTIVITY RELATIONSHIP OF OBESTATIN 
The quest for therapeutic applications of obestatin 
involves, as a first step, the determination of its 3D 
solution structure and the relationship between this 
structure and the biological activity of obestatin. On 
this basis, we have employed a combination of circular 
dichroism, nuclear magnetic resonance spectroscopy, 
and modelling techniques to determine the solution 
structure of human obestatin (1). Other analogues, 
including human non-amidated obestatin (2), the 
fragment peptides (6-23)-obestatin (3), (11-23)-
obestatin (4), and (16-23)-obestatin (5); and mouse 
obestatin (6) have also been scrutinized. These studies 
have been performed in a micellar environment to 
mimic the cell membrane (SDS micelles). Furthermore, 
structural-activity relationship studies have been 
performed by assessing the in vitro proliferative 
capabilities of these peptides in the human retinal 
pigmented epithelial cell line ARPE-19 (ERK1/2 and Akt 
phosphorylation, Ki67 expression, and cellular 
proliferation).225 
CIRCULAR DICHROISM 
Circular dichroism is a suitable and rapid approach to 
provide information about the secondary structural 
features of peptides such as obestatin in solution.216 
First, the influence of SDS micelles on the secondary 
structure of the different peptides was studied. A 
preliminary scanning of the conformational 
preferences of the peptides was performed in 25 mM 
PBS and in an SDS micelle solution. SDS was adopted 
based on the works of Schwyzer, who hypothesized 
                                                          
225 Alén BO, Nieto L, Gurriarán-Rodríguez U, et al. The NMR structure of 
human obestatin in membrane-like environments: insights into the 
structure-bioactivity relationship of obestatin. PLoS One. 2012;7:e45434.  
that previous contact with the membrane is essential 
for the peptide to adopt the proper conformation to 
further interact with its receptor.226 
As shown in Figure S1.1, the CD spectra of the 
peptides (40 μM) suggested that random coil 
conformations were prevalent in PBS, whereas the 
spectra recorded in the micelle solution indicated the 
presence of a certain amount of α-helical structure 
(Figure S1.2). Both human (1) and mouse obestatin (6) 
exhibited similar tendencies (Figure S1.3).  
 
Figure 1.1. Secondary structure analyses performed using the 
DICHROWEB web server with the CONTINLL algorithm and 
reference data set 4. The relative amounts of α-helix and β-sheet 
were determined by adding together the contributions from helix 
1 plus helix 2 and strand 1 plus strand 2, respectively, whereas the 
amounts of β-turn and random structure were read directly from 
the output. The peptides clearly showed greater helicity in SDS 
than in PBS. 
226 Schwyzer R. In search of the “bio-active conformation” – is it induced by 




The secondary structure analyses were performed 
using the DICHROWEB web server,214,215 with the 
following algorithms: CONTINLL, which incorporated 2 
different reference data sets, and K2d.215 The 
conformational weights of the secondary structures 
obtained with CONTINLL were paired with 2 different 
data sets for the data ranging between 190 and 240 
nm. Although an important caveat of this method is 
that the reference data sets are primarily appropriated 
for aqueous environments, it is nonetheless evident 
that the peptides in SDS have the greatest helicity 
(Table S1.1). An example of the obtained results is 
represented in Figure 1.1. 
STRUCTURE DETERMINATION USING NMR 
The NMR spectra of the peptides were collected in the 
presence of the SDS micelles. Peptides 1-6 provided 
well-dispersed 2D spectra. A small number of cross-
peaks were observed for peptides 2 and 3. Figures 
S1.4 and S1.5 exemplify the quality of the spectra, of 
which the amide region of the 2D NOESY spectra of 
human obestatin (1) and its truncated analogue (4) are 
shown. The assignment process was straightforward 
because most of the proton resonances of these 
peptides at 298 K and pH 6.5 were well resolved and 
narrow. The chemical shift assignment and collection 
of the NOE data were performed following standard 
procedures.208 The proton chemical shifts of the 
peptides in SDS micelles are summarized in the 
Supplementary Material (Tables S1.2 to S1.7). The 
experimental NMR data were used to generate 3D 
models of peptides 1-6. The 3D structures were 
calculated using the CYANA software based on the 
inter-proton distance restraints (sequential and 
medium-range NOE-derived restraints). The best 20 
structures, out of 50 calculated, were chosen 
                                                          
227 Berjanskii VM, Wishart DS. A simple method to predict protein flexibility 
using secondary chemical shifts. J Am Chem Soc. 2005;127:14970-1. 
according to the lowest values of the penalty (f) for the 
target function. A subsequent energy refinement was 
performed in explicit solvent using the AMBER 
program. The corresponding results, including the 
further analysis of the resulting structures performed 
using MOLMOL and PROCHECK-NMR, are shown 
below. 
Backbone HN amide and H-alpha 1H chemical shifts 
First, the variation of the backbone amide HN and Hα 
chemical shift values was monitored for significant 
changes that might have structural relevance. These 
chemical shifts in peptides 1-6 were, on average, 
shifted up field in relation to the typical values 
observed for random coils, as might be expected for 
helical structures (Figure 1.2).  
   Human obestatin (1) FNFNAPFDVGIKLSGVQYQQHSQAL-NH2 
   Human NA-obestatin (2) FNFNAPFDVGIKLSGVQYQQHSQAL 
   Human (6-23)-obestatin (3)                  DVGIKLSGVQYQQHSQAL-NH2 
   Human (11-23)-obestatin (4)                            LSGVQYQQHSQAL-NH2 
   Human (16-23)-obestatin (5)                                        YQQHSQAL-NH2 
   Mouse obestatin (6) FNFNAPFDVGIKLSGAQYQQHGRAL-NH2 
Table 1.1. The underlined residues were predicted to have 
secondary helical structure based on the HN and Hα chemical 
shifts indices that were determined using the RCI server 
(http://wishart.biology.ualberta.ca/rci). The residues within 
helical structures that extended over more than two residues are 
represented in bold; these residues are located primarily at the C-
terminus  
Furthermore, the chemical shift analysis performed 
using the RCI server227 predicted helical conformations 
for the residues located mainly at the C-termini of the 
peptides (Table 1.1). 
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Figure 1.2 shows the chemical shift indices (CSI) for 
the NH and Hα protons of the residues at the C-termini 
of some of these peptides. The CSIs for the NH and Hα 
protons of human obestatin (1) between residues 
Tyr16 and Leu23 are generally (with a few exceptions) 
negative and much stronger than those of the non-
amidated obestatin (2), indicating that the latter has a 
smaller percentage of helical structure at the C-
terminus. The CSIs for the HN and Hα protons of 
human (6-23)-obestatin (3) generally indicate a higher 
percentage of helical structure relative to (1), 
suggesting that the lack of the first 5 amino acids does 
not have an important conformational impact on the 
structure. 
 
Figure 1.2. Plot of the CSIs for residues at the C-termini of the 
studied peptides. (A) CSIs of the backbone amide protons (HN) 
and (B) CSIs of the alpha protons (Hα). The peptide sequence (6) 
is aligned with that of the other peptides. The CSI is defined as δobs 
- δrandom-coil. 
The truncated peptide 4, which lacks the first 10 
residues, has the strongest negative CSIs for both HN 
and Hα protons, thus providing further support for the 
formation of an α-helix at the C-terminus of this 
peptide. In the case of mouse obestatin (6), the 
negative CSIs for HN and Hα are indicative of an α-
helix, although the comparison with the human 
obestatin (1) shows considerable variations along the 
sequence without a clear trend. 
NOE pattern  
Figure 1.3 contains a summary of all (short, medium 
and long range) connectivities deduced from an 
analysis of the NOESY spectra of the peptides. It has 
been previously reported that poorly ordered 
structures of obestatin were observed in water 
solutions. These peptides generally exhibited bend 
structures in the central Lys10-Ala14 fragment.30,40 For 
peptides 1-6 in buffered SDS micelles, the backbone 
and side-chain proton NMR resonances could be 
completely assigned in a sequential manner with the 
aid of the TOCSY and NOESY spectra. A significant 
population of conformations containing an “ordered” 
α-helix is present, with characteristic short-range 
dNN(i, i+1) and medium-range dαN(i, i+3) and dαβ(i, 
i+3) NOE connectivities.208 Fairly strong dNN(i, i+1) and 
dαN(i, i+1) NOEs were observed for most of the 
residues, although some gaps resulted from 
resonance overlap.  
The data that were obtained clearly suggest the 
presence of a significant population of ordered α-
helical structures for these peptides in SDS micelle 
solutions. In fact, for human obestatin (1), clear 
medium- and long-range connectivities were 
observed including 1) medium-range Hαi/HNi+3 
(Gly8/Leu11, Lys10/Gly13, Leu11/Val14) and 
Hαi/Hβi+3 (Val7/Lys10, Gly8/Leu11, Gly13/Tyr16, 
Ser20/Leu23) connectivities and 2) a long-range 
Hαi/HNi+4 (Lys10/Val14) connectivity. For the non-
amidated peptide 2, fewer medium-range 
connectivities were observed relative to the amidated 
peptide 1, including 1) medium-range Hαi/HNi+3 
(Leu11/Val14, Gly13/Tyr16) connectivities but no 
Hαi/Hβi+3 connectivities and 2) a long-range 





Figure 1.3. Summary of sequential and medium-range NOE 
connectivities involving the HN, Hα and Hβ protons of the 
peptides in SDS micelles, as derived from CYANA calculation. The 
thickness of the bar indicates the intensities of the NOEs for the 
following peptides: (A) human obestatin (1), (B) human non-
amidated obestatin (2), (C) human (6-23)-obestatin (3), (D) human 
(11-23)-obestatin (4), (E) human (16-23)-obestatin (5) and (F) 
mouse obestatin (6). The asterisk (*) represents the C-terminal 
amidation of the molecule. The dagger (#) represents the 
differences between human obestatin (1) and mouse obestatin 
(6).  
For the truncated human (6-23)-obestatin (3), fewer 
medium-range connectivities were observed: 1) 
medium-range Hαi/HNi+3 (Gln17/Ser20, His19/Ala22) 
connectivities but no Hαi/Hβi+3 connectivities were 
observed, and 2) no long-range Hαi/HNi+4 
connectivities were observed. The presence of 
medium-range connectivities (Hαi/HNi+3, Hαi/Hβi+3) 
and long-range connectivities (Hαi/HNi+4) from Gly13 
to Leu23 confirmed the presence of a fairly well 
defined α-helical structure at the C-terminus of human 
(11-23)-obestatin (4): 1) medium-range Hαi/HNi+3 
(Gly13/Tyr16, Gln17/Ser20, Gln18/Gln21, 
Ser20/Leu23) and Hαi/Hβi+3 (Gly13/Tyr16, 
Gln15/Gln18, Gln17/Ser20, Ser20/Leu23) 
connectivities were observed, and 2) long-range 
Hαi/HNi+4 (Gly13/Gln17, Glu17/Gln21) connectivities 
were observed. The observed structure of the human 
(16-23)-obestatin (5) is not as well defined as that of 
4. Only residues His19/Leu23 are involved in α-helix 
formation: 1) medium-range Hαi/HNi+3 (His19/Ala22, 
Ser20/Leu23) connectivities and no Hαi/Hβi+3 
connectivities were observed; 2) a long-range 
Hαi/HNi+4 (His19/Leu23) connectivity was also 
observed. A fairly similar pattern of NOEs, especially at 
the C-terminal region of the peptide, was found in the 
SDS micelles compared with the structure previously 
reported in DPC/SDS micelles40 for mouse obestatin 
(6): 1) medium-range Hαi/HNi+3 (Ile9, Ser12, 
Gln17/Gly20, Gly20/Leu23; Hαi/Hβi+3 Val7/Lys10, 
Gly13/Tyr16) connectivities were observed; 2) no 
long-range Hαi/HNi+4 connectivities, however, were 
observed (bold residues are different from those of 1). 
3D structures 
The best 20 structures, which possessed the lowest 
total energies, were considered as representatives of 
human obestatin (1) and its analogues. None of these 
structures had NOE violations greater than 0.2 Å or 
dihedral angle violations greater than 2°. A summary 
of the structural characteristics of the different 
peptide ensembles is given in Table 1.2.  
The PROCHECK analysis of the 20 structures showed 
that almost all of the residues are in the most favored 
and ’additionally allowed’ regions of the 
Ramachandran plot. For instance, for 1, less than 3% 
of the residues were found outside the sterically 
allowed region of the Ramachandran plot. This fact is 
mostly due to Ala3, which is situated in the less-
defined region of the structure (Table 1.3). A view of 
the structures obtained for 1-6 superimposed along 
their backbones is shown in Figure 1.4. These 
representations show that these peptides primarily 
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adopt an α-helical conformation at the C-terminus 
(Table 1.3). The analysis of the bundle of 20 structures 
obtained for human obestatin (1) demonstrated that 
in most of the structures, residues Gly8-Leu11 were 
involved in an α-helix, whereas residues Val14-Gln17 
were involved in a 310 helix. In a few structures, 
residues Ser20-Leu23 were further involved in an α-
helix. This helical pattern induced under our SDS 
micelles conditions appears to be fairly similar to that 
previously reported in 33% TFE-water for the same 
peptide.30
 1 2 3 4 5 6 
Experimental restraints [a] 
      Sequential distances 267 145 145 184 123 284 
      Medium-range distances (i-j) < 5 99 28 31 63 38 68 
      Long-range distances (i-j) ≥ 5 2 0 0 0 2 7 
      Total 368 173 176 247 163 359 
      Final CYANA target function value (Å2) [b] 0.18 0.22 0.02 0.11 0.27 0.04 
RMS deviations from ideal geometry [c] 
      Bond lengths (Å) 0.005 0.005 0.004 0.004 0.004 0.005 
      Bond angles (º) 0.7 0.7 0.6 0.5 0.5 0.6 
      RMSD to mean coordinates (Å) [d] (14-20) (14-20) (14-20) (14-20) (16-23) (14-20) 
      Backbone N, Cα, C’ 0.42±0.21 1.49±0.56 0.55±0.23 0.09±0.04 0.49±0.24 0.46±0.39 
      All heavy atoms 1.19±0.38 2.69±0.78 1.24±0.27 0.49±0.22 1.50±0.40 0.93±0.52 
Ramachandran plot statistics [c] 
      Most favorable regions (%) 71.4 72.3 69.6 70.5 60.0 77.4 
      Additional allowed regions (%) 26.4 27.2 30.4 29.5 38.7 22.6 
      Generously allowed regions (%) 0.0 0.1 0.0 0.0 1.3 0.0 
      Disallowed regions (%) 2.2 0.3 0.0 0.0 0.0 0.0 
Table 1.2. Structural statistics for the ensemble of the best 20 structures of human obestatin (1), its fragments and mouse obestatin (6). 
The final CYANA target function value was computed for the structures calculated using CYANA. [b] Average values of the 20 final energy-
minimized CYANA conformers. [c] Calculated using PROCHECK-NMR. [d] Atomic differences are given as the average RMS difference of the 
mean coordinate structure (mean). Peptides: human obestatin (1), human non-amidated obestatin (2), human (6-23)-obestatin (3), human 




Table 1.3. The underlined residues were predicted to have 
secondary helical structure based on the HN and Halpha chemical 
shifts indices obtained using the RCI server 
(http://wishart.biology.ualberta.ca/rci). The residues within 
helical structures that extended over more than two residues are 
represented in bold; these residues are located primarily at the C-
terminus. The secondary helical structure obtained in our 
structures, as calculated by CYANA, included α-helix formation 
(green labels) and 310-helix formation (blue labels). 
Mean atomic RMSD values for the backbone atoms (5-
15) of 0.52±0.25 Å and for the heavy atoms (5-15) of 
1.09±0.32 Å were calculated for the best 20 
conformers of 1, and these values are fairly similar to 
those reported by Subasinghage under those 
experimental conditions.30 For the human non-
amidated obestatin (2), the formation of a 310 helix 
between residues Gly8-Ser12 and Val14-Gln17 was 
observed. Regarding peptide 3, a 310 helix between 
residues Gly8-Ser12, Val14-Gln17 and His19-Gln21 
was found. For the human (11-23)-obestatin (4), the 
α-helix structure extended from Tyr16 to Leu23. The 
small peptide 5 displays a short α-helix from Ser20 to 
Leu23. Finally, our data suggest that the mouse 
obestatin (6) contained a 310 helix between residues 
Gly8-Ser12 and Ala14-Gln17 and an α-helix between 
His19-Ala22. The calculated 3D structures also 
corroborate some details that were previously 
obtained from the qualitative 1H chemical shift 
analysis described above. As can be observed from 
these data, the amide moiety in 1 appears to be 
important for stabilizing the α-helix conformation 
between residues Ser20 and Leu23, and this moiety is 
absent in the non-amidated peptide (Figures 1.4.A 
and 1.4.B).  
PROLIFERATION 
GPR39 siRNA depletion  
GPR39 simultaneously signals via two parallel 
pathways, using either heterotrimeric G proteins or 
multifunctional adapters such as β-arrestin 1. 
Although recent work has identified this receptor as a 
target for obestatin action,70,71 no data are available 
for the proposed cell model of ARPE-19 cells, a human 
retinal pigment epithelial cell line.  
Therefore, the endogenous expression of GPR39 was 
first analyzed using immunocytochemistry (Figure 
1.5.A). Next, the effect of acute GPR39 deficiency was 
determined using siRNA. Under these conditions, the 
constructs exhibited a decrease in GPR39 expression 
by 55±1% (Figure 5B). In the presence of a non-
targeting control siRNA, the phosphorylation of 
human obestatin-activated Akt(S473) and 
ERK1/2(T202/Y204) were similar to that observed 
without any transfection. The silencing of GPR39 
subsequently decreased the levels of pAkt(S473) and 
pERK1/2(T202/Y204) with respect to the siRNA control 
(to 94±3% and 60±5%, respectively) following 
treatment with human obestatin (1, 100 nM) for 10 
min (Figure 1.5.B).  
   Human obestatin (1) FNFNAPFDVGIKLSGVQYQQHSQAL-NH2 
    Human NA-obestatin (2) FNFNAPFDVGIKLSGVQYQQHSQAL 
   Human (6-23)-obestatin (3)                  DVGIKLSGVQYQQHSQAL-NH2 
   Human (11-23)-obestatin (4)                             LSGVQYQQHSQAL-NH2 
   Human (16-23)-obestatin (5)                                         YQQHSQAL-NH2 
   Mouse obestatin (6) FNFNAPFDVGIKLSGAQYQQHGRAL-NH2 
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Figure 1.4. Superimposition of the 20 best representative structures of peptides 1 to 6, as calculated from the NMR data for the peptides 
in SDS micelles. (A) Human obestatin (1), (B) human non-amidated obestatin (2), (C) human (6-23)-obestatin (3), (D) human (11-23)-obestatin 





Figure 1.5. A. Immunocytochemical detection of GPR39 in ARPE-
19 cells. Objective magnification x20. B. The effect of siRNA 
depletion of GPR39 on pAkt(S473) and pERK1/2(T202/Y204) in 
ARPE-19 cells after human obestatin treatment (1, 100 nM, 10 
min). The ARPE-19 cells were transfected with GPR39 siRNA prior 
to obestatin 1 treatment. Equal amounts of protein in each sample 
were used to assess the expression of GPR39 by western blotting. 
The GPR39 level was expressed as the fold change relative to the 
control siRNA-transfected cells (mean±SEM). The protein 
expression was normalized relative to actin. The data are 
expressed as the mean±SEM. The asterisk (*) denotes P<0.05 
when comparing the treated control siRNA group with the control 
siRNA group; the dagger (#) denotes P<0.05 when comparing the 
GPR39 siRNA group with the control siRNA group. 
                                                          
228 Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of β-
arrestin- and G-protein-biased agonists. Trends Mol Med. 2011;17:126-39. 
ERK1/2 and Akt activation 
We examined the proliferative capabilities of the 
peptides by investigating ERK1/2 and Akt activation 
[pERK1/2(T202/Y204) and pAkt(S473)]. The curves 
obtained after the treatment of ARPE-19 cells with the 
peptides (100, 200 and 500 nM) exhibited a dose-
dependent pattern with a maximum at 200 nM (data 
not shown). This maximum is the concentration 
reflected in Figure 1.6. The pattern of ERK1/2 
phosphorylation (Figure 1.6.A) reached maximal 
levels within 10 min of human obestatin stimulation 
(1, 200 nM) and decreased to basal levels after 60 min. 
Conversely, the pAkt(S473) maximal levels were 
reached after 10 min of stimulation with human 
obestatin (1, 200 nM), and the activation was 
maintained for at least 60 min (Figure 1.6.B). In 
contrast, the human non-amidated obestatin (2) did 
not influence pAkt(S473), and exhibit even a slight 
inhibitory effect on pERK1/2(T202/Y204). From these 
data, it can be deduced that amidation is a 
prerequisite for maintaining the bioactivity of 
obestatin. Obestatins 3 and 5 had no effect on either 
pAkt(S473) or pERK1/2(T202/Y204). Intriguingly, the 
obestatin analogue 4 induced selective coupling to the 
Akt signalling pathway and exhibited no effect on the 
ERK1/2 route over the time course of the assay.  
This particular ligand is processed from full length 
obestatin and is present in the stomach.1 In this sense, 
this peptide appears to selectively enhance a 
restricted subset of active GPR39 conformations that 
are capable of promoting specific aspects of the 
signalling pathway within the GPR39-induced 
network, particularly β-arrestin-mediated signalling 
mechanisms. This result suggests that this molecule 
may act as a potential β-arrestin-biased agonist.228  




Figure 1.6. Time-course of the effect of the different peptides on ERK1/2 [pERK 1/2 (T202/Y204)] and Akt [pAkt HM (S473)] 
phosphorylation in ARPE-19 cells. The serum-starved cells were treated with the peptides (200 nM) at 37 °C for the indicated times. The 
cells were lysed and analyzed using SDS-PAGE with specific antibodies. ERK1/2 and Akt phosphorylation were quantified using densitometry 
and expressed as the fold change relative to the phosphorylation obtained for unstimulated cells (mean±SEM of five independent 
experiments). 
To date, biased ligands have been identified for 
different G protein-coupled receptors, denoting a new 
class of pharmacological ligands capable of selective 
modulation.229 Regarding the species-specific role of 
obestatin, the effect of human (1) and mouse (6) 
obestatin on pERK1/2(T202/Y204) and pAkt(S473) was 
compared under the same experimental conditions 
described previously. Mouse obestatin (6) treatment 
                                                          
229 Reiter E, Ahn S, Shukla AK, et al. Molecular mechanism of β-arrestin-
biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol 
Toxicol. 2012;52:179-97. 
did not induce any significant change in either 
pERK1/2(T202/Y204) or pAkt(S473) during the tested 
period (Figure 1.6.C and D). This result demonstrates 
that, in this system, the changes in primary (Val14Ala, 
Ser20Gly and Gln21Arg) and secondary structure 






Figure 1.7. Immunocytochemical analysis of the Ki67 expression in ARPE-19 cells after 24 h of proliferation. A) Control. B) 10% FBS (v/v). 
C) 100 nM human obestatin (1). D) 100 nM human non-amidated obestatin (2). E) 100 nM human (6-23)-obestatin (3). F) 100 nM human 
(11-23)-obestatin (4). G) 100 nM human (16-23)-obestatin (5). H) 100 nM mouse obestatin (6). The magnification was 20x. I) Quantification 
of the immunocytochemical expression of Ki67 in ARPE-19 cells after treatment with 10% FBS (v/v; 100±2), 100 nM human obestatin (1; 
84±1%), 100 nM human non-amidated obestatin (2; 33±2%), 100 nM human (6-23)-obestatin (3; 56±3%), 100 nM human (11-23)-obestatin 
(4; 67±3%), 100 nM human (16-23)-obestatin (5; 50±2%) and 100 nM mouse obestatin (6; 32±2%). The expression of Ki67 was expressed as 
the fold change relative to the expression level in FBS-treated cells in the positive control (mean±SEM). J) BrdU incorporation in ARPE-19 
cells after treatment with 10% FBS (v/v; 100±1), 100 nM human obestatin (1; 84±4%), 100 nM human non-amidated obestatin (2; 39±2%), 
100 nM human (6-23)-obestatin (3; 30±1%), 100 nM human (11-23)-obestatin (4; 52±3%), 100 nM human (16-23)-obestatin (5; 34±3%) and 
100 nM mouse obestatin (6; 35±1%). The BrdU incorporation was expressed as the fold change relative to the level in FBS-treated cells in 
the positive control (mean±SEM). The data are expressed as the mean±SEM. The asterisk (*) denotes P<0.05 when comparing the peptide-
treated ARPE-19 cells groups with the human obestatin (1)-treated group.
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Ki67 expression and proliferation 
The activation of the ERK1/2 and Akt signalling 
network results in the activation of a series of 
transcription factors that induce alterations in the 
expression of a variety of genes involved in the 
stimulation of cell proliferation. Among these factors, 
Ki67 is a labile non-histone nuclear protein that is 
intimately involved in the cell cycle.230 The expression 
of Ki67 exhibits a good relationship with the growing 
fraction in several system models, and this factor is not 
expressed during the repair processes of DNA.231 Thus, 
Ki67 is considered to be a marker of cell proliferation. 
Consequently, the mitogenic effect of the peptides 
was tested by analyzing the expression of Ki67 in 
ARPE-19 cells using an immunocytochemical analysis. 
The experiments were performed at 24 h post-
stimulation with the different peptides (100 nM). 
Figure 1.7 shows a representative experiment of the 
six independent assays. Human obestatin (1) exhibited 
a clear increase in immunostaining for Ki67 (Figure 
1.7.C), which was comparable to the positive control 
[10% FBS (v/v)]; Figure 1.7.B). The negative control 
(without stimuli) is shown in Figure 1.7.A. In 
accordance with the results from the immunoblots, 
the expression of Ki67 was marginally detected for 
non-amidated obestatin (2) and mouse obestatin (6) 
(Figure 1.7.D). Alternatively, human (6-23)-obestatin 
(3) and human (16-23)-obestatin (5) exhibited weak 
Ki67 expression (Figures 1.7.E to 1.7.G, respectively), 
and the expression was higher for human (11-23)-
obestatin (4) (Figure 1.7.F). These results resemble the 
proliferative capabilities of human obestatin (1; 
84±4%) and the different peptides measured in terms 
                                                          
230 Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: 
prognostic and predictive potential. Lancet Oncol. 2010;11:174-83. 
of BrdU incorporation, in which only peptide 4 
























231 Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal 
antibody reactive with a human nuclear antigen associated with cell 
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CHAPTER 2: NMR INTERACTION BETWEEN OBESTATIN AND GPR39 RECEPTOR USING 
LIVING CELLS
Since the discovery of obestatin, there have been 
several studies aimed at determining which are the 
minimal structural requirements that permit to detect 
obestatin receptor biological activity.225 At the present 
moment, no data are available regarding the bioactive 
conformation of obestatin and its mode of interaction 
of GPR39 at the key-binding site. In any case, the 
proper structure-activity relationship study should be 
based on the knowledge of the bioactive 
conformation of obestatin when bound to the 
receptor. NMR techniques are suitable to this end 
when working with isolated protein receptors or 
receptor-rich living cells. Provided that the system 
holds the right kinetic features, these experiments, 
with living cells, could avoid the requirement for 
isolating the protein receptor. On this basis, the 
approach presented herein aims at the determination 
of the bioactive conformation of obestatin when 
interacting with its receptor, GPR39, in quasy-
physiological conditions. Thus, the NMR analysis of the 
interaction of human obestatin (1) and several 
fragment peptides with the obestatin receptor 
(GPR39) was performed in the HEK293 cell line bearing 
the GPR39 receptor. 
CSP EFFECTS AND NOE PATTERN IN OBESTATIN 
TRUNCATES  
The NMR spectra of the human obestatin peptides, (6-
23)-obestatin (3), (11-23)-obestatin (4), (16-23)-
obestatin (5), and the fragment peptide (1-10)-
obestatin (7) were collected in the presence of H2O, 
PBS, and HEK293 cells, both wild type (WT) and 
transiently GPR39-transfected cells (GPR39). As non-
amidated obestatin (2) and mouse obestatin (6) had 
no biological effects on proliferation or stimulation of 
intracellular signalling targets triggered by 1,225 they 
were excluded from the analysis. However, the 
fragment peptide (1-10)-obestatin (7) was 
incorporated due to the importance acquired by its 
counterpart 4, as it discovered itself as a possible 
endogenous biased ligand for GPR39. 
The NMR spectra of the peptides were collected in the 
presence of H2O, PBS, WT cells and GPR39 cells. All the 
peptides provided well-dispersed 2D spectra. The 
assignment process was straightforward because 
most of the proton resonances of these peptides at 
298 K and pH 6.5 were well resolved and narrow. The 
chemical shift assignment and collection of the NOE 
data were performed following standard 
procedures208 and obtained from the analysis of the 
1H-2D TOCSY and NOESY/ROESY spectra of the 
peptides. The proton chemical shifts of all of the 
peptides in H2O, PBS, WT cells, and GPR39 cells, are 
summarized in the Supplementary Material section 
(Tables S2.1 to S2.30).  
Exclusive chemical shift perturbation (CSP) effects 
occurring in the samples were identified by 
comparison among spectra: the two obtained for 
transfected and WT cells, the spectrum of the peptide 
in PBS, and the spectrum in H2O. CSPs of all peptides 
were calculated taking into account the differences in 
the chemical shifts (δ) between PBS:H2O, WT:PBS and 
GPR39:WT spectra. Figures 2.1 to 2.5 show a 
representation of the CSPs for the different molecules 
analysed in this chapter. During analysis, the 
numbering of the residues of each peptide is initiated 
in the equivalent corresponding position of the full-
length obestatin 1. 
The evaluation of the spectra (using the following 




revealed the subsequent changes, which are 
described below. For human (16-23)-obestatin (5), the 
comparison PBS:H2O, showed very weak negative 
CSPs for Gln18, Ser20, Gln21, Ala22 and Leu23 (Table 
S2.5) for the amide protons. This smooth effect for 
NHs contrasted with the large positive CSPs observed 
for the side chain protons of the peptide residues, with 
the exception of His19, for which no data was 
available. For instance, for Gln18 there are positive 
CSP effects of +0.23, +0.36, +0.35, and 0.32 ppm for 
Hα, Hβ1, Hβ2, and Hγ, respectively (Table S2.5). The 
comparison WT:PBS, showed no information for the 
amide protons as the WT sample lacks the data for 
these protons (maybe due to fast exchange of these 
protons with the solvent). However, CSP changes for 
the side chains protons are in the range of -0.01 to 
+0.06 ppm. When comparing the GPR39:WT samples, 
only effects for the side chain protons were observed, 
and in the same range than for the WT:PBS 
comparison. 
Regarding human (11-23)-obestatin (4), similar results 
were obtained for the amide protons, with the 
drawback of losing the amide protons in the WT 
sample. However, the CSP effects observed for the 
side chain protons in the PBS:H2O comparison were 
not significant (range in the order of -0.03 to 0.01 ppm, 
Table S2.11). 
The analysis of the (1-10)-peptide 7 data, afforded 
similar results (Table S2.17). The CSPs observed for 
the PBS:H2O comparison were very intense and 
varying from the negative CSPs observed for the amide 
protons (-0.41 ppm for Asn2 or -0.34 for Lys10) to the 
positive CSPs observed for all of the side chain protons 
with values ranging from +0.1 for Hα of Asn2 to +0.45 
ppm for the Hγ of Val7. The negative values observed 
for the amide protons might indicate a tendency to an 
α-helix organisation. The data for the WT:PBS 
provided not less surprising results. All of the amide 
protons presented significant positive CSP effects, but 
opposite to those for PBS:H2O, ranging from +0.11 
ppm observed for Asp6 or Gly8, to the value of +0.18 
observed for Ala3. This feature could indicate a 
tendency to reorganization to a β-strand-like 
structure, although it could have the meaning of a loss 
of the α-helix pattern. Regarding to the GPR39:WT 
comparison, no significant CSP values were observed.  
Human (6-23)-obestatin (3) is the longest truncate but 
lacking the first five residues of the obestatin moiety, 
which include the only Pro. The same pattern than in 
7 was observed for the PBS:H2O comparison: mostly 
negative and intense CSPs (-0.36 and -0.46 ppm for 
His19 and Ser12, respectively). In the WT:PBS 
comparison, all of the amide visible protons presented 
positive and large CSPs. It is important to highlight the 
values for Ser12 and His19 (Ser12: +0.63, +0.2, and 
+0.03 ppm for NH, Hα, and Hβ1/β2, respectively; and 
His19: +0.39, +0.2, +0.06, and -0.03 ppm for NH, Hα, 
Hβ1, and Hβ2, respectively), however, no SCE effects 
were observed for this system. The GPR39 sample 
compared to WT presented very small negative CSPs 
for all of the amide protons except for His19 (0.00 
ppm). These changes in the CSP signs could indicate 
that some conformations were more stabilised 








Figure 2.1. Plot of the 1H CSPs for (16-23)-obestatin (5) residues between spectra. CSPs were calculated by (δPBS–δH2O), (δHEK-WT–δPBS) and 
(δHEK-GPR39–δHEK-WT) for all detected protons. Only significant differences between PBS and H2O spectra in all residues were found. 
 
 
Figure 2.2. Plot of the 1H CSPs for (11-23)-obestatin (4) residues between spectra. CSPs were calculated by (δPBS–δH2O), (δHEK-WT–δPBS) and 



















































Figure 2.3. Plot of the 1H CSPs for residues of (1-10)-obestatin (7) between spectra. CSPs were calculated by (δPBS–δH2O), (δHEK-WT–δPBS) and 
(δHEK-GPR39–δHEK-WT) for all detected protons. Only significant differences between PBS and H2O spectra in all residues were found. 
 
Figure 2.4. Plot of the 1H CSPs for residues of (6-23)-obestatin (2) betwee spectra. CSPs were calculated by (δPBS–δH2O), (δHEK-WT–δPBS) and 






























































    Results 
 
99 
Concerning peptide secondary structures, the NOESY 
spectra showed mainly short-range connectivities. 
Almost invariably, only sequential NOEs were found in 
all of the spectra. For human (16-23)-obestatin (5), 
(11-23)-obestatin (4) and (6-23)-obestatin (3) only 
fairly strong δNN(i, i+1) and δαN(i, i+1) NOEs were 
observed for most of the residues, although some 
gaps resulted from resonance overlap, which would 
indicate no secondary structure. In addition to the 
sequential NOEs, truncate 7 also showed a medium-
range NOE connectivity δαN(i, i+2) between Phe1 and 
Ala3 in GPR39 enriched-cells, which could imply a 
conformational change in the presence of the 
receptor. However, the NOE pattern suggested a 
random coil conformation for all obestatin truncates 
samples. 
In the absence of medium- and long-range 
connectivities, we decided to apply the analysis of the 
CSI. The CSI is a semi empirical protocol to determine 
the secondary structure of a peptide.232 This approach 
compares the Hα chemical shifts of every residue 
within the peptide of interest with those described for 
the corresponding amino acid in an average of random 
coil structures. Although the method has its 
drawbacks, especially if chemical shift assignments are 
mis-referenced or incomplete, it accurately matches 
the 75-80% of the data determined by X-ray 
crystallography, even for small proteins. Thus, we 
employed the CSI protocol to verify the results 
suggested by the truncate NOE pattern. The CSI values 
for all samples in H2O, except for the (6-23)-truncate 5 
and the (1-10)-truncate 7, showed the characteristics 
of unstructured peptides (Tables S2.6, S2.12, S2.16, 
and S2.24) in line with NOESY data. The analysis of the 
CSI of 5 (Table S2.6) and 7 (Table S2.16) showed an α-
helix preference, with the exception of His19 and 
                                                          
232 Wishart DS, Sykes BD. Chemical shifts as a tool for structure 
determination. Methods Enzymol. 1994;239:363-92. 
Leu23 (CSI = 0) in 5; and Ala3, Val7 and Ile9 (CSI=0) in 
7. This helical-trend structure is consistent with the 
large positive CSPs effects observed for the side chain 
protons of the peptide residues in the PBS:H2O 
comparison for both peptides. 
CSP EFFECTS AND NOE PATTERN IN HUMAN 
OBESTATIN 
Regarding full-length human obestatin (1), NMR data 
showed intriguing results. In the PBS:H2O comparison, 
significant CSPs changes were found (range in the 
order of -0.05 to +0.05 ppm; Table S2.29), mainly for 
the amide region. In contrast, the data from the 
WT:PBS showed significant positive CSPs effects in all 
of the observed amide protons (ranging from +0.11 to 
+0.21 ppm) and weak differences for the side chain 
protons, with the exception of Gly13 (-0.10 ppm in Hα) 
and Pro4 (-0.18 ppm in Hβ). These positive CSPs could 
imply a β-strand reorganization or a loss of helical 
structures in WT living cells. But, the most interesting 
results were found between the GPR39:WT spectra 
(Figures 2.6 and 2.7; Table S2.29). Very strong CSPs 
were found for Pro4 (-0.31, -0.41 and -0.31 ppm in 
Hβ1, Hβ2 and Hγ, respectively) and His19 (+0.10 and 
+0.18 ppm in Hα and Hβ, respectively) in the presence 
of GPR39 cells. This difference in Pro4 between the 
spectra of both cell systems (WT and GPR39) could be 
a considerable difference for obestatin. It is important 
to mention that human obestatin (1), together with (1-
10)-obestatin (7) are the only peptides that keep Pro4 
in the structure, and the CSPs observed for Pro4 in 1 
could involve an E/Z isomerization of this residue 
(Figure 2.7). However, the absence of slow 
conformational exchange (SCEs) effects and/or double 
sets of signals for obestatin in presence of the GPR39-





possibility without confirmation. The data obtained 
from NOESY spectra pointed to an obestatin random 
coil conformation in H2O. Only sequential δNN(i, i+1) 
and δαN(i, i+1) NOEs were found. In PBS, the presence 
of an osmolyte such as phosphate ion could induce 
changes in the chemical shifts in amide proton, 
indicative of some type of structural reorganization,233 
but the absence of well resolved and narrow NOEs and 
the analysis of the CSI data (Table S2.30) led us to 
postulate that the most of the peptide was in random 
coil. 
 
Figure 2.5. Plot of the 1H CSPs for residues of human obestatin (1) between spectra. CSPs were calculated by (δPBS–δH2O), (δHEK-WT–δPBS) and 
(δHEK-GPR39–δHEK-WT) for all detected protons. Only significant differences in amide protons between PBS and HEK-WT spectra were found. 
Furthermore, Pro4 and His19 residues showed significant CSPs in the presence of receptor, in comparison with WT cells. 
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In the presence of an SDS micellar environment that 
mimics the cell membrane, there is a rearrangement 
of the peptide that entails the formation of small areas 
of helix 310 and alpha helix as was explained in chapter 
1. In the presence of WT living cells, the ROESY spectra 
could not be assigned and analysis of CSI showed 
unstructured conformations. In addition, CSI data and 
NOE pattern for human obestatin (1) in the presence 
of receptor, showed strong δNN(i, i+1) and δαN(i, i+1) 
NOEs, and a weak medium-range δαN(i, i+2) NOE 
between Leu11 and Gly13, suggesting that equilibrium 
tended to be shifted to a random coil conformations 
as well as happened with obestatin truncates. 
 
Figure 2.6. Superposition of amide region of 2D TOCSY spectra for human obestatin in HEK-WT (blue) and HEK-GPR39 (red) cells. His19 





Figure 2.7. Superposition of alpha region of 2D TOCSY spectra for human obestatin in HEK-WT (blue) and HEK-GPR39 (red) cells. Pro4 
showed large CSPs in different protons in the presence of living receptor-enriched cells. 
3D STRUCTURE OF HUMAN OBESTATIN 
The NMR assays performed might indicate that full-
length obestatin (1) is unstructured in the presence of 
H2O, PBS and WT cells. In GPR39-transfected cells, 
NOE pattern and CSPs data may suggest that receptor 
could induce a further stabilized secondary structure. 
Taking into account NOE restrictions, the possibility of 
a conformational change in His19 and Pro4, and the 
fact that GPR39 could be acting as a prolyl cis-trans 
isomerase, we calculated the three-dimensional 
structures of human obestatin using the protocols of 
refinement CYANA (Figures 2.8 and 2.9). Prolines 
could adopt two possible conformations E ( = 180⁰) 
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and Z (ω = 0⁰), therefore, the best 6 structures for each 
conformation with a ω torsion restriction in Pro4, 
which possessed the lowest total energies, were 
considered as representatives of human obestatin in 
GPR39-enriched cells. None of these structures had 
NOE violations greater than 0.2 Å or dihedral angle 
violations greater than 2°. The analysis of the bundle 
of 6 structures obtained for human obestatin for E 
configuration showed a possible helix structure 
between residues Ala3 and Phe5, which are 
overlapped. In the Z configuration, the 6 calculated 
structures presented an overlying between Phe1 and 
Lys10 which could being part of and helical 
configuration, however, according to described above, 
the largest part of the peptide appeared to be 
unstructured both in the E and Z conformations.
 
 
Figure 2.8. Possible conformations of human obestatin in 
presence of GPR39 receptor. Six structures of human obestatin 
were calculated using CYANA, with a ω torsion restriction in Pro4 
in E configuration. Residues between 3-5 are overlapped.  
 
 
Figure 2.9. Possible conformations of human obestatin in 
presence of GPR39 receptor. Six structures of human obestatin 
were calculated using CYANA, with a ω torsion restriction in Pro4 
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CHAPTER 3: OBESTATIN/GPR39 SIGNALLING 
OBESTATIN/GPR39 INTERACTION  
Obestatin was initially discovered as the cognate 
ligand for GPR391 in 2005. However, several groups 
published their results challenging these data. Chartrel 
et al, one year later, published that human obestatin 
was not able to drive GPR39 internalization.74 In the 
same year, some groups proposed Zn+2 as the 
endogenous agonist of GPR39 due to its ability to 
activate inositol phosphate accumulation.55,60,74,75 
Nevertheless, the same group published that Zn+2 
treatment diminished GPR39 basal phosphorylation, 
even at concentrations of 1 µM. In 2015, Camiña’s 
group using co-immunoprecipitation experiments 
demonstrated the binding of obestatin to GPR39 in 
cultured C2C12 myoblast cells.73 Our results 
concerning the obestatin/GPR39 system also 
supported this piece of information. 
The controversy generated by the obestatin/GPR39 
system regarding its mode of interaction, or more 
importantly, whether there was any kind of 
interaction, prompted us to investigate the first steps 
in obestatin signalling, which means GPR39 
phosphorylation and internalization. 
GPR39 phosphorylation induced by obestatin 
We measured receptor phosphorylation to assess 
obestatin effects via the GPR39 receptor. GFP-GPR39 
receptor was immunoprecipitated from transiently 
transfected HEK293 cells loaded with 32Pi, and, using 
the GPR39 or GFP antibodies, radiolabelled proteins 
were detected by gel autoradiography or Western 
blotting. Several bands were observed for GPR39, the 
main at 60 kDa (Figure 3.1). These bands could 
represent the increasing glycosylation state of 
receptor proteins as they reach maturity and 
potentially the presence of receptor dimers. A basal 
phosphorylation for GPR39 was observed, similar to 
those previously described for this receptor.51 This 
basal phosphorylation could represent a high 
constitutive activity for GPR39. In the example 
presented in Figure 3.1, 32Pi incorporation was 
augmented by obestatin treatment (200nM, 5min). 
The radioactive labelling of the immunoprecipitated 
receptor showed that obestatin increased a ∼109% 




Figure 3.1. GPR39 phosphorylation activated by obestatin. 
HEK293 cells expressing GPR39 cells were loaded with 50 µC 32Pi 
for 1h before treatment with human obestatin (200nM, 5 min; left 
panel). Levels of 32Pi incorporation were quantified by 
densitometry, normalized to GPR39-GFP, and expressed as fold 
increase relative to the untreated control cells. Immunoblots are 
representative of three independent experiments. The data are 






Next, we tested the effect of obestatin on receptor 
endocytosis by confocal microscopy in HEK293 cells 
transiently expressing the human GPR9 receptor. 
Internalization of GPR39 tagged with GFP was 
analysed 20, 40, 60 and 120 min after obestatin 
treatment (500 nM). 
 
Figure 3.2. Time course of GPR39-GFP internalization in HEK293-GPR39-GFP cells after stimulation with obestatin. The localization of the 
GPR39 expressed in transiently transfected HEK293 cells was visualized by confocal microscopy in cells incubated for different times at 37 ⁰C 
in the absence or presence of 500 nm obestatin.  
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In the resting cells, fluorescence associated with the 
receptor was predominantly confined to plasma 
membrane for all the time tested (Figure 3.2). 
Obestatin was rapidly bound to the GPR39 and caused 
clustering of the receptor on the plasma membrane 
within a few minutes. During the subsequent 
internalization of the obestatin-GPR39 complex, the 
receptor was detectable in punctate intracellular 
structures, which were evident for up to 20 min. At 
this time, even the GPR39 began to appear in deeper 
compartments adjacent to the nucleus (Figure 3.2). 
However, after 120 min incubation, the fluorescent 
vesicles were concentrated near the membrane, and a 
moderate labelling appeared at the cell surface again, 
suggesting that receptor could have being recycled 
(Figure 3.2). 
GPR39-RTKs CROSS-TALK: DIFFERENTIAL RTK 
PHOSPHORYLATION AND PROTEASES 
EXPRESSION PATTERNS 
In gastric cancer cells, once obestatin activates GPR39, 
two routes are triggered in parallel:142 i) sequential 
activation of Gi, PI3K, PKCε novel and Src and the 
subsequent ERK1/2 activation; and ii) a β-arrestin 1-
mediated signalling pathway that implies the 
recruitment of Src to the β-arrestin 1 scaffolding 
complex causing Akt phosphorylation. In this way, Src 
acts as a switch that activates MMPs to initiate the 
proteolytic release of the EGF-like ligands onto the cell 
surface, which later bind to EGFR.  
This signalling network adds a new component to the 
intracellular signalling targets regulated by obestatin. 
The transactivation of EGFR-induced by obestatin 
could imply a key mechanism by which MMPs regulate 
these diseases. Supporting this hypothesis, numerous 
studies have shown that alterations in the expression 
and/or mutations in members of the family of 
receptors EGFR/ErbB are present in tumours and cell 
lines derived from these tumours, and these changes 
may contribute to the progression of cancer.153,154,155 
In this sense, obestatin is added to the group of MMPs 
regulator factors, which have been implicated in 
diverse human diseases, such as inflammatory 
diseases and cancer.151,152   
Summarizing, MMPs and RTKs are key pieces in the 
pathology of cancer. Assuming that the 
obestatin/GPR39 system might play a role in the 
development, maintenance and malignancy of cancer, 
especially of gastric cancer, the aim of the present 
study is to elucidate the detailed activation/regulation 
mechanism of GPR39 and receptor tyrosine kinases 
cross-talk triggered by obestatin; to identify MMPs 
activated by obestatin; and to study the possible 
implications in gastric tumour development. As a 
model, the human gastric cancer cell lines KATO III and 
AGS were used to describe the differential RTKs 
phosphorylation pattern and the proteases implicated 
in the intracellular signalling pathway of obestatin.  
Differential RTK phosphorylation pattern activated 
by obestatin in AGS and KATO III cells 
We performed phospho-RTK arrays to determine the 
phosphorylation profile of growth factor RTKs in AGS 
and KATO III cells in response to obestatin. The degree 
of the differential activation of growth factor RTK 
proteins between human obestatin treated or 
untreated cells (200 nM, 10 min) was quantitated by 
dot blot (49 phosphorylated growth factor RTK 
antibodies evaluated on the membrane). Obestatin 
treated or untreated cells protein samples were 
incubated on separate RTK membranes followed by 
densitometric measurements of dot blots. 
The diverse RTKs were differentially activated in 
obestatin treated or untreated AGS cells (Figure 3.3). 




this study, significantly greater expression levels were 
observed with 18 of the phosphorylated RTKs in the 
obestatin treated compared with untreated samples. 
The significant mean (n=4 dots) fold changes of 
activation of RTKs in obestatin treated over that of 
untreated AGS cells were: EGFR (126.7±1.1%), ErbB2 
(152.2±0.1%), ErbB3 (125.7±2.6%), ErbB4 
(139.9±7.9%), fibroblast growth factor receptor 4 
(FGFR4, 132±6.4%), insulin R (128.6±1,3%), insulin-like 
growth factor  (IGF) 1 receptor (IGF1R, 125.9±0.7%), 
tropomyosin receptor kinase C (TrkC, 170.9±4.6%), 
ephrin type A receptor (EphA1, 121.1±1.3%), EphB2 
(137.2±1.8%), fms-like tyrosine kinase 3 (Flt3, 
156.4±4.1%), c-Ret (136.4±7.1%), macrophage colony-
stimulating factor receptor (M-CSFR, 131.3±1.8%), 
Mer (129±2.2%), receptor tyrosine kinase-like orphan 
receptor 2 (ROR2, 128.6±0.1%), RYK (126.9±0.5%), 
discoidin domain receptor 1 (DDR1, 115.6±2.2%), 
DDR2 (119.6±2.2%), mast/stem cell growth factor 
receptor (SCFR, 86.7±0.7%) and FGFR1 (94.6±0.0%) . 
These receptors basically belong to the EGF, insulin, 
FGF, ephrin and DDR growth factor gene families. 
All the members of the EGFR family in array were 
significant activated by obestatin. Among them, ErbB2 
was the most activated receptor, followed by ErbB4, 
EGFR and ErbB3. The ErbB receptor family comprises 
four receptors: EGFR (ErbB1/HER1), ErbB2 (neu, 
HER2), ErbB3 (HER3) and ErbB4 (HER4). There is a 
wealth of clinical data demonstrating the importance 
of ErbB receptors in the development and malignancy 
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of human cancer. In gastric cancer, the EGF 
receptor/ligand system seems to be involved in the 
regulation of gastric mucosal proliferation and 
progression of gastric carcinoma. Increased EGFR 
binding has been observed in gastric carcinomas in 
comparison to adjacent normal gastric mucosa. 
Moreover, elevated EGFR levels have been found in 
gastric carcinoma with worse prognostic factors and it 
is considered like an indicator of poor prognosis.234,235 
The overexpression of ErbB2 in gastric carcinomas was 
first described by Yonemura et al in 1991. These 
findings were confirmed by many other studies, which 
provided further evidence that the highest rate of 
overexpression was found in patients with advanced 
disease, and that ErbB2 altered expression can be 
considered as an independent predictor of 
outcome.236 In fact, in gastric cancer, two of the most 
frequently amplified RTKs were EGFR (7.7%) and 
ErbB2 (7.2%).237 More recently, several studies 
reported evidences that considered HER3 
overexpression as a predictor of poor prognosis and 
survival. However, this prognostic role has not yet 
reached a consensus.238 
Insulin receptor and IGF1R were significantly activated 
too. IGF1R is overexpressed in gastric cancer tissues as 
compared with normal mucosa. Moreover, IGF 
receptors are almost universally expressed in gastric 
carcinomas.239 IGF1R is associated with a poor 
response to chemotherapy and poor outcomes in 
Stage I–IV of gastric cancer. Furthermore, high levels 
of receptor are associated with tumour size, quantity 
237 Morishita A, Gong J, Masaki T. Targeting receptor tyrosine kinases in 
gastric cancer. World J Gastroenterol. 2014;20:4536-45. 
238 Wang L, Yuan H, Li Y, et al. The role of HER3 in gastric cancer. Biomed 
Pharmacother. 2014;68:809-12. 
239 Kashyap MK. Role of insulin-like growth factor-binding proteins in the 
pathophysiology and tumorigenesis of gastroesophageal cancers. Tumour 
Biol. 2015;36:8247-57. 
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of stroma, depth of wall invasion, lymph node 
metastasis, TNM stage, and differentiation status.240 
IGF1R expression was related to venous invasion too. 
It was reported that the IGF1R axis influences MMP7 
and promotes tumour progression and invasion in 
gastrointestinal cancer protecting tumour cells against 
apoptosis induced by cytotoxic drugs241 and 
promoting EMT.242 
The most activated receptor was TrkC. Some years 
ago, it was reported that Trk receptors family probably 
played a unique role in gastric cancer cell apoptosis by 
a novel Ras or Raf signal transduction pathway,243 
however, recent reviews showed that high expression 
of TrkA or TrkC may play significant roles in tumour 
progression, metastasis, and outcomes in gastric 
cancer. TrkC expression was correlated with clinical 
stage, lymph node metastasis, microvessel density, 
lymph vessel density, and poor prognosis, as well as 
regulated the secretion of MMP2 and MMP9.244  
EphA1 and EphB2 were the significant obestatin-
activated members of EphR family in AGS cells. There 
have been some reports showing that Eph families are 
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associated with proliferation and invasion of 
gastrointestinal cancers. High expression of EphA1 
may play a critical role in tumour progression, 
metastasis, and survival in gastric cancer. It is believed 
that EphA subgroup generally enhances tumour 
progression by activating Jak/Stat and Akt/PI3K 
signals. Furthermore, EphA1 has the possibility of 
being a target of molecular targeted therapy by 
inhibiting angiogenesis like the mechanism of VEGF 
inhibitor, associating EphA1 with cell proliferation, 
motility, and invasiveness in gastric carcinomas.245,246 
Controversially, literature shows EphB2 as a negative 
biomarker for gastric carcinogenesis and suggests that 
EphB2 may have tumour suppressor activities in 
gastric cancer.247,248,249 
Flt3,250 and c-Ret are receptors involved in 
proliferation, differentiation and cell migration, and c-
Ret is a mediator in gastric cancer251 and 
neuroendocrine tumours.252 RYK and ROR are 
implicated in Wnt signalling in tumour invasion during 
carcinogenesis;253 and DDR receptors regulate the cell 
adhesion to the extracellular matrix, and are involved 
246 Wang J, Dong Y, Wang X, et al. Expression of EphA1 in gastric carcinomas 
is associated with metastasis and survival. Oncol Rep. 2010;24:1577-84. 
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in migration, playing an important role in tumour cell 
invasion and up-regulating the expression of MMP2,   
7 and 9.254 
In addition, the only two down-regulated receptors by 
obestatin were SCFR (c-Kit) and FGFR1.  Surprisingly, 
mutations in c-Kit are associated with gastrointestinal 
stromal tumours (GISTs), the most common 
mesenchymal neoplasms in gastrointestinal tract. 
Furthermore, c-Kit–positive status may be a significant 
indicator of good prognosis in gastric cancer 
patients.255 The fact that obestatin diminished the 
activation of this receptor could involve obestatin in 
malignancy of gastric cancer. 
On the other hand, the activation of RTKs in KATO III 
cells after obestatin treatment (200nM, 10 min) 
showed a different pattern of phosphorylation (Figure 
3.3). We found differences in EGF, insulin, VEGF, 
ephrin and Tie receptor families. The significant mean 
(n=4 dots) fold changes of activation in obestatin-
treated KATO III cells were: EGFR (138.6±0.3%), IGF1R 
(144.8±2.3%) and EphA1 (135.8±5.2%) as well as in 
AGS cells; macrophage-stimulating protein receptor 
(MSPR, 144±0.6%), angiopoietin receptor 1 (Tie1, 
120.1±0.5%), VEGFR3 (114.9±3.1%), EphA3 
(120.2±3.1%) and EphA5 (132.8±3.4%). Otherwise, 
                                                          
254 Fu HL, Valiathan RR, Arkwright R, et al. Discoidin domain receptors: 
unique teceptor tyrosine kinases in collagen-mediated signaling. J Biol 
Chem. 2013;288:7430-74. 
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Mer (76.1±3.1%), Tie2 (62±3.0%), TrkA (65,6±2.1%) , 
EphA6 (71.8±0.3%) and EphA7 (96.5±0.6%) showed a 
relevant decrease in phosphorylation levels under 
obestatin treatment. 
Overexpression of MSPR has been significantly 
associated with tumour size, depth of invasion, lymph 
node metastasis, tumour stage and poor survival in 
human gastric cancer indicating that this receptor is 
associated with tumour progression via the inhibition 
of apoptosis and cell cycle arrest.256,257 VEGFR3 is 
reported implicated in cell migration/invasion of 
human gastric cancer cells.258 Furthermore, VEGF 
/VEGFR3 system regulates lymphangiogenesis.259  
Regarding EphR family in KATO III cells, we found that 
obestatin increased activation of EphA3 and EphA5. 
EphA3 mRNA and protein expression was significantly 
higher in gastric cancer than in normal mucosa and 
correlated with TNM stage, poor prognosis and VEGF 
expression, playing important roles in the 
angiogenesis and the prognosis of gastric 
carcinoma.260 A recent report showed that EphA5 
gene is expressed at very low levels in gastric cancer 
and gastric mucosa and did not show any significant 
differences.261 
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Figure 3.3. Differential expression of phosphorylated growth factor RTKs in obestatin treated compared to untreated AGS and KATO III 
cells. Out of the 49 RTKs analysed in the Phosphorylation of Receptor Tyrosine Kinases Array, 18 and 8 growth factor RTKs were highly 
activated (P < 0.02–0.03) in obestatin-treated (200 nM, 10 min) compared to untreated AGS and KATO III cells, respectively. These RTKs 




However, EphA5 receptor is a protein that mediates 
the communication between pancreatic islets to 
regulate the pancreatic insulin secretion stimulated by 
glucose,262 thus, the increased activation caused by 
obestatin in EphA5 phosphorylation enhanced the 
activity of obestatin in pancreas and insulin 
metabolism.91,101,103 On the other hand, EphA6 and 
EphA7 are down-regulated by obestatin. Both RTKs 
are implicated in cell adhesion and migration.245 
Moreover, EphA7 expression was significantly lower in 
gastric cancer as compared with either intestinal 
metaplasia or non-metaplastic mucosa.261  
By last, we found that exogenous obestatin 
administration in KATO III cells produced antagonistic 
effects in the two members of Tie receptor family; Tie1 
receptor was activated whereas Tie2 was down-
regulated. The Tie receptors are receptors that bind 
angiopoietins, protein growth factors required for the 
angiogenesis. Both receptors seem to be implicated in 
gastric carcinogenesis. Ties were highly expressed in 
human gastric adenocarcinoma cells and the results 
suggest that the Ang-Tie complex is one of the factors 
involved in the cellular differentiation and progression 
of human gastric adenocarcinoma,263 correlating with 
higher TNM stage, lymph node metastasis as well as 
distance metastasis.264,265 However, several reports 
showed that in the presence of Tie1, the ligand 
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independence and basal Tie2 activity are attenuated, 
concluding that Tie1, in its normal role, antagonizes 
Tie2 function.266 This piece of information 
corroborates the data observed in KATO III cells, which 
supports the inhibitory effects of Tie1 on Tie2 
activation.267,268 
These results showed that the obestatin/GPR39 
system signalling pathways are more complex than 
might have been expected, supporting the role of the 
different RTKs in obestatin signalling via the GPR39 
receptor.  
Differential protease expression pattern activated 
by obestatin in AGS and KATO III cells 
As mentioned above, MMPs are involved in the 
signalling pathway of obestatin142 and play an 
important role in critical processes in the pathology of 
cancer.269 Therefore, we have also studied the 
differential expression of several proteases, both in 
AGS and KATO III cell lines after exogenous 
administration of obestatin.  
In this case, cells were stimulated with obestatin for 
24 hours, lysate and secretome were collected to 
detect both intracellular and secreted proteases. This 
time-window was selected in order to allow synthesis 
and secretion of the proteases. 
266 Seegar TC, Eller B, Tzvetkova-Robev D, et al. Tie1-Tie2 interactions 
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Figure 3.4.  Differential expression of proteases in obestatin treated compared to untreated AGS cells. Out of the 34 proteases analysed in 
the array, 27 proteases in cell lysates and 13 in secretome were highly expressed (P < 0.05) in obestatin-treated (200 nM, 24 h) compared to 
untreated AGS cells. These proteases belong to the ADAM, CTS, KLK and MMP families. Only CTSE in lysates; and secreted ADAM9, KLK10, 
KLK13 and PSEN1 were down-regulated by obestatin. 200 μg of cell lysate and secretome were run on each array.  
We performed protease arrays to determine the 
expression profiles. The degree of differential 
expression between human obestatin treated or 
untreated cells (200 nM, 24 h) was quantitated by dot 
blot (34 proteases antibodies evaluated on the 
membrane). Obestatin treated or untreated cells 
protein samples were incubated on separate 
proteases membranes followed by densitometric 
measurements of dot blots. 
The diverse proteases were differentially expressed in 
obestatin treated or untreated AGS cells (Figure 3.4). 
The significant mean (n=4 dots) fold changes of 
expression in obestatin treated over that of untreated 
AGS cell lysates and secretomes were described 
below. Of the 34 proteases evaluated on the array 
membrane for this study, we have observed that the 
expression of 27 proteases in cells lysates and 13 in 




Otherwise, only cathepsin E (CTSE) in lysates; and 
secreted ADAM9, kallikrein 10 (KLK10), KLK13 and 
presenilin-1 (PSEN1) were down-regulated by 
obestatin (Figure 3.4). The most outstanding increases 
are proteases of the ADAM, CTS, KLK and MMP 
families.  
Obestatin increased in 133.9±0.1% and 489.8±25.0% 
the expression of ADAM9 and ADAMTS13 
respectively. ADAM9 is a cell-surface membrane 
glycoprotein with oncogenic properties that is 
overexpressed in several cancers, playing an 
important role in gastric cancer proliferation and 
invasion.270 However, ADAMTS13 is negatively 
correlated with the VEGF-VEGFR2 system and 
signalling pathway in gastric cancer.271   
Almost all CTSs altered its expression after obestatin 
treatment, but CTSB (193.4±3.9%) and CTSV 
(189.2±4.9%) experimented one of the greatest 
increment. It was reported that CTSB and CTSL were 
significantly higher in gastric cancer as compared to 
paired normal mucosa. CTSB levels were also 
significantly associated with TNM stage, nodal status, 
histological grade, and DNA ploidy in stomach 
carcinomas.272,273,274  Tumours with overexpression of 
CTSs have powerful potential for invasiveness in the 
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early stage of gastric carcinoma. Moreover, CTSs may 
be one of the determinants of the metastatic route.275 
CTSV and X/Z/P have different roles in tumour 
processes too.276 In all cases, it was shown a greater 
increase in the fraction of secretome, because not 
only these proteases carry out their function within 
the lysosome, but also are known for their ability to 
degrade extracellular matrix components, such as 
proteoglycans, collagen and elastin. Surprisingly, CTSE 
(87.2±0.1%) was the only protease down-regulated in 
AGS cell lysates. It is a gastric aspartyl protease found 
in highest concentration in the surface of epithelial 
mucus-producing cells of the stomach. It is the first 
aspartic proteinase expressed in the foetal stomach 
and is found in more than half of gastric cancers.277,278 
Furthermore it is considered as a marker of both 
gastric differentiation and signet-ring cell 
carcinoma.279 
In the case of the KLKs, all of them were overexpressed 
after obestatin treatment, especially KLK6 
(139.8±4.4%) both in lysates and secretomes. KLK6 is 
a trypsin-like serine protease, and it has been shown 
to be upregulated in several cancers. KLK6 is 
significantly upregulated and secreted in gastric 
275 Dohchin A, Suzuki JI, Seki H, et al. Immunostained cathepsins B and L 
correlate with depth of invasion and different metastatic pathways in early 
stage gastric carcinoma. Cancer. 2000;89:482-7. 
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cancer tissues and sera.280 Furthermore, its expression 
was positively correlated with nodal involvement, 
advanced-stage disease and survival, suggesting that 
KLK6 might be used as a potential biomarker and 
therapeutic target for gastric cancer.281 In cells 
secretomes, we found lower levels of KLK10 
(30.2±0.1%) and mainly KLK13 (47.7±2.3%) in 
obestatin-treated samples. It could be due to the role 
of KLK13 as a favourable prognostic biomarker for 
gastric cancer patients' survival. A decreased in KLK13 
expression was demonstrated in poorly differentiated 
gastric tumours282 and its expression is implicated in 
the molecular pathways that are triggered after 
administration of anticancer agents on gastric cancer 
cells.283  
All the MMPs, with the exception of MMP7, MMP8 
and MMP9, showed higher expression levels triggered 
by obestatin; in fact, the most overexpressed protease 
was MMP1 (690.6±10.0%). Increased production and 
activation of MMP1, 2, and 3 may contribute to the 
remodelling of the cancer cell microenvironment.284 
Moreover, MMP1 plays a critical role in the invasion of 
gastric cancer,285,286 and related to MMP10, this pro-
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metastatic function may be related with H. pylori 
infection.287 
Finally, it has to be pointed out the controversial data 
about one protease. PSEN1 levels were significant 
increased (447.0±9.9%) in stimulated cell lysates, but 
lower than controls in secretome (58.3±1.5%). PSEN1 
is a protease involved in the processes of apoptosis, 
cell adhesion to the matrix, as well as in the Notch 
signalling pathway.288 In addition, it is involved in the 
pathology of Alzheimer´s disease and cancer.289 
Concerning KATO III cells, regarding the significant 
mean (n=4 dots) fold changes of expression in cell 
lysates and secretomes, we have also found a 
pronounced overexpression for 23 proteases in the 
lysates after obestatin treatment (200nM, 24 h; Figure 
3.5). However, obestatin only had effect on the 
secretion of 10 of them, increasing CTSA (131.2±0,5%), 
CTSB (114.6±1.1%), CTSD (107.0±0.3%), CTSX/Z/P 
(124.4±0.5%), DPPIV/CD26 (109.8±1.7%) and PC9 
(125.3±1.5%) levels; and decreasing ADAMTS13 
(87.5±0.2%), KLK3 (78.3±2.6%), MMP2 (83.4±0.6%)  
and PSEN1 (87.0±2.9%)  releasing.  
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Figure 3.5.  Differential expression of proteases in obestatin treated compared to untreated KATO III cells. Out of the 34 proteases analysed 
in the array, 23 proteases in cell lysates and 6 in secretome were highly expressed (P < 0.05) in obestatin-treated (200 nM, 24 h) compared 
to untreated KATO III cells. These proteases belong to the ADAM, CTS, KLK and MMP families. Only secreted ADAMTS13, KLK3 MMP2 and 
PSEN1 were down-regulated by obestatin. 200 μg of cell lysate and secretome were run on each array.  
The most acute increment of the proteases in cells 
lysates was observed for ADAM8 (406.9±19.6%), 
ADAMTS1 (398.7±15.5%), CTSC (162.8±1.1%), KLK3 
(358.4±12.6%), KLK13 (365.1±7.1%); MMP3 
(261.9±14.2%), MMP13 (273.1±0.2%), neprilysin 
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(CD10; 384.9±1.4%), PC9 (293.0±14.3%), proteinase 3 
(PTRN3; 861.0±7.5%) and urokinase-type plasminogen 
activator (uPA; 172.1±1.3%). All of them are proteases 
implied in degradation of extracellular matrix. Besides, 
CTSC,290 KLK3,291 KLK13292 and MMPs269 encourage 
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invasion of tumour cells. ADAM8 is related to the 
degree of histological differentiation, the size, 
recurrence, metastasis and tumour stage,293 and 
ADAMTS1 has an anti-angiogenic role blocking VEGF-
routes, but it is also associated with inflammatory 
processes and is responsible for the plasticity and 
aggressiveness of tumour cells.294  
The expression levels of CD10, PC9 and especially 
PRTN3 were highly augmented.  All of them are 
proteases involved in peptide295 and matrix 
degradation and in cell invasion in several oncogenic 
processes.296 PC9 was discovered as an excellent 
marker in gastric cancer.297 uPA expression is related 
to poor prognosis in stomach carcinomas and human 
gastric cancer cells invasiveness via the ERK1/2, 
nuclear factor-kappa-light-chain-enhancer of 
activated B cells (NF-κB), and adaptor protein 1 (AP-1) 
signalling pathways.298,299 PRTN3 degrades 
extracellular matrix proteins and active MMP2 
promoting cell invasion.300  
As well as in AGS cells, ADAMTS13 (197.2±1.9%) and 
MMP1 (392.7±18.0%) expression was highly increased 
after obestatin administration. 
This protease expression profile for both cell lines 
supports the implication of these proteases in the 
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neutral endopeptidase (CD10): a multifaceted environment actor in stem 
cells, physiological mechanisms, and cancer. Stem Cells. 2011;29:389-96. 
297 Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, et al. SILAC-based 
quantitative proteomic analysis of gastric cancer secretome. Proteomics 
Clin Appl. 2013;7:355-66. 
signalling pathway triggered by obestatin via the 
GPR39 receptor.  
Differential RTK phosphorylation pattern in human 
adenocarcinomas 
In order to validate the results obtained in the human 
cancer cell lines (AGS and KATO III), samples of human 
stomach were investigated. In this way, four human 
samples were selected for the study: one sample of 
healthy stomach (as control), and three of human 
gastric adenocarcinomas, represented by a WD, a MD 
and a PD adenocarcinoma.  
First, we tested GPR39 expression by immunoblot 
(Figure 3.6). GPR39 was expressed in all of the samples 
with an intensity that varies among them, with the 
highest expression in the MD adenocarcinoma (1.59 
a.u.). 
Therefore, we performed phospho-RTK arrays to 
determine the phosphorylation profiles of RTKs in 
human stomach samples. The differential activation of 
RTK proteins between healthy gastric mucosa and 
gastric adenocarcinomas was quantitated by dot blot 
as well as in cells. The significant mean (n=2 dots) fold 
changes of activation of RTKs in adenocarcinomas 
over that of healthy mucosa sample were described 
below (Figure 3.7). 
 
298 Tang Z, Sheng H, Zheng X, et al. Upregulation of circulating cytokeratin 
20, urokinase plasminogen activator and C-reactive protein is associated 
with poor prognosis in gastric cancer. Mol Clin Oncol. 2015;3:1213-20. 
299 Khoi PN, Xia Y, Lian S, et al. Cadmium induces urokinase-type 
plasminogen activator receptor expression and the cell invasiveness of 
human gastric cancer cells via the ERK-1/2, NF-κB, and AP-1 signaling 
pathways. Int J Oncol. 2014;45:1760-8. 
300 Pezzato E, Donà M, Sartor L, et al. Proteinase-3 directly activates MMP-
2 and degrades gelatin and Matrigel; differential inhibition by (-) 






Figure 3.6. GPR39 expression in paraffin-embedded tissue 
samples of human stomach. GPR39 was observed in the four 
samples: human healthy stomach (healthy), a well differentiated 
(WD), a moderately differentiated (MD) and a poorly 
differentiated (PD) adenocarcinoma. Equal amounts of protein in 
each sample were used to assess the expression of GPR39 by 
Western blotting. Protein expression was normalized for actin.  
In the WD adenocarcinoma compared with healthy 
mucosa sample FGFR2 (188.4±2.9%), IR 
(193.1±11.0%), VEGFR2 (155.7±2.9%), EphA1 
(257.9±11.4%) and RYK (581.2±19.3%) were more 
activated in tumour tissue. Conversely, decreased 
phosphorylation levels in Erb2 (44.5±23.0%), Axl 
(42.5±8.0%), ROR2 (16.6±22.5%), and Tie1 
(36.9±5.3%) were shown. 
On the 49 RTKs evaluated on the array, significant 
phosphorylation changes were observed in 27 
receptors in the MD adenocarcinoma. Erb4 
(404.1±7.9%), FGFR2 (222.3±2.7%), FGFR3 
(305.6±6.3%), FGFR4 (514.1±22.3%), IR (351.9±1.1%), 
IGF1R (207.6±7.0%), Mer (289.0±11.1%), hepatocyte 
growth factor receptor (HGFR, 236.7±8.4%),  MSPR 
(162.7±1.9%), platelet derived growth factor receptor 
a (PDGFRa, 322.7±7.7%), PDGFRb (278.1±5.0%), Flt3 
(399.0±4.5%), MCSFR (438.2±8.2%), c-Ret 
(420.2±3.4%), TrkA (321.1±18.7%), TrkC (238.6±3.3%), 
VEGFR1 (210.9±5.3%), VEGFR2 (167.5±2.9%), VEGFR3 
(253.4±5.7%), MusK (333.6±1.3%), EphA1 
(428.9±4.1%), ALK (466.5±8.6%), DDR1 (589.2±17.0%), 
EphA5 (425.5±9.4%) and EphA10 (259.3±2.0%), were 
highly activated. However, Axl (72.3±7.1%), and Tie1 
(56.8±1.9%) levels were reduced. 
In PD adenocarcinoma, 9 RTKs were differentially 
expressed compared to the healthy sample. Increased 
levels of IR (182.6±0.1%), Flt3 (206.4±10.1%), c-Ret 
(184.2±2.2%), MusK (168.2±0.8%), EphA1 
(342.2±6.8%), EphA5 (263.5±8.1%), EphA10 
(368.6±7.3) and EphB3 (231.9±13.8%) were detected. 
On the other hand, Axl (74.6±5.8%) activation were 
reduced. 
Significant phosphorylation differences in ErbB3, 
FGFR1, Dtk, SCFR, ROR1, Tie2, DDR2 and the vast 
majority of EphR were not found.  
EphA1 and insulin receptor were more activated in 
adenocarcinomas than in the mucosa healthy 
controls. Otherwise, Axl activation were down-
regulated in tumour tissues. 
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Figure 3.7. Differential expression of phosphorylated growth factor RTKs in human healthy mucosa and gastric adenocarcinomas. Out of 
the 49 RTKs analysed in the Phosphorylation of Receptor Tyrosine Kinases Array, 9 in WD, 27 in MD and 9 RTKs in PD adenocarcinomas were 
differentially activated (P < 0.05) compared to healthy mucosa. EphA1 and insulin receptor were more activated in all adenocarcinomas than 




Differential protease expression pattern in human 
adenocarcinomas 
With regard to proteases, we performed protease 
expression arrays to determine their profiles in the 
same human stomach samples used in RTK arrays. The 
significant mean (n=2 dots) fold changes of expression 
were described below. The diverse proteases were 
differentially expressed in human healthy mucosa or 
gastric adenocarcinomas (Figure 3.8).  
On the 34 proteases evaluated on the array, 
significantly expression changes were observed in 11 
proteases in the WD adenocarcinoma compared with 
healthy mucosa sample. ADAM9 (116.9±3.0%), 
CTSX/Z/P (179.6±2.4%), KLK3 (128.8±2.0%) and KLK6 
(150.1±4.5%) were more expressed in tumour tissue. 
Conversely, decreased levels in ADAMTS13 
(53.6±6.6%), CTSB (74.6±3.3%), CTSS (68.7±1.6%), 
CTSV (54.1±4.6%), CTSD (39.7±7.1%), KLK7 
(61.5±4.2%) and PSEN1 (79.7±7.8%) were observed. 
In the MD adenocarcinoma, increased levels of  CTSA 
(126.4±0.6%), CTSC (167.2±4.6%), CTSL (180.5±0.3%), 
CTSV (169.0±2.3%), CTSX/Z/P (329.8±1.3%); MMP1 
(1634.0±4.6%), MMP2 (119.6±2.0%), MMP7 
(470.2±5.8%), MMP9 (291.8±2.0%) and uPA 
(217.1±6.9%) were found. However, ADAMTS13 
(75.4±4.7%), CTSD (65.7±0.5%), KLK7 (70.7±7.2%) and 
PSEN1 (76.6±2.8%) levels were reduced. 
23 proteases were differentially expressed in PD 
adenocarcinoma compared to healthy sample. CTSA 
(143.3±3.1%), CTSD (189.6±1.6%), CTSL (151.4±4.7%), 
CTSX/Z/P (282.9±1.9%), KLK7 (311.3±0.9%), KLK10 
(569.9±1.4%), MMP9 (507.9±2.4%), MMP12 
(172.0±3.1%), and uPA (214.1±3.8%) were clearly 
overexpressed. By contrast, family of ADAM 
proteases, ADAM8 (42.7±3.8%), ADAM9 (39.4±1.9%) 
and ADAMTS13 (50.9±8.8%), CTSB (53.5±6.0%), CTSE 
(38.1±9.6%), CTSS (86.4±6.0%), DPPIV/CD26 
(53.8±3.2%), KLK3 (48.9±4.8%), MMP2 (58.0±3.5%), 
MMP3 (53.5±17.9%), MMP8 (45.7±12.7%), MMP13 
(42.7±17.6%), PC9 (44.6±6.3%) and PSEN1 
(38.3±0.7%) were greatly reduced. 
Significant differences in expression patterns of 
ADAMTS1, KLK5, KLK11 and KLK13 were not found.  
ADAMTS13 and PSEN1 levels were more expressed in 
mucosa of the healthy control than in 
adenocarcinoma samples. Otherwise, CTSX/Z/P 






















Figure 3.8. Differential expression of proteases in healthy stomach and gastric adenocarcinomas human samples.  Out of the 34 proteases 
analysed in the array, 11 in WD, 18 in MD and 23 proteases in PD adenocarcinomas showed a different expression (P < 0.05) compared to 
healthy mucosa. ADAMTS13 and PSEN1 levels were more expressed in mucosa healthy controls than in all adenocarcinoma samples. 
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CHAPTER 4: THE ROLE OF THE OBESTATIN/GPR39 SYSTEM IN HUMAN GASTRIC 
ADENOCARCINOMAS 
Obestatin and the GPR39 receptor were reported to 
be involved in the control of mitogenesis of gastric 
cancer cell lines; however, the relationship between 
the obestatin/GPR39 system and gastric cancer 
progression remains unknown. In the present study, 
we determined the expression levels of the 
obestatin/GPR39 system in human gastric 
adenocarcinomas and explored their potential 
functional roles. Twenty-eight patients with gastric 
adenocarcinomas were retrospectively studied, and 
clinical data were obtained. The role of 
obestatin/GPR39 in gastric cancer progression was 
studied in vitro using the human gastric 
adenocarcinoma AGS cell line.301 
OBESTATIN AND GPR39 ARE EXPRESSED IN AGS CELLS 
As a model for this study, we selected the gastric 
adenocarcinoma AGS cell line. This cell line was 
derived from an untreated human adenocarcinoma of 
the stomach and retained the same cytological 
characteristics as the original malignant cells obtained 
from the patient.302 As seen in Figure 4.1, the 
expression of the obestatin/ GPR39 system was 
detected by immunocytochemistry. Intense and 
diffuse obestatin immunostaining was found in the 
cytoplasm (Figure 4.1.1), whereas GPR39 was 
detected in the perinuclear region (Figure 4.1.3). No 
immunostaining was found when obestatin or GPR39 
antibodies were preadsorbed with homologous 
peptides (Figure 4.1.2 and 4.1.4, respectively).  
                                                          
301 Alén BO, Leal-López S, Alén MO, et al. The role of the obestatin/GPR39 
system in human gastric adenocarcinomas. Oncotarget. 2016;7:5957-71.  
 
Figure 4.1. Obestatin and GPR39 are expressed in AGS cells. A) 
Immunocytochemical expression of obestatin and GPR39. 1) 
Obestatin immunoreactivity was intense and diffuse in the 
cytoplasm. 2) The preadsorption control [performed applying the 
primary antibody plus obestatin (10 nmol/mL per control peptide)] 
showed no immunoreactivity. 3) The expression of GPR39 
presented a perinuclear location. 4) The preadsorption control 
[performed applying the primary antibody plus GPR39 control 
peptide (10 nmol/mL per control peptide)] showed no 
immunoreactivity. Objective magnification x20. 
Moreover, an electron micrograph of obestatin 
expression showed a diffuse cytoplasmic pattern 
(Figure 4.2.2), while GPR39 was located in the mature 
face of the Golgi area, as well as a clear expression in 
the cell membrane, mainly located in the microvilli 
(Figure 4.2.3 and 4.2.4, respectively). 
302 Barranco SC, Townsend CM Jr, Casartelli C, et al. Establishment and 
characterization of an in vitro model system for human adenocarcinoma 





Figure 4.2. Electron micrograph of obestatin and GPR39 
expression. 1) Morphology of the AGS cells in culture. 2) The 
expression of obestatin in the AGS cells showed a diffuse 
cytoplasmic pattern (gold particles). 3) The expression of GPR39 
was located in the mature face of the Golgi area. 4) The expression 
of GPR39 was located in the cell membrane, mainly in the 
microvilli (gold particles). 
OBESTATIN INDUCES PROLIFERATION IN AN 
AUTOCRINE/PARACRINE MANNER IN AGS CELLS 
As Figure 4.3 shows, obestatin (100 nM and 200 nM) 
exerted a mitogenic effect in the AGS cell line (162±1% 
and 181±2%, respectively) by means of BrdU 
incorporation. The neutralization of obestatin (100 
nM) by anti-obestatin Ab preincubation diminished 
the BrdU incorporation to control levels. The 
autocrine/paracrine role of obestatin was tested by a 
combination of serum-free conditioned medium from 
AGS cells obtained at 24 and 48 h (CM24 and CM48, 
respectively) with neutralizing obestatin antibody.  
 
Figure 4.3. Mitogenic effect of obestatin in the AGS cells. AGS 
cells were treated with FBS (10%, v/v), OB (100 nM and 200 nM), 
OB-Ab (10 μg/mL), OB (100 nM) plus OB-Ab, CM24, CM48, 
CM24+OB-Ab and CM48+OB-Ab, and cell proliferation was 
evaluated after 48 h by means of BrdU incorporation. The data 
were expressed as a percentage of the basal proliferation of the 
untreated cells (Mean ± SEM). The asterisk (*) denotes P<0.05 
when comparing the OB treated group with the control untreated 
group; the dagger (#) denotes P<0.05 when comparing the OB or 
CM plus OB Ab group with the OB or CM treated group.  
The treatment of AGS cells with CM24 caused an 
increase in proliferation, which was completely 
abolished by CM24 + anti-obestatin Ab treatment. 
Similar results were obtained with the CM48 
treatment, but with a higher impact. Likewise, the 
immunocytochemical   analysis  of   the   proliferation   




Figure 4.4. Immunocytochemical expression of Ki67 in AGS cells after 24 hour of proliferation. 1. Control without treatment. 2. 10% FBS. 
3. 100nM OB. 4. 100nM OB+OB-Ab (10 µg/mL). 5. CM24. 6. CM24+OB-Ab. 7. CM48. 8. CM48 +OB-Ab. Objective magnification x20.  
marker Ki67303 confirmed the proliferative activity of 
obestatin (Figure 4.4). The Ki67-immunopositive cells 
after obestatin treatment (100 nM, 24h; Figure 4.4.3) 
were similar to those obtained with FBS (Figure 4.4.2). 
Anti-obestatin Ab clearly reduced the Ki67 expression 
levels with respect to standard conditions (Figure 
4.4.4). Furthermore, the presence of the anti-
obestatin Ab reduced the Ki67 expression of AGS cells 
treated with CM24 (Figure 4.4.6 and 4.4.5, 
respectively), whereas Ab treatment partly decreased 
Ki67 expression in CM48-treated cells (Figure 4.4.8 
and 4.4.7, respectively). This discrepancy with CM24 
might be due to the numerous factors secreted by the 
cells, which were present in CM after 48 h. 
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OBESTATIN PROMOTES CELL MOBILITY AND 
INVASION VIA EMT AND CYTOSKELETON 
REMODELLING IN AGS CELLS 
AGS cells are organized in clusters of polygon-shaped 
cells, few actin short stress fibres, and no lamellipodia 
with their cobblestone-like phenotype. These actin 
filaments in the form of stress fibres and the thin 
network formed at the edges could be depolymerized 
by the removal of serum, although the phenomenon 
was reversible when the cells were returned back to 
serum containing medium.304  We then analysed the 
effect of obestatin on the morphology and 
cytoskeleton in serum-free medium to avoid 
interference (Figure 4.5). Under these conditions, 
obestatin treatment (200 nM, 24 h) promoted the 
dissociation of the cell clusters and induced cellular 
elongation with the formation of filopodia-like 
304 Palovuori R, Perttu A, Yan Y, et al. Helicobacter pylori induces formation 
of stress fibers and membrane ruffles in AGS cells by Rac activation. 




structures (blue arrows) and lamellipodia-like 
structures (green arrows) typical of motile cells. 
Obestatin also induced strong actin polymerization 
including the development of stress fibres (pink 
arrows). Obestatin-treated cells presented the 
scattering/hummingbird-like phenotype previously 
reported in the case of H. pylori infection, mimicking 
an EMT.305 
 
Figure 4.5.  Effect of obestatin on the cytoskeleton reorganization 
in AGS cells. The AGS cells were stimulated with 200 nM OB for 24 
h. Cells were stained with Phalloidin CruzFluor-594 (red) to 
visualize F-actin and DAPI (blue) to visualize the nucleus. Scale 
bar=20 µm. The image at the right represents a higher 
magnification view of the obestatin treated cells (scale bar=40 
µm). Obestatin treatment induced cellular elongation with the 
formation of filopodia-like structures (blue arrows), lamellipodia-
like structures (green arrows) and the development of stress fibres 
(pink arrows). Images are representative for at least three 
independent experiments. 
We analysed whether obestatin was driving cell 
migration using a wound-healing assay. As shown in 
                                                          
305 Bessède E, Staedel C, Acuña-Amador LA, et al. Helicobacter pylori 
generates cells with cancer stem cell properties via epithelial-
mesenchymal transition-like changes. Oncogene. 2014;33:4123-31. 
Figure 4.6, obestatin-treated cells exhibited a 
significant increase in their migration capability when 
compared with the control (P < 0.05, Figure 4.6).  
Figure 4.6. Migration of AGS cells promoted by obestatin. The 
AGS cells were treated or not with obestatin (200 nM). The wound 
was calculated by tracing along the border of the scratch using 
ImageJ64 analysis software and the following equation: %wound 
closure=[[wound area (0 h)-wound area (x h)]/ wound area (0 h)] 
x 100. The asterisk (***) denotes P<0.001 when comparing the 
treated with the untreated control group.  
Additionally, the inverted version of the classical 
Boyden chamber invasion assay222 (Figure 4.7), 
showed that the AGS cells were able to migrate 
through the membrane, mimicking basement 
membrane invasion and invade into the Matrigel as an 
extracellular matrix when obestatin was applied on 
top of the Matrigel as a chemoattractant (200 nM). 
The extent of cell invasion was quantified by 
measuring the fluorescence intensity at each confocal 
section every 5 μm from the membrane, and the 
differences between the untreated and treated cells 
were statistically significant (P < 0.001; Figure 4.7 right 
panel). 




Figure 4.7. Obestatin promotes invasion in AGS cells. Sequential confocal microscopy sections scanned every 5 μm from the membrane to 
the top of the Matrigel in an inverted invasion assay. Obestatin (200 nM) was used as a chemoattractant. Right panel. Mean fluorescence 
intensity (a.u.) quantified at the indicated sequential confocal sections. Bars, SEM; *** P<0.001. 
 
EMT is proposed to regulate the acquisition of 
migratory and invasive capability, which is a crucial 
mechanism in the initial steps in of metastatic 
progression.306 Because obestatin increased migration 
and invasion, we assessed obestatin’s influence on 
EMT by examining the expression of E-cadherin, β-
catenin, vimentin, and N-cadherin (Figure 4.8). 
Obestatin treatment (200 nM) increased β-catenin 
(active form) and N-cadherin levels after 12 h (127±7% 
and 112±3%, respectively), whereas vimentin levels 
showed an intense augmentation along the tested 
period of time with a maximum at 24 h (158±19%). E-
cadherin was not detected in the AGS cells, at least at 
the limits of immunoblot detection (data not shown). 
Indeed, this cell line harboured an E-cadherin 
mutation, leading to a truncated form of the protein 
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Figure 4.8. Immunoblot analysis of the EMT in AGS cells. The AGS 
cells were stimulated with obestatin (200 nM) for 12, 24, and 48 h 
and the blots were incubated with the corresponding antibodies 
to N-cadherin, β-catenin and vimentin. The protein expression was 
normalized relative to GAPDH. The data were expressed as 
mean±SEM obtained from intensity scans of six independent 
experiments. The asterisk (*, **, ***) denotes P<0.05, P<0.01 and 
P<0.001 when comparing the treated with the untreated control 
group.  






Figure 4.9. Immunoblot analysis of the pro-angiogenic activation 
of obestatin in AGS cells. The AGS cells were stimulated with 
obestatin (200 nM) for 12, 24, and 48 h and the blots were 
incubated with the corresponding antibodies to VEGF, VEGFR2 and 
PEDF. The protein expression was normalized relative to GAPDH. 
The data were expressed as mean±SEM obtained from intensity 
scans of six independent experiments. The asterisk (*, **, ***) 
denotes P<0.05, P<0.01 and P<0.001 when comparing the treated 
with the untreated control group. 
Regarding the VEGF/VEGFR2 system, obestatin 
increased the VEGF and VEGFR2 levels at 12 h and 48 
h (VEGF: 126±5% and 128±12%; VEGFR2: 140±21% 
and 134±20%, respectively; Figure 4.9), whereas it 
decreased the anti-angiogenic factor PEDF levels with 





OBESTATIN EXERTS ITS ACTIONS THROUGH THE 
GPR39 RECEPTOR IN AGS CELLS  
First, the effect of acute GPR39 deficiency on 
obestatin signalling was determined by treatment of 
AGS cells with a GPR39 siRNA. Under these conditions, 
the constructs decreased GPR39 expression by 65±2% 
(Figure 4.10). 
 
Figure 4.10. Effect of GPR39 knockdown by siRNA on obestatin-
activated pAkt(S473) and pERK1/2(T202/Y204) in AGS cells. The 
AGS cells were transfected with GPR39 siRNA prior to obestatin 
treatment (200 nM, 10 min). GPR39 was expressed as a fold of its 
level to control siRNA-transfected cells (n=3). Activation of Akt 
[pAkt(S473)] and ERK1/2 [pERK1/2(T202/Y204)] was expressed 
relative to the control siRNA-transfected cells. Equal amounts of 
protein in each sample were used to assess the expression of 
GPR39 by western blotting. The level of proteins was expressed as 
fold change relative to the control siRNA-transfected cells 
(mean±SEM). The protein expression was normalized relative to 
actin. The data were expressed as mean±SEM obtained from 
intensity scans of independent experiments. The asterisk (*) 
denotes P<0.05 when comparing the treated control siRNA group 
with the control siRNA group; the dagger (#) denotes P<0.05 when 
comparing the GPR39 siRNA group with the control siRNA group. 




Figure 4.11. Effect of SiRNA depletion of GPR39 on obestatin-
activated Ki67 expression in AGS cells. The AGS cells were 
transfected with GPR39 siRNA prior to obestatin treatment (200 
nM, 24 h). Expression of Ki67 was denoted as a fold of the 
respective levels in control siRNA-transfected cells (n=3). Equal 
amounts of protein in each sample were used to assess the 
expression of GPR39 by western blotting. The level of proteins was 
expressed as fold change relative to the control siRNA-transfected 
cells (mean±SEM). The protein expression was normalized relative 
to actin. The data were expressed as mean±SEM obtained from 
intensity scans of independent experiments. The asterisk (*) 
denotes P<0.05 when comparing the treated control siRNA group 
with the control siRNA group; the dagger (#) denotes P<0.05 when 
comparing the GPR39 siRNA group with the control siRNA group.  
In the presence of an si-control, the obestatin-
activated Akt(S473) and ERK1/2(T202/Y204) 
phosphorylations were identical to the levels 
observed with the untransfected cells (data not 
shown). The silencing of GPR39 decreased subsequent 
pAkt(S473) and pERK1/2(T202/Y204) with respect to 
the control siRNA by 43±3% and 40±4% upon 
treatment of obestatin (200 nM, 10 min; Figure 4.10), 
respectively. Second, the effect of acute GPR39 
deficiency on Ki67 expression was evaluated. Under 
these conditions, the constructs decreased GPR39 
expression by 53±7% (Figure 4.11). The GPR39 
knockdown decreased obestatin-induced Ki67 
expression by 70±4% (Figure 4.11) with respect to si-
control. Immunocytochemistry confirmed decreased 
levels of Ki67 in GPR39 knockdown cells compared 
with control cells (Figure 4.12). 
  
Figure 4.12. Effect of GPR39 knockdown by siRNA on the 
immunocytochemical expression of obestatin-activated Ki67 in 
AGS cells. The AGS cells were transfected with GPR39 siRNA prior 
to obestatin treatment (200 nM, 24 h). 1) siRNA control without 
treatment. 2) siRNA GPR39 without treatment. 3) siRNA control 








Figure 4.13. Effect of GPR39 knockdown by siRNA on the cytoskeleton reorganization in AGS cells. The AGS cells were transfected or not 
with GPR39 siRNA prior to obestatin treatment (200 nM, 24 h). Cells were stained with Phalloidin CruzFluor-594 (red) to visualize F-actin, 
anti-GPR39 antibody (green) to visualize the knockdown of the receptor and DAPI (blue) to visualize the nucleus. Objective magnification 
x63. Scale bar=20 μm. Images are representative for at least three independent experiments.  
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The above results implicated the obestatin/GPR39 
system in EMT and cell motility, possibly by 
cytoskeletal modulation. Consistent with a role in 
actin polymerization, the GPR39 knockdown cells 
exhibited depolymerization and redistribution of the  
cellular F-actin, diminishing lamellipodia formation 
compared to the control cells after obestatin 
treatment (Figure 4.13). Taken together, these results 
suggest that the obestatin/GPR39 system induces 
cytoskeleton remodeling to facilitate AGS cell 
migration and invasion. 
GPR39 AND OBESTATIN EXPRESSION IN HUMAN 
HEALTHY STOMACH TISSUE 
As shown in Figure 4.14, no GPR39 expression was 
detected in the mucous cells of the gastric pits. Weak 
positivity was observed in parietal cells, whereas 
intense immunostaining was present in the chief cells 
located at the base of the oxyntic glands (Figure 
4.14.A and 4.14.B). Regarding obestatin expression, 
the obestatin-IR endocrine cells were localized from 
the neck to the base of the gastric glands in the oxyntic 
mucosa (Figure 4.14.C and 4.14.D). These cells were 
small and roundish and showed typical morphology of 
closed-type endocrine cells, which were devoid of 
elongation contacting the lumen.34 
GPR39, OBESTATIN AND Ki67 EXPRESSION IN 
HUMAN GASTRIC ADENOCARCINOMAS 
The characteristics of the patient samples and the 
results obtained in the gastric adenocarcinomas 
studied are summarized in Table 4.1.  
 
Figure 4.14. GPR39 and obestatin are expressed in human 
healthy stomach tissue. Immunohistochemical expression of 
GPR39 and obestatin in normal stomach. A) There was no GPR39 
expression in the mucous cells of the gastric pits. A weak positivity 
was observed in parietal cells, whereas an intense immunostaining 
was present in the chief cells. Objective magnification x4. B) Higher 
magnification view (x10) of the GPR39 immunostaining in the chief 
cells. C) Obestatin immunoreactivity was only observed in 
neuroendocrine cells of oxyntic glands (x4). D) At higher 
magnification, obestatin producing cells were recognized as small 







Laurén classification Age Sex Size (cm) TNM staging obestatin GPR39 Ki67 (%) 
Well differentiated        
Intestinal 72 F 3.0 pT4N2M1 NM-NC 2+, homogeneous 39 
Intestinal 81 F 6.8 pT2bN1 0 1+ homogeneous 44 
Intestinal 67 M 3.5 pT4N3M1 NM-NC 1+ heterogeneous 48 
Intestinal 53 M 5.0 pT3N1 NM-NC 1+ heterogeneous 59 
Intestinal 81 F 4.3 pT2 NM-NC 1+ heterogeneous 53 
Intestinal 83 M 1.7 pT1N0 NM-NC 0 homogeneous 66 
Intestinal 69 F 4.3 pT4 0 1+ homogeneous 37 
Intestinal 76 M 4.3 pT3N1 NM-NC 2+, heterogeneous 37 
Intestinal 81 M 7.5 pT3N3 NM-NC 2+ 71 
Moderately differentiated 
Intestinal 88 F 6.5 pT3 0 1+ 53 
Intestinal, with SRC 84 F 7.0 pT4N3M1 NM-NC 1+ 79 
Intestinal 68 F 6.8 pT4N3 0 2+ heterogeneous 72 
Intestinal 53 F 2.0 pT4N1 0 1+ 49 
Intestinal 40 M 2.1 pT4 0 2+ 69 
Intestinal 72 M 7.5 pT4N3 NM-NC 2+ 37 
Intestinal 49 F 4.2 pT3N1 0 2+ 93 
Intestinal 82 F 7.5 pT4N3 0 2+, heterogeneous 81 
Intestinal 61 M 5.1 pT4N2 NM-NC 2+ 51 
Intestinal 85 M 7.5 pT4N0 NM-NC 1+ 68 
Poorly differentiated 
Intestinal 76 M 7.0 pT3N3Mx 0 2+ 21 
Diffuse, with SRC 58 F 1.6 pT2Nx NM-NC 2+, SRC negative 20 
Mixed 67 M 5.7 pT3N3 NM-NC 2+ 19 
Mixed, with SRC (<50%) 80 F 7.5 pT3N0 NM-NC 3+ 37 
Diffuse 78 F 6.0 pT4N0 NM-NC 2+ 23 
Intestinal 85 M 6.5 pT2N1 NM-NC 3+ 63 
Mixed, with SRC 79 F 4.9 pT4N1 0 3+ 31 
Intestinal 64 M 4.5 pT4N2 0 3+ 30 
Diffuse, with SRC 62 F 2.3 pT2N1 0 2+, heterogeneous 47 
Table 4.1. Summary of the characteristics and the obestatin, GPR39 and Ki67 immunostaining results of the gastric adenocarcinomas 
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Figure 4.15 shows the results obtained for obestatin, 
GPR39, and Ki67 in the samples of human gastric 
adenocarcinomas, represented by a WD and a PD 
adenocarcinoma (Figure 4.15.A and 4.15.B, 
respectively). In these samples, obestatin (Figure 
4.15.A.1 and 4.15.B.1) was negative in all of the gastric 
adenocarcinomas studied (Figure 4.15.A.3 and 
4.15.B.3), whereas intense staining was found in the 
neuroendocrine cells of the healthy gastric mucosa 
(Figure 4.15.A.2 and 4.15.B.2), although it was 
negative in the rest of the oxyntic mucosa. By contrast, 
GPR39 positivity was present in all of the tumours with 
varying intensity according to the classification of the 
samples. Lower expression was found in WD tumours 
(mostly 1+), and the highest expression was observed 
in the PD adenocarcinomas (2+/3+ or 3+, 
predominantly). The Golgi staining was more intense, 
in general, for the WD adenocarcinomas (Figure 
4.15.A.4 and 4.15.A.5), was diminished for the MD 
and was not detectable in the majority of the analysed 
PD adenocarcinomas, although three of them 
presented high positivity in the Golgi area (Figure 
4.15.B.4 and 4.15.B.5). 
Ki67 immunohistochemistry using an MIB-1 antibody 
was used to evaluate the proliferative activities. Ki67 
immunohistochemistry produced a mean Ki67 
proliferative index (PI) of 50.4%±1.6 in the WD, 
65.2%±1.9 in MD and 29.5%±1.8 in PD 
adenocarcinomas (Figure 4.15.C: WD/MD, 
***P<0.001; MD/PD, *P<0.05; and WD/PD, *P<0.05). 
                                                          
308 Lee HE, Kim MA, Lee BL, et al. Low Ki-67 proliferation index is an 
indicator of poor prognosis in gastric cancer. J Surg Oncol. 2010;102:201-
6. 
These results support previous data demonstrating 
that low Ki67 PI might lead to an unfavorable 
prognosis as it has been correlated to poorly 
differentiated histology, an advanced T stage, lymph 
node metastasis, and greater expression of EMT-
related proteins.308 Strong and enigmatic male 
dominance has been described in the incidence of 
gastric cancer with a male-to-female ratio of 
approximately 2:1, and these differences may be 
related to the protective effect of estrogens, especially 
for the intestinal-type adenocarcinomas.309 Regarding 
Ki67 expression, we observed the following results for 
males: WD, 56.2%±6.2; MD, 56.2%±7.6; and PD: 
33.3%±10.2. For female patients, the results were as 
follows: WD, 45.5%±3.4; MD, 71.2%±6.9; and PD, 
31.6%±4.9, with statistically significant differences 
between WD/MD, and MD/PD (*P<0.05 and 
**P<0.01, respectively). However, the results for 
GPR39 expression correlated with the 
dedifferentiation of the tumour, with increased 
expression from WD (1.22 a.u.±0.2), MD (1.60 
a.u.±0.2), to PD (2.44 a.u.±0.2) (Figure 4.15.D: WD/PD, 
**P<0.01; and MD/PD, **P<0.01; Figure 4.15.D). The 
expression levels organized by sex followed the same 
tendency, although the differences between the 
groups were statistically significant only in females 
(WD/PD, *P<0.05; and MD/PD, *P<0.05). These 
patterns of expression are summarized in Figure 
4.15.C and 4.15.D, and Table 4.2 shows the 
correlations in these samples.  
309 Chandanos E, Lagergren J. Oestrogen and the enigmatic male 




Figure 4.15. GPR39, obestatin and Ki67 expression in human gastric adenocarcinomas. A. Immunohistochemical expression of obestatin, 
GPR39, and Ki67 in a well differentiated gastric adenocarcinoma. 1) Obestatin expression is negative in all gastric adenocarcinomas studied. 
Positive expression of obestatin is only observed as an intense stain in neuroendocrine cells of gastric mucosa, being negative in mucous 
cells of the gastric pits and in the rest of the fundic glands. Objective magnification x4. 2) Higher magnification view of obestatin positivity in 
the healthy surround of the tumour (x20). 3) Obestatin expression is negative in the well-differentiated gastric adenocarcinoma (x20). 4) The 
intense expression of GPR39 is present in the tumour, whereas no immunostaining was found in the superficial areas of the mucosa (x4). 5) 
Higher magnification view of GPR39 positivity (x20). 6) Low Ki67 expression was found in this well-differentiated adenocarcinoma. B. 
Immunohistochemical expression of obestatin and GPR39 in a poorly differentiated gastric adenocarcinoma. 1) Obestatin expression is 
negative in all gastric adenocarcinomas studied. Positive expression of obestatin is only observed as an intense stain in neuroendocrine cells 
of gastric mucosa, being negative in mucous cells of the gastric pits and in the rest of the fundic glands (x4). 2) Higher magnification view of 
obestatin positivity in the healthy surround of the tumour (x20). 3) Obestatin is negative in the poorly differentiated gastric adenocarcinoma 
(x20). 4) The intense expression of GPR39 is present in the tumour, whereas no immunostaining was found in the superficial areas of the 
mucosa (x4). 5) Higher magnification view of GPR39 positivity (x20). 6) High Ki67 expression was found in this poorly differentiated 
adenocarcinoma. C. Graphical representation of the Ki67 levels of expression in the studied gastric adenocarcinomas. The asterisk (*, **, 
***) denotes P<0.05, P<0.01 and P<0.001 when comparing groups. D. Graphical representation of the GPR39 levels of expression in the 
studied gastric adenocarcinomas. The asterisk (*, **, ***) denotes P<0.05, P<0.01 and P<0.001 respectively, when comparing groups. 












Table 4.2. Pearson Correlation of the data. Correlation coefficient (r) below and P-values above the diagonal. * means significant at the 0.05 
level (2-tailed); ** means significant at the 0.01 level (2-tailed); and *** means significant at the 0.001 level (2-tailed). N = 28. 
  
 Age Sex Size Differentiation GPR39 Ki67 expression 
Age - 0.640 0.002** 0.797 0.682 0.823 
Sex 0.09 - 0.812 0.651 0.902 0.780 
Size 0.57 -0.05 - 0.477 0.217 0.633 
Differentiation -0.05 0.9 0.14 - 0.000*** 0.049* 
GPR39 
expression 
-0.08 -0.02 0.24 0.66 - 0.182 
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CHAPTER 5: PEPSINOGEN I SECRETION: THE FUNCTION OF THE OBESTATIN/GPR39 
SYSTEM IN HUMAN STOMACH
In previous chapters we described the expression of 
obestatin/GPR39 system in healthy human stomach as 
well as in human gastric adenocarcinomas. The 
positivity found for GPR39 in the chief cells of healthy 
stomach samples prompted us to investigate the 
relationship between the obestatin/GPR39 system 
and the secretion of pepsinogen in an in vitro model 
that endogenously expressed the three components 
of the study: obestatin, GPR39 and pepsinogen. 
GPR39 receptor and pepsinogen PGI expression was 
determined in human stomach samples by 
immunohistochemistry. PGI secretion after 
exogenous administration of obestatin was 
determined by the haemoglobin method and by 
immunoblot in the gastric adenocarcinoma cell line 
AGS. The influence of the acute GPR39 deficiency on 
PGI secretion after obestatin treatment was 
determined using siRNA knockdown of GPR39. 
GPR39 IS EXPRESSED IN THE CHIEF CELLS OF THE 
OXYNTIC MUCOSA OF THE HUMAN STOMACH 
In chapter 4 it was reported the expression of the 
GPR39 receptor and obestatin in the healthy mucosa 
of the stomach and their implication in the 
development of gastric adenocarcinomas. Obestatin 
positive expression was found exclusively in the 
neuroendocrine cells localized from the neck to the 
base of the gastric glands in the oxyntic mucosa 
(Figure 4.13.C). Concerning the GPR39 expression, 
intense positivity was found in the chief cells of the 
oxyntic glands (Figure 5.1.A). GPR39 positivity was 
also detected in a few cells located between the neck 
and the base of the glands. These cells might be 
immature chief cells migrating towards the base of the 
oxyntic gland, namely, pre-chief cells or transitional 
cells. Indeed, it has been described that chief cells 
derive from an intermediate cell type, characterized 
by abundant mucinous vesicles in the neck of the 
gland, the mucous-neck cells, through a process of 
transdifferentiation.310  
Regarding pepsinogen I, intense staining was observed 
in the chief cells of the oxyntic mucosa. The mentioned 
cells were filled with numerous large secretion 
granules showing specific labelling for pepsinogen I 
(Figure 5.1.F). This positivity was also found in mucous 
cells of the glandular necks (mucous neck cells) and in 
a few cells located at the boundaries between the 
neck and the base (Figure 5.1.D). Figure 5.2 shows 
detailed zones of the neck region of the oxyntic glands. 
The serial sections (3 μm) utilized for the 
immunohistochemistal technique, showed that the 
mucous neck cells were pepsinogen I positive and 
GPR39 negative, and that the pre-chief cells were 
positive for both proteins (Figure 5.2.C and 5.2.F). 
To confirm this finding, we studied GPR39 and 
pepsinogen expression by immunofluorescence. As 
shown in Figure 5.3, the pre-chief cells 
immunoreactive for GPR39 (green) were also positive 
for pepsinogen I (red). In addition, a few mucous neck 
cells were found to be strongly immunolabelled for 
pepsinogen I but negative for GPR39 (Figure 5.3.C).
                                                          
310 Goldenring JR, Nam KT, Mills JC. The origin of pre-neoplastic metaplasia 





Figure 5.1. Immmunohistochemical expression of GPR39 and pepsinogen I in human healthy stomach. Expression at the base of the 
oxyntic gland. A. There was no GPR39 expression in the mucous cells or parietal cells of the gastric pits. An intense immunostaining was 
present in the chief cells situated at the base of the oxyntic glands. Objective magnification x4. B. Magnification view (x10) of the GPR39 
intense immunostaining in the chief cells of the oxyntic glands. C. At higher magnification, GPR39 producing cells were clearly recognized 
with brownish staining in the cytoplasm. Parietal cells were negative for GPR39 (x40). D. Serial section (3 μm) of the same sample labelled 
for pepsinogen I. The intense PGI expression was observed mainly in the chief cells at the base of the oxyntic glands (x4), although few 
scattered cells were positive in the neck zone. E. Magnification view of the PGI positivity at the base of the oxyntic gland (x10). F. A higher 
magnification view shows that PGI expressing cells were filled with numerous secretion granules showing a specific labelling for PGI. Parietal 
cells were negative for PGI (x40).  
Figure 5.3.D, E and F, show magnifications of the 
gastric glands sections (x20). At the lower region of the 
glands, pepsinogen I and GPR39 expression was found 
in the chief cells (Figure 5.3.D). The upper region 
shows a few cells positive for pepsinogen only, the 
mucous neck cells (Figure 5.3.E), whereas they were 
more abundant in the neck section (Figure 5.3.F). In 
the last region, GPR39 positivity was limited to some 
pepsinogen I positive cells morphologically 
intermediate and topographically interposed between 
mucous neck cells and chief cells, the pre-chief cells 
(Figure 5.3.F).311 Taking into account the found 
location for GPR39, obestatin might regulate 
pepsinogen secretion in the chief cells, an important 
fact for the digestive process in the stomach.  
 
                                                          
311 Cornaggia M, Capella C, Riva C, et al. Electron immunocytochemical 
localization of pepsinogen I (PgI) in chief cells, mucous-neck cells and 
transitional mucous-neck/chief cells of the human fundic mucosa. 
Histochemistry. 1986;85:5-11. 
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Figure 5.2. Immmunohistochemical expression of GPR39 and pepsinogen I in human healthy stomach. Expression at the neck of the 
oxyntic gland. A. General view of GPR39 expression in the oxyntic mucosa. Objective magnification x4. B. Magnification view (x10) of the 
GPR39 intense immunostaining in few cells of the neck section. C. At higher magnification, GPR39 producing cells were clearly recognized 
with brownish staining in the cytoplasm. These cells might be immature chief cells emerging to the base of the oxyntic gland (pre-zymogenic 
cells; x40). D. Serial section (3 µm) of the same sample labelled for pepsinogen I (x4). E. Magnification view of the PGI positivity at the neck 
zone (x10). F. A higher magnification view shows two cell types showing a specific labelling for PGI. The pre-zymogenic cells immunereactive 
for GPR39 were also positive for PGI. In addition, a few mucous neck cells were found to be strongly immunolabelled for PGI but negative 






Figure 5.3. Immunofluorescence detection of GPR39 and pepsinogen I in human healthy stomach The figure shows the 
immunofluorescence detection of pepsinogen (red, A) GPR39 (green, B) in the same section of the gastric mucosa. Objective magnification 
10x. Micrograph C (Merge) shows the colocalization of both proteins in the same cells mainly at the base of the oxyntic glands. D. At the 
lower region of the glands, pepsinogen I and GPR39 expression was found in the chief cells (pink arrow). E. The upper region shows a few 
cells positive for pepsinogen and GPR39, the pre-chief cells (blue arrow). F. The mucous neck cells were more abundant in the neck region 
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OBESTATIN STIMULATES PEPSINOGEN I SECRETION 
IN AGS CELLS 
Previous works of our research group demonstrated 
that the obestatin/GPR39 system operates as an 
autocrine/paracrine signal in AGS cells.301 Moreover, 
several groups described that the AGS cells were able 
to secrete pepsinogen I.312,313 In this way, the AGS cell 
line302 expressed the three components of the study: 
GPR39, obestatin and pepsinogen I, being a suitable 
model for our analysis. First, we performed a dose-
response curve to evaluate the optimum dose of 
obestatin (200 nM, data not shown). The kinetic study 
of PGI secretion after obestatin treatment (200 nM) 
showed an augment in its secretion for all of the time 
tested, with a maximum at 40 min post stimulation 
(159±31% over control 98±16%; Figure 5.4; upper 
panel). This secretion was measured by using the 
haemoglobin method.223 We corroborated this 
information by immunoblot at 40 min with similar 
results. Thus, obestatin treatment (200 nM) 
augmented pepsinogen secretion in a 43±6% over 








                                                          
312 Basque JR, Chénard M, Chailler P, et al. Gastric cancer cell lines as 
models to study human digestive functions. J Cell Biochem. 2001;81:241-
51. 
 
Figure 5.4. Obestatin stimulated pepsinogen I secretion in AGS 
cells. Upper panel) Kinetic study of PGI secretion after obestatin 
treatment (200 nM) at 30, 40, 50 and 60 min post stimulation. This 
secretion was measured by using the haemoglobin method. The 
data were expressed as mean±SEM obtained from 3 independent 
experiments. The asterisk (*) denotes P<0.05 when comparing 
groups. Bottom panel) Immunoblot detection of PGI in the 
secretome of AGS cells at 40 min after obestatin treatment (200 
nM). Ponceau S staining (bottom panel) is shown to demonstrate 
total protein loading among lanes. The PGI expression was 
normalized relative to a band developed after Ponceau S 
treatment. The level of proteins was expressed as fold change 
relative to the control untreated cells. The data were expressed as 
mean±SEM obtained from intensity scans of 3 independent 
experiments. The asterisk (*) denotes P<0.05 when comparing 
groups. 
 
313 Chan EC, Chen KT, Lin YL. Vacuolating toxin from Helicobacter pylori 
activates cellular signaling and pepsinogen secretion in human gastric 




PEPSINOGEN SECRETION IS MEDIATED BY GPR39 
To ascertain that the effect of obestatin on 
pepsinogen secretion described above was mediated 
by the GPR39 receptor, we tested the influence of the 
acute GPR39 deficiency by siRNA knockdown in AGS 
cells (Figure 5.5). Under these conditions, the 
constructs exhibited a decrease in the GPR39 
expression by 83±4% in the cell lysate. Firstly, to check 
the efficiency of obestatin action in this cell line, we 
tested the effect on Akt phosphorylation at S473 
[pAkt(S473)]. In the presence of a non-targeting 
control siRNA, the phosphorylation of human 
obestatin-activated Akt(S473) were similar to that 
observed without any transfection (data not shown). 
The silencing of the GPR39 subsequently decreased 
the levels of pAkt(S473) with respect to the control 
siRNA by 63±2% following treatment with obestatin 
(200 nM, 40 min). As happened for pAkt(S473), cells 
transfected with siRNA targeting GPR39 led to a 
significant decrease in obestatin-stimulated 
pepsinogen secretion respect to control siRNA 











Figure 5.5. Effect of GPR39 knockdown by siRNA on obestatin-
stimulated pepsinogen I secretion in AGS cells. The AGS cells were 
transfected with GPR39 siRNA prior to obestatin treatment (200 
nM, 40 min). GPR39, pAkt(Ser473) were measured in the cell 
lysate. The protein expression was normalized relative to actin. 
Equal amounts of protein in each sample were used to assess the 
expression of GPR39 by western blotting. PGI was measured in the 
secretome of the cells. Ponceau S staining (bottom panel) is shown 
to demonstrate total protein loading among lanes. The PGI 
expression was normalized relative to a band developed after 
Ponceau S treatment. The level of proteins was expressed as fold 
change relative to the control siRNA-transfected cells. The data 
were expressed as mean±SEM obtained from intensity scans of 3 
independent experiments. The asterisk (*) denotes P<0.05 when 
comparing the treated control siRNA group with the control siRNA 
group; the dagger (#) denotes P<0.05 when comparing the GPR39 
siRNA group with the control siRNA group. 
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CHAPTER 6: OBESTATIN/GPR39 SYSTEM IN HUMAN CANCER LINES. EFFECTS ON 
PROLIFERATION AND INVASIVENESS  
The obestatin proliferative effect and its signalling 
mechanisms had been already described for two 
gastric cancer cell lines: AGS and KATO III cells.123,142 In 
AGS cells, obestatin also had an autocrine/paracrine 
role on proliferation and played a key role in the 
skeleton reorganization promoting invasion and 
migration of these cells, altering the expression of 
proteins involved in the EMT. Taken together, these 
data show an important implication of the 
obestatin/GPR39 system in the development of gastric 
tumours. GPR39 is a GPCR expressed in many tissues 
of the human body with specific physiological 
functions on them. Our recent data regarding 
obestatin and GPR39 in gastric cancer, prompted us to 
investigate the role of this system in the development 
of other cancers in human body.  
OBESTATIN AND GPR39 ARE EXPRESSED IN CANCER 
CELL LINES  
As a first approach, obestatin and GPR39 expression 
was invesigated in eight cancer cell lines (Table 6.1). 
As seen in Figure 6.1, the expression of the 
obestatin/GPR39 system was detected by 
immunocytochemistry in the cell lines of the study: 
                                                          
314 Fogh J, Trempe G. New human tumor cell lines. In Human Tumor Cells 
in vitro. Plenum Press, New York. 1975;115-59. 
315 Lieber M, Mazzetta JA, Nelson-Rees W, et al. Establishment of a 
continuous tumor-cell line (panc-1) from a human carcinoma of the 
exocrine pancreas. Int J Cancer. 1975;15:741-7. 
316 Soule HD, Vazguez J, Long A, et al. A human cell line from a pleural 
effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973;51:1409-
16. 
317 Pattillo RA, Gey GO. The establishment of a cell line of human hormone-
synthesizing trophoblastic cells in vitro. Cancer Res. 1968;28:1231-6. 
318 Kaighn ME, Narayan KS, Ohnuki Y, et al. Establishment and 
characterization of a human prostatic carcinoma cell line (PC-3). Invest 
Urol. 1979;17:16-23. 
HT-29, PANC-1, MCF7, BeWo, PC3, A431, A549 and 
SW872. All of the cell lines expressed the 
obestatin/GPR39 system at different levels of intensity 
and presented enhanced expression generally related 
to mitotic cells. No immunostaining was found when 
obestatin or GPR39 antibodies were preadsorbed with 
homologous peptides (data not shown). 
Table 6.1. Relation of the human cell lines used in this work. 
319 Giard DJ, Aaronson SA, Todaro GJ, et al. In vitro cultivation of human 
tumors: establishment of cell lines derived from a series of solid tumors. J 
Natl Cancer Inst. 1973;51:1417-23. 
320 Lieber M, Smith B, Szakal A, et al. 1976 A continuous tumor-cell line from 
a human lung carcinoma with properties of type II alveolar epithelial cells. 
Int J Cancer. 1976;15;17:62-70. 
321 Fogh J, Wright WC, Loveless JD. Absence of HeLa cell contamination in 
169 cell lines derived from human tumors. J Natl Cancer Inst. 1977;58:209-
14. 
322 Sekiguchi M, Sakakibara K, Fujii G. Establishment of cultured cell lines 
derived from a human gastric carcinoma. Jpn J Exp Med. 1978;48:61-8. 
Cell lines Origin 
HT-29314  Colorectal adenocarcinoma 
PANC-1315  Pancreatic carcinoma 
MCF7316  Breast adenocarcinoma 
BeWo317  Choriocarcinoma 
PC3318  Prostate adenocarcinoma 
A431319  Epidermoid carcinoma 
A549320  Lung carcinoma 
SW872321  Liposarcoma 





Figure 6.1. Immunocytochemical expression of obestatin and GPR39 in several human cancer cell lines. (See text below). Objective 
magnification x20. 
HT-29. Intense and diffuse obestatin immunostaining 
was found in the cytoplasm, with an increased 
expression associated to mitosis. Intense GPR39 
immunostaining but in a lesser extension than 
obestatin, also with increased pattern associated to 
mitosis.  
PANC-1. Intense and localized perinuclear obestatin 
immunostaining was found, probably associated to 
Golgi, with increased expression associated to mitosis. 
Intense and diffuse GPR39 immunostaining was found 
in the cytoplasm. 
MCF7. Intense and diffuse obestatin immunostaining 
was found in the cytoplasm. Intense and diffuse 
GPR39 immunostaining was found, but in a lesser 




BeWo. Faint and diffuse obestatin immunostaining 
was found in the cytoplasm, with increased expression 
associated to mitosis. Faint and diffuse GPR39 
immunostaining was found, also augmented in 
mitosis. Some cells appeared to exhibit Golgi staining. 
PC3. Intense and diffuse obestatin immunostaining 
was found in the cytoplasm, although some cells 
presented perinuclear location, probably Golgi 
associated. Variable GPR39 staining was found, from 
faint to intense, always in a diffuse pattern. 
A431. Intense and diffuse obestatin immunostaining 
was detected. Intensity augmented in mitosis. Intense 
GPR39 immunostaining was found with perinuclear 
location. Also increased expression associated to 
mitosis. 
A549. From faint to intense diffuse obestatin 
immunostaining was found in the cytoplasm. Mitotic 
cells presented increased expression. Diffuse pattern 
for GPR39 was found in the cytoplasm with a few cells 
showing perinuclear location. 
SW872. Intense and diffuse cytoplasmic obestatin 
expression was detected, also increased in mitotic 
cells. The cells presented diffuse cytoplasmic GPR39 
expression. Some cells presented increased Golgi 
expression 
OBESTATIN CAUSES CYTOSKELETON 
REORGANIZATION AND INCREASES PROLIFERATION 
IN KATO III CELL LINE 
KATO III cell line was established from a signet ring cell 
carcinoma of the stomach, in which single cells 
diffusely infiltrate the surrounding tissues. They grow 
in vitro floating free and have cytological features of 
signet ring cells.322 In our study, this cell line presented 
cytoplasmic immunoreactivity for obestatin and 
GPR39 (Figure 6.2; upper panel), difficult to locate due 
to the small size of the cell cytoplasm. Then, we 
analysed the effect of obestatin on the morphology 
and cytoskeleton in serum-free medium (Figure 6.2; 
bottom panel). Under these conditions, obestatin 
treatment (200 nM, 24 h) seriously affected the 
spherical morphology of these cells causing 
observable cytoskeleton reorganization. Obestatin 
induced cellular elongation with the formation of 
filopodia-like and/or lamellipodia-like structures 
typical of motile cells. In addition, obestatin treated 
cells presented GPR39 expression (green) located in 
the perinuclear region of the cytoplasm.  
 
Figure 6.2. Upper panel. Immunocytochemical expression of 
obestatin and GPR39 in KATO III cells. Bottom panel. Obestatin 
effect in the cytoskeleton of KATO III cells. Cells were stimulated 
for 24 h with 100 nM OB. Cells were stained with rhodamine 
phalloidin (red) to visualize F-actin, anti-GPR39 antibody (green) to 
visualize the transfection of the receptor and DAPI (blue) to 
visualize the nucleus. Objective magnification x63. Scale bar=20 
μm. Images are representative for at least three independent 
experiments.  
Regarding proliferation of KATO III cells (Figure 6.3; 
upper panel), obestatin treated cells presented a 
significant increase in their proliferation compared to 





Figure 6.3. Upper panel. Mitogenic effect of obestatin in KATO III 
cells. Cells were treated with 100 nM obestatin, 40 µM ZnCl2, 40 
µM ZnCl2 plus 100 nM obestatin, and 10% FBS. Cell proliferation 
was evaluated after the times indicated in Table 3. The data were 
expressed as a percentage of the basal proliferation of the 
untreated cells (Mean ± SEM). Bottom panel. Mitogenic effect of 
obestatin in HT-29 cells. Cells were treated with 100 nM obestatin, 
40 µM ZnCl2, 40 µM ZnCl2 plus 100 nM obestatin, and 10% FBS. 
Cell proliferation was evaluated after the times indicated in Table 
3. The data were expressed as a percentage of the basal 
proliferation of the untreated cells (Mean ± SEM).  
As positive control, 10% FBS was used and KATO III 
proliferation increased to 336.00±8.20%. Due to the 
nature of KATO III cells, we quantified obestatin effect 
on proliferation by manual counting. To test whether 
the results were comparable to BrdU incorporation, 
we decided to perform the same experiments with the 
adherent HT-29 cell line. The results for HT-29 cell line 
(135.90±1.62%; Figure 6.3; bottom panel) were 
similar to those obtained by BrdU incorporation 
(140.00±3.02%; Figure 6.4).  
Zn+2 has been described as a ligand for GPR39.55 After 
bibliographic work, we selected the dose found in 
literature used to activate GPR39.55 To test the effect 
of Zn+2 on proliferation, we treated the KATO III cells 
with 40 µM Zn+2. The results were striking: KATO III 
cells were apoptotic after Zn+2 treatment 
(31.20±3.04%). However, the viable cells presented in 
the sample were able to proliferate significantly when 
they were co-treated with the obestatin plus Zn+2 
cocktail (56.40±2.21%). These results correlated with 
the numbers of cell viability. The HT-29 cell line 
showed similar results regarding proliferation and 
apoptosis (Figure 6.3; bottom panel). 
OBESTATIN STIMULATES PROLIFERATION OF CANCER 
CELL LINES VIA GPR39  
After the verification of the obestatin/GPR39 system 
expression in the cell lines of the study, we next 
analysed the effect of exogenous administration of 
obestatin on cell proliferation by BrdU incorporation.  
Cell line OB  s.e. P value Sig. PT PDT 
HT-29 140.00 3.02 0.0001 **** 48 23 
PANC-1 220.06 3.26 0.0002 *** 96 52 
MCF7 161.50 0.61 0.0038 ** 72 38 
BeWo 188.92 5.71 0.0001 **** 96 40 
PC3 132.63 5.48 0.0048 ** 72 25 
A431 127.00 7.27 0.0199 * 48 24 
A549 139.74 4.65 0.0009 *** 72 22 
SW872 122.11 5.86 0.0068 ** 72 65 
KATO IIIa 144.00 3.10 0.0042 ** 48 36 
Table 6.2. Obestatin mitogenic effect on the cell lines of the 
study. The obestatin effect on proliferation was measured by BrdU 
incorporation, except for the non-adherent KATO III cell line, which 
was performed by manual counting. OB: obestatin, 100 nM. Sig: 
significance. PT: proliferation time (h). PDT: population double time (h).  a 





Figure 6.4. A. Mitogenic effect of obestatin in several cancer cell lines. Cells were treated with 100 nM obestatin and cell proliferation was 
evaluated after the corresponding times indicated in Table 3 by means of BrdU incorporation. The data were expressed as a percentage of 
the basal proliferation of the untreated cells (Mean ± SEM). B. Immunoblot expression of GPR39 and EGFR in the cell lines of the study. 
GPR39 expression was detectable in considerable amount in all the cell lines tested. EGFR expression was low in most of the cell lines except 
in A431 and PANC-1 cells. Protein expression was normalized by GAPDH.  C. Representation of the GPR39 and EGFR expression related to 
BrdU data normalized to PDT and ET.  
As Figure 6.4.A shows, obestatin (100 nM) exerted a 
mitogenic effect in all of the tested cell lines. Obestatin 
maximum effect was observed in the PANC-1 cell line 
(220.06±3.26%). Nevertheless, the obestatin 
mitogenic effects were significant in all cell lines 
tested. Obestatin effect was less pronounced in the 
SW872 and the A431 cell lines (122.11±4.86% and 
127.00±7.27%, respectively). Table 6.2 summarizes 
the data obtained for the cell lines of the study. Our 
studies about the obestatin/GPR39 system described 
the existent crosstalk between GPR39 and EGFR.142 To 
unveil the role of EGFR in our systems, GPR39 and 
EGFR immunoblot were performed. As Figure 6.4.B 
shows, GPR39 expression was detectable in 
considerable amount in all the cell lines tested; 




lines. High expression was detected in A431323 and 
PANC-1324 cells, as previously described. BrdU data 
normalized to population doubling time (PDT) and to 
experimental time (ET) related to GPR39 and EGFR 
expression is represented in Figure 6.4.C 
Nevertheless, GPR39 crosstalk to RTKs is not only 
limited to EFGR. Obestatin activated RTKs screening 
involved other RTKs as was mentioned in Chapter 3.As 
mentioned above, the obestatin mitogenic effect was 
more pronounced for the PANC-1 cell line and in a 
much lesser extension in A431 cells. To ascertain 
whether obestatin effect was mediated by GPR39, we 
tested the effect of the GPR39 acute deficiency in 
PANC-1 cells (Figure 6.5) and the overexpression of 
the receptor in A431 cells (Figure 6.6). First, the effect 
of acute GPR39 deficiency on obestatin effects was 
determined by treatment of PANC-1 cells with a 
GPR39 siRNA. In the presence of a si-control, the 
proliferation of PANC-1 cells were similar to the levels 
observed with the untransfected cells (131.85±3.14% 
and 136.15±4.00%, respectively). The silencing of 
GPR39 decreased subsequent obestatin mitogenic 
effect with respect to the control siRNA 
(108.28±6.41%) upon treatment of obestatin (100 nM, 
48 h; Figure 6.5.A), respectively. Second, the effect of 
acute GPR39 deficiency on cytoskeleton 
reorganization was evaluated (Figure 6.5.B). 
Obestatin treatment promoted the dissociation of the 
cell clusters and induced cellular elongation with the 
formation of filopodia/lamellipodia-like structures 
typical of motile cells in the untransfected cells and in 
the control siRNA cells.  
 
Figure 6.5. A. Mitogenic effect of obestatin in the PANC-1 cells. PANC-1 cells were treated with FBS (10%, v/v) (positive control, data not 
shown) and obestatin (100 nM; OB). Cell proliferation was evaluated after 48 h by means of BrdU incorporation. The data were expressed as 
a percentage of the basal proliferation of the untreated cells (Mean ± SEM). B. Effect of GPR39 knockdown by siRNA on the cytoskeleton 
reorganization in PANC-1 cells. The PANC-1 cells were transfected or not with GPR39 siRNA prior to obestatin treatment. Cells were 
stimulated for 24 h with 100 nM OB. Cells were stained with Phalloidin CruzFluor-594 (red) to visualize F-actin, anti-GPR39 antibody (green) 
to visualize the knockdown of the receptor and DAPI (blue) to visualize the nucleus. Objective magnification x63. Scale bar=20 μm. Images 
are representative for at least three independent experiments.
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Obestatin also induced strong actin polymerization 
including the development of stress fibres. The 
silencing of GPR39 caused the loss of the cytoskeleton 
reorganization promoted by obestatin. However, in 
the case of A431 cells (Figure 6.6.A), overexpression 
of GPR39 caused a significant augment in obestatin-
promoted proliferation respect to the empty vector 
(+GFP), which is similar to untransfected cells 
(381.58±7.71%, 100.00±21.08, and 102.21±10.09, 
respectively). The impressive augment on BrdU 
incorporation after GPR39 overexpression might be 
due not only to the presence of GPR39, but to the 
large expression of EGFR present in this cell line.  
Regarding the structural phenotype of obestatin-
treated A431 cells, obestatin effect was more 
pronounced in GPR39 enriched cells and promoted a 
clear cellular elongation and the formation of 
lamellipodia-like structures. Obestatin also induced a 
stronger actin polymerization and the expression of 
stress fibres, enhancing an invasive phenotype (Figure 
6.6.C). Consistent with a role in actin polymerization, 
the GPR39 knockdown PANC-1 cells exhibited 
depolymerisation and redistribution of the cellular F-
actin, diminishing lamellipodia formation compared to 
the control cells after obestatin treatment (Figure 
6.5.B). However, GPR39-overexpressing A431 cells, 
presented increased effect regarding cytoskeleton 
reorganization (Figure 6.6.C). Taken together, these 
results suggest that the obestatin/GPR39 system 
induces cytoskeleton remodelling to facilitate cell 
migration and invasion. 
 
Figure 6.6. A. Mitogenic effect of obestatin in A431 cells. A431 cells were treated with FBS (10%, v/v) and obestatin (100 nM; OB). Cell 
proliferation was evaluated after 48 h by means of BrdU incorporation. The data were expressed as a percentage of the basal proliferation 
of the untreated cells (Mean ± SEM).  B/C. Effect of GPR39 overexpression on the cytoskeleton reorganization in A431 cells. The A431 cells 
were transfected or not with GPR39 plasmid prior to obestatin treatment. Cells were stimulated for 24 h with 100 nM OB. Cells were stained 
with Phalloidin CruzFluor-594 (red) to visualize F-actin, anti-GPR39 antibody (green) to visualize the transfection of the receptor and DAPI 






















Classically, agonists of the GPCRs have been thought 
to display a linear efficacy in which activation of the 
receptor-related signalling network (e.g., G protein 
signalling, receptor phosphorylation, β-arrestin 
recruitment and internalization) is associated with the 
degree of the receptor activation, and this activation 
ranges from partial to full. Nonetheless, it is now 
recognized that β-arrestins initiate and determine the 
signals with different spatial and temporal patterns, 
thus resulting in singular cellular and 
pathophysiological consequences. This fact introduces 
a new concept that proposes the efficacy of G protein-
coupled receptors as pluridimensional factors. This 
conclusion means that G protein-coupled receptors 
exhibit different active conformations that are able to 
trigger either the full range of receptor-associated 
activities or a subset of these activities. In this context, 
it appears that human obestatin (1) stabilizes the 
GPR39 conformations that are necessary for the 
complete signalling associated with the G protein and 
β-arrestin downstream pathways. This ligand action is 
clearly determined by amidation at the C-terminus of 
human obestatin (1), which was shown to be essential 
for signalling in all downstream pathways of the G 
protein- and β-arrestin-mediated signalling with the 
subsequent activation of ERK1/2 and Akt, respectively. 
As deduced from the structural studies, human non-
amidated obestatin (2) does not possess the α-helical 
pattern of 1, such as the α-helix formed between 
Ser20 and Leu23 and the α-helix formed from Gly8 to 
Lys11. Instead, a 310 helix appears between Gly8 and 
Ser12. This structural change may be responsible for 
the negligible effect of 2 on the expression of Ki67, 
which is not comparable to that caused by human 
obestatin (1). To date, Ki67 has not been 
unequivocally associated with either the G protein- or 
β-arrestin-mediated signalling. In fact, although Ki67 
has been recognized as a relevant prognostic and 
predictive marker for proliferation, the exact 
intracellular regulation remains obscure. For 3, the 
absence of the first five residues appears to be the key 
to the inability of this peptide to stabilize the GPR39 
conformations associated with the activation of the G 
protein-dependent and β-arrestin-dependent 
signalling transductions. Furthermore, the impaired 
effect of peptide 3 on the expression of Ki67 compared 
with that induced by 1 reinforces the previous 
hypothesis. Regarding human (11-23)-obestatin (4), 
the loss of the first ten residues leads to a significant 
change in structure. This peptide presents the longer 
segment of an α-helix spanning from Tyr16 to Leu23. 
The biological data show that this ligand induces a 
selective coupling to only the β-arrestin portion of the 
GPR39 downstream signalling pathways. This 
evidence suggests that this peptide stabilizes a 
receptor conformation distinct from that induced by 
1. Interestingly, 4 exhibited a higher level of Ki67 
expression than the other truncated obestatin 
analogues did. It is tempting to speculate that the 
structure of this ligand represents a key element 
needed for the stabilization of the GPR39 
conformation coupled to β-arrestin signalling, thus 
controlling its interaction patterns and related 
functions. Finally, human (16-23)-obestatin (5) 
possesses a helical structure at its C-terminus. 
Nevertheless, its small size does not seem to be able 
to modulate the full range of GPR39 activities. 
Altogether, these results support the notion that more 
than one active conformation of GPR39 indeed exists 
and that the different ligands are able to stabilize a 





The behaviour of mouse obestatin (6) is also unique. 
This peptide is the same size as 1 and is also subject to 
amidation at its C-terminus. Moreover, 6 displays a 
characteristic pattern of helix sets: Gly8-Ser12, Ala14-
Gln17, and His19-Ala22. Indeed, the first two helical 
regions are coincident with the 310-helix fragment 
present in 3. However, the presence of this type of 
helix in 6 does not result in the activation of the human 
GPR39 receptor in ARPE-19 cells. In fact, mouse 
obestatin (6) did not activate either G protein-
dependent or β-arrestin-dependent signal 
transduction over the time period studied. 
Additionally, this peptide failed to induce Ki67 
expression, which is similar to the behaviour of human 
non-amidated obestatin (2). An inspection of the 
primary sequence indicated that the differences in 
primary structure between 1 and 6 are limited to only 
three amino acid residues, namely Val14Ala, Ser20Gly 
and Gln21Arg. The major dissimilarity is observed for 
Arg21, which can be positively charged. Spatially, this 
residue is located only two residues away from the 
neighbouring amidated Leu23. Thus, these structural 
differences may be responsible for the different 
bioactivities observed. Thus, in our biological model 
system, the activity of obestatin is species-specific. 
 In summary, a structure-activity relationship for 
obestatin has been derived by employing this peptide 
and several analogues as ligands for the seven-
transmembrane receptor GPR39. The analysis of the 
data suggests that amidation at the C-terminus of 
human obestatin (1) is essential for this molecule to 
adopt an α-helix structure. This α-helix exists between 
Ser20 and Leu23 and from Gly8 to Lys11. The presence 
of this structure correlates with the stabilization of the 
GPR39 conformations that are necessary for the full 
range of receptor activities, e.g., G protein-dependent 
and β-arrestin-dependent signalling. Indeed, the 
change of this α-helix to a 310 helix or the loss of this 
α-helical pattern can be correlated with the absence 
of complete activation, as observed for non-amidated 
obestatin (2). Additionally, GPR39 is able to adopt 
multiple active conformations, which are related to 
the activation of specific signalling mechanisms. In 
particular, human (11-23)-obestatin (4) is able to 
induce selective coupling to a portion of the 
downstream signalling pathways, e.g., β-arrestin-
dependent signalling. This observation supports the 
idea that 4 stabilizes a receptor conformation 
different from that induced by human obestatin (1). 
Most likely, this activity is related to the presence of 
the α-helix segment from Tyr16 to Leu23. Because this 
peptide is present in the stomach, it might represent 
the first example of an endogenous biased ligand for 
GPR39. Finally, mouse (6) and human obestatin (1) 
exhibit clear conformational differences beyond their 
differences in primary structure. The mouse analogue 
adopts a distinct 3D structure, which cannot activate 
human GPR39. This evidence supports the existence of 
a species-specific activity. Overall, the data presented 
herein provide a new structural background, which 
could be useful for the development of particular 
ligands that are able to discernibly improve, diminish 








In cells, proteins interact specifically with receptors, 
co-factors, ligands and other peptides, generating a 
cellular environment difficult to replicate. Biomimetic 
approaches of structure determination have made 
very valuable contributions to undestanding the roles 
of many proteins. However, the accurate structural 
basis of their biological functions require observations 
in living cells. Its non-invasive character and its ability 
to provide data at atomic resolution make 
heteronuclear multi-dimensional NMR spectroscopy 
ideally suited for the task.325 In this context, we have 
used NMR techniques to determine the solution 
structure of human obestatin (1) and the fragment 
peptides (6-23)-obestatin (3), (11-23)-obestatin (4), 
(16-23)-obestatin (5) and (1-10)-obestatin (7) in H2O, 
PBS and HEK293 both wild type and transiently GPR39-
transfected cells.  
1H and 2D spectra data of obestatin truncates showed 
non-significant and very weak differences in their 
structure between samples. Significant CSPs effects in 
PBS solution might indicate a tendency to a α-helix 
organisation, for 3 and 7. Nevertheless, NOE pattern 
appeared to reveal random coil conformations in all 
solutions with only strong sequential δNN(i, i+1) and 
δαN(i, i+1) NOEs. CSI analysis was employed due to the 
absence of extensive medium- and long-range NOE 
data and its application as a predictive approach for 
small proteins. In this sense, all truncates showed 
unstructured characteristics in H2O, excluding 5 and 7. 
These last peptides presented data consistent with 
some tendency to helicoidal structures in H2O. 
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Regarding full-length obestatin samples, NMR data 
showed some noteworthy results. In H2O and PBS 
solutions, our findings on CSPs changes, NOE pattern 
and CSI analysis pointed to a fairly high percentage of 
random coil conformations for this molecule. In the 
presence of wild type living cells, positive CSPs effects 
were found, which may imply a β-strand 
reorganization or a loss of helical structures in cells 
lacking receptor. Significantly, important CSPs changes 
were observed in Pro4 and His19 hydrogens when 
comparing WT:GPR39 resonances. Prolines hold a 
distinctive cyclic structure in its side chain that implies 
an exceptional conformational rigidity. This 
characteristic affects the rate of peptide bond 
formation between Pro and other amino acids and its 
behaviour as a structural disruptor of secondary 
structure elements such as α-helix and β-sheets. 
However, Pro is commonly found as the first residue 
of an α-helix and also in the edge strands of the β-
sheets. Furthermore, peptide bonds to proline are 
able to populate both the cis and trans isomers.326 The 
data observed for Pro4 in receptor-enriched cells 
might involve an E/Z obestatin isomerization. 
However, we did not found any SCE effect and/or 
double sets of signals for obestatin in the presence of 
HEK-GPR39 cells in the TOCSY spectrum that would 
indicate the presence of two conformers in 
equilibrium. Furthermore, the NOE pattern and the 
CSI analysis pointed to obestatin as an unstructured 
molecule, as well as happened for obestatin truncates. 
Nevertheless, considering the possibility of a 
conformational change in the Pro4 residues, the data 
observed for His19 and the only non-sequential NOE 
326 Fischer G, Bang H, Mech C. Determination of enzymatic catalysis for the 
cis-trans-isomerization of peptide binding in proline-containing peptides. 




observed between Leu11 and Gly13, 3D structures of 
human obestatin were calculated. The data suggested 
that obestatin was only partially structured. The 
analysis of the bundle of the 6 structures obtained for 
the E configuration showed a possible helix structure 
between residues Ala3 and Phe5, which were 
overlapped. In the Z configuration, the bundle of the 6 
structures presented an overlapping in the area from 
Phe1 to Lys10, which could form part of a helix 
conformation. Although these results are indicative of 
certain structuration in the molecule, a larger zone of 
obestatin appeared to be unstructured. 
Peptides usually adopt several conformations in 
solution. Therefore, in most of the cases, the 
assessment of one single 3D structure is unrealistic 
and, indeed, NMR may easily generate virtual 
conformations, when ensemble averages are not 
properly taken into account. A good strategy to 
decrease conformational exchange is the use of low 
temperatures before the freezing point (0-8 °C). It has 
been speculated that these temperatures may induce 
the formation of structure that is similar to the 
conformation of the peptide in the receptor bound 
state.42 Although in all the experiments described 
herein, the temperature was set at 5 °C, we could only 
infer a certain change in obestatin conformation when 
obestatin was placed in the presence of living cells. 
Although some extra signals were observed in the 
TOCSY spectra for the GPR39-enriched cells, these 
peaks could not be unambiguously assigned to a 
certain residue, in order to corroborate the existence 
of SCE effects in this system. However, when 
comparing both cell types, specific CSPs were 
observed for Pro4 and His19. These signals observed 
for Pro4 in the presence of GPR39, might be indicative 
of the possible proline cis/trans isomerization, which 
exclusively arose in the presence of the receptor and 
that, prior to bind to its receptor, obestatin (1) needs 

























Since obestatin discovering, many troublesome issues 
surrounded this small peptide. The first outstanding 
fact was its opposite function to ghrelin orexigenic 
action. The second, but not less critical, was its 
receptor, the GPR39. Obestatin did not have a good 
beginning. Very soon after Zhang’s work was 
published, several groups discarded its actions 
regarding feeding.56,127 Only one year later, Holst et al 
published their work regarding the GPR39 receptor: 
obestatin was not able to activate this receptor, but 
Zn+2 did.55 However, all these results might be 
questionable. It was not until 2008 that De 
Spiegeleer’s group demonstrated the quality of the 
obestatin peptides supplied by several companies 
concluding that these peptides were not suitable to 
obtain good and unquestionable results.76 Regarding 
the obestatin binding assays to GPR39, the same 
group demonstrated in 2012 that iodinated obestatin 
was also a mixture of poly-iodinated peptides.327 
Indeed, already in 2008, Zhang mentioned this 
subject.77 Along these years, we had some noteworthy 
results regarding obestatin structure and bioactivity, 
and demonstrated that obestatin biological effect is 
species-specific: mouse and human obestatin have 
different primary and secondary structures and, in 
consequence, different bioactivities.  
GPCRs are regulated by phosphorylation and this 
process is a key event in determining the signalling 
properties of this receptor super-family. The process 
of stimulus-dependent receptor phosphorylation was 
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mediated by both PKA328 and G-protein-coupled 
receptor kinases (GRKs).329,330 These different protein 
kinases, activated by distinct mechanisms, were able 
to phosphorylate different sites on the receptor and 
these varying GPCR “barcodes” resulted in different 
signalling outcomes, β-arrestin recruitment and 
internalization.  
Having all this information in mind, our recent results 
regarding GPR39 phosphorylation and internalization 
were not a surprise. Although some groups proposed 
Zn+2 as the endogenous agonist of GPR39 due to its 
ability to activate inositol phosphate accumulation, 
amazingly, Zn+2 treatment diminished GPR39 basal 
phosphorylation. However, in our hands, obestatin 
was able to activate GPR39 phosphorylation above 
basal levels. This basal phosphorylation could 
represent a high constitutive activity for this receptor, 
mainly due to the critical importance of its C tail 
domain. 
Receptor desensitization together with its 
internalization also represents an important 
physiological mechanism that modulates receptor 
response and acts as an information filter for 
intracellular signalling. Chartrel et al published in 2006 
that obestatin did not promote GPR39 internalization 
and did not have effects in GPR39-transfected cells.74 
With regard to the internalization driven by obestatin, 
our results showed that its addition induced GPR39 
internalization and endocytosis in receptor-enriched 
329 Benovic JL, Mayor FJ, Somers RL, et al. Light-dependent phosphorylation 
of rhodopsin by beta-adrenergic receptor kinase. Nature. 1986;321:869-
72. 
330 Bouzo-Lorenzo M, Santo-Zas I, Lodeiro M, et al. Distinct phosphorylation 
sites on the ghrelin receptor, GHSR1a, establish a code that determines the 




cells. The kinetic studies of GPR39 internalization 
showed that the obestatin-GPR39 complex was 
internalized in a time-dependent manner, showing a 
surface GPR39 loss over maximum at about 20 min on 
obestatin stimulation. Furthermore, the confocal 
microscopy results suggested the hypothesis that the 
complex might be being recycled by early endosomes 
and did not degradate in lysosomes. Additional studies 
are required to further investigate receptor 
internalization pathway. 
We proposed a signalling mechanism for obestatin 
involving two routes triggered in parallel: the ERK1/2 
and Akt signalling pathways (Scheme 1). Once 
obestatin receptor is activated, a signalling pathway is 
mediated by β-arrestin 1 involving the recruitment 
and activation of Src into a β-arrestin-scaffolded 
complex. Thus, Src functions as a switch that activates 
MMPs to initiate the proteolytic release of EGF-like 
ligands at the cell surface and then bind to EGFR. 
Ligand binding drives receptor dimerization, leading to 
activation of the intrinsic kinase and 
autophosphorylation of specific docking sites, among 
them for PI3K, and ending in the activation of Akt. 
Several studies have shown that Zn+2 induces EGFR 
phosphorylation through the extracellular release of 
EGF-like ligands that are mediated by MMPs. It might 
be possible that the stimulatory effects of Zn+2 on 
GPR39 signalling might be due to the activation of 
MMP-EGFR since obestatin requires EGFR 
transactivation and MMP activities. 
It is widely demonstrated that the alteration in the 
expression of many members of the superfamily of 
RTKs is present in tumours and derived cell lines, and 
that these changes contribute to the development and 
progression of cancer.147,148 In this chapter, our results 
showed that obestatin induced RTKs phosphorylation, 
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which belonged mainly to the EGF, insulin, TrK, VEGF 
and ephrin receptor families. The four ErbB family 
members were significant activated by obestatin. All 
of them are important therapeutic targets and their 
downstream pathways regulate EMT, migration, and 
tumour invasion by FAK or Rho GTPases modulation 
and the increment of MMP9 activity.331 Furthermore, 
receptor combinations produce synergies that have 
clear potential in cellular proliferation associated with 
tumour progression.144 ErbB receptors form either 
homo- or hetero-dimers following ligand binding, and  
each dimer shows different affinity for ligands and 
different signalling properties.154  In this way, 
cooperation of ErbB receptors in obestatin 
transduction pathway could be necessary to induce 
cell transformation.  
The role of obestatin in glucose metabolism70 and its 
ability to act throughout insulin receptor71 have been 
already demonstrated. Insulin-like ligands bind to 
IGF1R and activate downstream signalling through 
IRSs to regulate cell proliferation via the Ras-Raf-
MAPK pathway or survival and cell cycle progression 
via the PI3K/AKT/mTOR pathway.239 Ras signalling 
pathways are also triggered by Trk receptors to the 
control of cell survival, proliferation, and 
differentiation.244  Obestatin treatment displayed a 
notable activation of IGF1R, in line with the previous 
studies mentioned above and significantly up-
regulated several Trks. All together, these data point 
to a strong interaction with signalling pathways 
proposed for the obestatin/GPR39 system.123,142 
On the other hand, the results in both cell lines 
showed that obestatin could also be implied in 
metastatic processes. Eph and Tie receptors regulate 
several biological processes including angiogenesis, 
and vascular system development.263,265 VEGFR family 




plays a crucial role in pathological angiogenesis 
activating downstream signalling of the phospholipase 
(PLC)γ-PKC-MAPK pathway but not Ras pathway for 
cell proliferation.332 Moreover, other obestatin-
activated RTKs are implicated in Wnt signalling in 
tumour invasion253 and regulate MMPs expression.254  
In summary, the results obtained in both cell lines in 
response to obestatin corroborated the involvement 
of this peptide on proliferation, survival and cell 
differentiation; and diverse oncogenic processes like 
migration, invasion and angiogenesis. Its effect on 
glucose and insulin metabolism was also confirmed.70 
The differences in the phosphorylation patterns 
activated by obestatin in AGS and KATO III cells could 
be due to the morphological and/or molecular 
differences between both cell lines. The former has 
epithelial morphology;302 however, the latter has 
spherical morphology322 and is composed by two cell 
subtypes (floating and adherent).333 For instance, the 
opposite effects observed for several RTKs, as the Axl 
and ephrin families could be due to these distinctive 
characteristics. Mer is involved in the regulation of the 
cytoskeletal dynamics,334 and EphA6 and EphA7 are 
implied in cell adhesion and migration.245 The fact that 
obestatin inhibited the activation of these receptors in 
the KATO III cells and stimulated their phosphorylation 
in AGS cells, might be associated to processes related 
to the epithelial-mesenquimal and the mesenquimal-
epithelial transitions. Further investigations will be 
needed to clarify the precise role of obestatin in these 
processes. 
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MMPs have been reported as key regulators in the 
signalling pathway triggered by obestatin via the 
GPR39 receptor.142 The protease expression profile 
obtained in response to obestatin in gastric cancer 
cells pointed to the involvement of other proteases in 
addition to MMPs. These proteases are all of them 
closely related to the pathology of cancer. 
Comparing the results obtained in both cell lines, AGS 
and KATO III, obestatin had a more potent stimulatory 
effect in AGS cells. ADAMs family, CTSs, some KLKs and 
MMPs were the most overexpressed proteases in both 
cell lysates. ADAMs are a family of transmembrane 
and secreted metalloendopeptidases335 and are 
characterized by a functional protease domain, which 
indicates that their biological function mainly depends 
on protein-protein interactions.336 On the other hand, 
CTSs and KLKs are enzyme proteins with proteolytic 
activity differentially expressed in many human 
tumours and are potential cancer biomarkers. 290,337  
These enzymes are involved in processes of plasticity, 
malignancy, tumour invasion and metastasis that 
carry on a poor prognosis of these pathologies. 
Additionally, MMPs are endopeptidases capable of 
degrading all kinds of extracellular matrix proteins, but 
also can process bioactive molecules. All MMPs were 
overexpressed by obestatin in both cell line lysates. In 
fact, MMP1, a protease that plays a major role in the 
invasion of gastric cancer,285,286  was one of the most 
up-regulated proteins. MMPs are also thought to play 
a major role in cell behaviours such as cell 
proliferation, migration, differentiation, angiogenesis, 
335 Wolfsberg TG, Straight PD, Gerena RL. ADAM, a widely distributed and 
developmentally regulated gene family encoding membrane proteins with 
a disintegrin and metalloprotease domain. Dev Biol. 1995;169:378-83.   
336 Edwards DR, Handsley MM, Pennington CJ. The ADAM 
metalloproteinases. Mol Aspects Med. 2008;29:258-89.  
337 Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new 




apoptosis and host defence338 in addition to tumour 
invasion and metastasis.155 However, obestatin was 
unable to stimulate the secretion of all of them in 
KATO III cells. The presence of two subpopulations and 
their ratio in KATO III cells could explain the different 
and, a priori, conflicting results compared to AGS cells. 
Finally, PSEN1 data were noticeable in AGS cells. Its 
expression was up-regulated, but obestatin treatment 
had inhibitory effects on its secretion. This result will 
need further investigations.  
Summarizing, all proteases resulted overexpressed by 
obestatin, both in AGS and KATO III cells. These 
proteins are involved in degradation of extracellular 
matrix, as well as migration and invasion processes. 
Many of them have been considered as biomarkers of 
poor prognosis in numerous types of cancer, 
especially gastric cancer. These results on proteases 
and those mentioned above for RTKs, enhanced the 
role of obestatin in the oncogenic process. 
The RTKs and MMPs array results from human gastric 
adenocarcinomas samples were heterogeneous. The 
wide range of functions of the different RTKs and 
proteinases families, varying according to the tissue or 
the process in which they are involved, makes difficult 
to establish the connection between cell lines and 
tissues. However, most of the up-regulated proteins 
observed in gastric adenocarcinomas are involved in 
oncogenic processes, many of them specifically in 
gastric cancer, which are in line with our previous 
results and the bibliography.  
RTKs expression in human gastric adenocarcinoma 
tissue did not present any correlation with tumour 
differentiation or being compared to healthy tissue. 
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Only the EphA1 and insulin receptor resulted more 
activated in worse-prognosis adenocarcinomas. By 
contrast, Axl was down-regulated in tumour tissues 
compared to the healthy sample. Surprisingly, the MD 
sample showed the highest differences with 
significant augments in the expression of more than 
half of the RTKs compared to the other samples. 
PDGF receptors, c-Ret and ALK were highly activated 
in MD adenocarcinoma. PDGF family is correlated with 
cancer progression and metastasis of gastric 
carcinoma.339 Furthermore,  c-Ret is a molecular 
regulator in gastric inflammatory and cancer.251 
However, Tie1 was significantly down-regulated in MD 
and WD samples. EphA5 and EphA10 were more 
phosphorilated in adenocarcinomas of worse 
prognosis. EphA5 gene had significantly increased CpG 
methylation in gastric cancer vs non-metaplastic 
mucosa,261 however, no EphA10 data was found for 
gastric cancer in the existing literature. In WD 
adenocarcinoma, the most activated receptor was the 
Wnt receptor, RYK. Regarding the VEGF family, only 
VEGFR2 in the WD and all of them in the MD sample 
were more activated, respect to healthy tissue.  The 
overexpression of ErbB2 in gastric carcinomas and its 
status as one of the main stomach cancer biomarkers, 
has been confirmed by many studies;236,237 
nevertheless, our data were not conclusive.  
Regarding proteases expression patterns, the 
adenocarcinomas presented significant variations 
compared to the healthy sample. PSEN1 and 
ADAMTS13 resulted more expressed in the healthy 
controls than in the adenocarcinoma samples. 
However, it has been recently published that PSEN1 is 
dramatically up-regulated in gastric cancer tissues 





compared with their benign counterparts.340 
Meanwhile, ADAMTSs are related to anti-angiogenic 
capabilities,341,342 and ADAMTS13 is involved in 
suppressing tumour cell invasion in some tumour as 
the  gastric cancer.343,344 
Concerning to the CTS family, CTS X/Z/P expression 
clearly increased with the dedifferentiation of the 
tumour. CTSA, CTSD and CTSL were found to be up-
regulated and, CTSC, CTSE and CTSS down-regulated in 
the PD adenocarcinoma. CTSV, however, was found 
up-regulated in the MD sample. An association 
between H. pylori infection, a strong up-regulation of 
CTSX/Z/P and development of gastric cancer have 
shown.345 Furthermore, it was reported that CTSL 
were significantly higher in gastric cancer272 and CTSE 
was found in highest concentration in the surface of 
epithelial mucus-producing cells of the stomach.278  
In the KLKs family, we observed a pronounced 
expression of KLK7 and KLK10 in the PD 
adenocarcinoma. It is already known that KLK7 
facilitates tumour invasion and metastasis by 
degradation of extracellular matrix components and 
KLK10 is involved in carcinogenesis and is being used 
as a biomarker in this pathology.346  
MMPs alterations in expression are mainly related to 
MMP1 and MMP9, being highly expressed in the MD 
and the PD samples, respectively. Both of them have 
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special importance in gastric cancer.347 Surprisingly, 
MMP2, 3, 7 and 8 were down-regulated in the PD 
sample compared to the healthy tissue. In the 
remaining proteases, differences in adenocarcinomas 
compared to control samples were also found for PC9 
and uPA. 
In this chapter, we found that obestatin is able to 
actively bind GPR39 and triggered signalling pathways 
involved in oncogenic processes in gastric cancer. In 
addition, the GPR39-RTK crosstalk is not only limited 
to the EGFR, but instead depends on the available 
RTKs present in the samples/tissues, and regulated the 
expression of proteases involved in processes and 
pathways already described for obestatin. All these 
data, together with the fact that human gastric 
adenocarcinomas expressed GPR39 allows us to 
hypothesize that the obestatin/GPR39 system might 
play a key role in the development and progression of 
gastric cancer.  
344 Koo BH, Oh D, Chung S, et al. Deficiency of von Willebrand factor-
cleaving protease activity in the plasma of malignant patients. Thromb. 
Res. 2002;105:471-6.  
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protease-like gene, the expression of which is down-regulated during 
breast cancer progression. Cancer Res. 1996;56:3371-9. 
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In this chapter, we determined the role of the 
obestatin/ GPR39 system in regulating motility, EMT, 
and invasion of adenocarcinoma cells. First, we found 
that obestatin promoted cell mobility and invasion by 
inducing EMT and cytoskeleton remodeling in AGS 
cells. Second, we showed that GPR39 was present in 
the chief cells located at the base of the oxyntic glands, 
while obestatin was identified in the neuroendocrine 
cells of the oxyntic glands. Third, the GPR39 pattern 
correlated with the dedifferentiation of gastric 
adenocarcinomas, and the obestatin expression was 
negative. We propose that the obestatin/GPR39 
system displays an enhancer role in the development 
and progression of gastric adenocarcinoma. 
The obestatin/GPR39 system has important regulatory 
roles in controlling proliferation and differentiation 
through a fine modulation of key players in these 
cellular pathways. Specifically, the obestatin/GPR39 
system has been described to act as a pro-proliferative 
signal in gastric cancer cells, namely, KATO III and 
AGS.123,142 For simplicity, and similar to the human 
gastric adenocarcinomas, we used the AGS cell line, 
which expresses the obestatin/GPR39 system and 
retains the characteristics of the parent tumour. In this 
study, our findings implicated an autocrine/paracrine 
regulation of cell proliferation, which activated Ki67 
expression. Furthermore, this study shows that the 
obestatin/GPR39 system is a key regulator of EMT. 
This conclusion is based on the observation that 
obestatin induced a repertoire of biochemical 
(increased β-catenin, N-cadherin, and vimentin) and 
morphological (increased formation of lamellipodia) 
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changes, that are characteristic of EMT. Thus, 
cytoskeleton reorganization induced by obestatin/ 
GPR39, shifting its epithelial phenotype to an invasive-
like one, facilitated tumour migration, invasion, and 
metastasis. Recent studies have implicated mTORC1 
and mTORC2 as key regulators of EMT.348 Indeed, 
GPR39 activates mTOR signalling via the β-
arrestin/MMP/EGFR/Akt pathway.142 Additionally, 
obestatin was shown to increase the expression of 
VEGF and its receptor isoform VEGFR2 in these cells. 
Conversely, PEDF expression was down-regulated. 
Notably, the VEGF/VEGFR2 system is primarily 
responsible for both normal and tumour-related 
angiogenesis.349 This finding implies that VEGF, which 
is produced by obestatin-stimulated cells, provides 
the needed vascularization of the developing tumour. 
This postulate is further supported by the down-
regulation of the anti-angiogenic factor PEDF.350 
In healthy human stomachs, positive expression of 
obestatin was observed in the neuroendocrine cells, 
while GPR39 expression was identified in the chief 
cells of the oxyntic glands. Therefore, the idea of an 
autocrine positive feedback of obestatin was ruled 
out; however, an endocrine mechanism by which 
obestatin accesses its own transmembrane receptor 
to optimally mediate receptor-ligand interactions is 
possible. Taking into account the GPR39 location, 
obestatin may regulate pepsinogen secretion in the 
chief cells, an important fact for the digestive process 
in the stomach.  
350 Zhang Y, Han J, Yang X, et al. Pigment epithelium-derived factor inhibits 
angiogenesis and growth of gastric carcinoma by down-regulation of VEGF. 




A particularly interesting result is that chief cells 
expressed GPR39 together with the expression found 
in human adenocarcinomas. This fact might relate this 
cell type to the origin of the gastric adenocarcinoma. 
Indeed, the potential correlation between the chief 
cells and gastric cancer has been proposed.351,310 
These studies provided direct evidence by lineage 
tracing that under pathophysiological loss of acid-
secreting parietal cells, the chief cell lineage can itself 
transdifferentiate into a mucous cell metaplasia, 
designated spasmolytic polypeptide expressing 
metaplasia, a precancerous lesion in stomach. 
Particularly in the presence of inflammation, this 
metaplastic lineage can regain proliferative capacity 
and, in humans, may also further differentiate into 
intestinal metaplasia. Thus, mature gastric chief cells 
have the ability to act as cryptic progenitors and 
reacquire proliferative capacity within the context of 
mucosal injury and inflammation 
Of major clinical significance was the observation that 
the GPR39 expression found in gastric 
adenocarcinomas correlated with the 
dedifferentiation of the tumour. The histologic type is 
important for estimating tumour progression and the 
outcomes of patients with gastric carcinoma, as it 
represents an independent prognostic factor among 
the pathological variables of the tumour.352 In that 
sense, the correlation found for GPR39 and the 
histologic type endorse the use of this receptor as a 
marker of tumour progression.  
In conclusion, the present work addresses the role of 
the obestatin/GPR39 system in regulating motility, 
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EMT, and invasion of gastric adenocarcinoma cells. 
More importantly, the levels of GPR39 expression in 
these tumours provide the rationale for including 




















352 Adachi Y, Yasuda K, Inomata M, et al. Pathology and prognosis of gastric 






Results from Chapter 5 offer three major findings 
related to the secretion of pepsinogen in response to 
obestatin. First, GPR39, the obestatin receptor was 
expressed intensely in the chief cells of the human 
stomach, which are the pepsinogen secretory cells. 
Second, exogenous obestatin increased pepsinogen 
release from an in vitro model: the AGS cells, being 
detectable at protein level in culture medium. Third, 
this stimulatory effect was mediated by the GPR39 
receptor. Thus, obestatin has a functional role on chief 
cells, exerting a stimulatory action on pepsinogen 
secretion.  
Obestatin and ghrelin are two peptides emerging from 
the same preproprotein, preproghrelin. Both are 
produced and secreted by the same cells in the oxyntic 
mucosa of the stomach, and were believed to possess 
opposing functions regarding feeding. Ghrelin 
orexigenic action is well established, but obestatin 
anorexigenic action was rapidly discarded. Among the 
multiple actions discovered for ghrelin, it has been 
described its acidic stimulatory effect in the parietal 
cells of the stomach. This influence of ghrelin on acid 
secretion is thought to be mediated via the release of 
histamine from ECL cells.353 However, with the 
exception of our works on cancer cells of the 
stomach,123,142,301 although numerous actions have 
been described for obestatin, none of them had a 
relationship with the main site of obestatin 
production, the stomach.  
It is clear nowadays, that GPR39 receptor mediates 
obestatin actions in many cell lines and tissues. Our 
findings for GPR39 in the chief cells of the stomach, led 
us to propose a possible action for obestatin in healthy 
stomach, pepsinogen secretion. In fact, using an in 
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vitro model of a cell line that endogenously expresses 
the GPR39 and secretes pepsinogen, we 
demonstrated that an exogenous administration of 
obestatin stimulates the pepsinogen release. This data 
proposes functionality for obestatin in the healthy 
stomach.  
The signalling mechanisms underlying this novel 
action described for obestatin will be discussed. The 
regulatory mechanisms for pepsinogen secretion are 
not fully understood. As it was mentioned in the 
introduction, two main pathways are implicated in 
pepsinogen secretion. The first pathway implies the 
activation of adenylate cyclase (AC), with an increase 
in the cAMP and subsequent activation of PKA. The 
second one implies the activation of PLC, with the 
consequent hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2), resulting in the formation of 
inositol trisphosphate (IP3) and  diacylglycerol (DAG). 
IP3 and DAG increase calmodulin-dependent protein 
kinase II (CaMKII) activation and PKC, respectively. The 
first data regarding obestatin signalling, reported that 
this peptide stimulated cAMP production,1 being a 
plausible mechanism for obestatin stimulatory effect 
on pepsinogen secretion. Considering the second 
pathway, it has been described that obestatin did not 
produce any intracellular calcium mobilization,128 nor 
activated the typical calcium-dependent PKCs: PKCα, β 
and γ,123 ruling out this possibility.  
However, it has been reported that rat gastric chief 
cells are strongly stained to proteinase-activated 
receptor 2 (PAR2),354 and that PAR2 triggers 
pepsinogen secretion in guinea pig gastric-isolated 
354 Kawao N, Sakaguchi Y, Tagome A, et al. Protease-activated receptor-2 
(PAR-2) in the rat gastric mucosa: immunolocalization and facilitation of 




chief cells,355 leading to the hypothesis that PAR2 
modulates pepsinogen secretion, although the 
signalling mechanisms remained to be investigated. 
PARs comprise a class A GPCR family, which activate 
complex intracellular signalling networks. These 
intricate mechanisms include interactions with other 
PARs, GPCRs, receptors tyrosine kinase and 
serine/threonine kinase (RTKs and receptor 
serine/threonine kinase RSTKs, respectively) and 
signal transducers at both the signalling and receptor 
trafficking level. Moreover, PARs differ from the usual 
GPCRs because they exhibit a unique mechanism of 
proteolytic activation.356  
Obestatin exerts its actions through mechanisms that 
imply the activation of two main signalling routes 
activated in parallel via de GPR39 receptor: i) Gi-
protein mediated ERK1/2 activation;123 and ii) ß-
arrestin 1-mediated Akt signalling pathway involving 
the EGFR cross-talk through the MMPs.142 Data from 
chapter 3 gives support to the transactivation process 
triggered by obestatin. Analysis of protein arrays 
comprising 34 proteases showed that obestatin 
stimulated the secretion of diverse proteases, 
especially several human KLK-related peptidases. 
These KLKs could be involved in the activation of the 
PARs present in AGS cells, PAR2 among them, and 
might be an alternative via regulating the pepsinogen 
secretion stimulated by obestatin.  
In summary, the system obestatin/GPR39 has a 
function in the chief cells of the human stomach, 
indicating a regulation of the secretion of pepsinogen. 
Nevertheless, the exact mechanisms involved in the 
obestatin stimulated pepsinogen secretion need 
further investigations. 
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As it has been mentioned before, the GPR39 is a GPCR 
ubiquitously expressed in the human body with 
specific functions regarding the location. For instance, 
GPR39 is expressed in the chief cells of the stomach, 
and exerts a role in pepsinogen secretion (see Chapter 
5). However, in pathological conditions as cancer, this 
receptor becomes overexpressed and together with 
obestatin provokes stimulatory effects on regulating 
motility, EMT, and invasion of gastric adenocarcinoma 
cells (see Chapter 4).  
In this chapter, obestatin effects were tested in nine 
human cancer cell lines that endogenously expressed 
both obestatin and the GPR39 receptor. Obestatin 
showed an enhancer effect in all of the cancer cell 
lines tested on proliferation, skeleton reorganization 
and invasiveness via the GPR39 receptor, 
demonstrating that its mitogenic and invasive 
potential is not only limited to the gastric 
adenocarcinoma cells;301 therefore, the system might 
be an enhancer of cancer development in other 
tissues of the human body.  
Regarding proliferation, obestatin most remarkable 
effect was observed in the PANC-1 cells. The effect on 
the rest of the cell lines tested was variable; being the 
less affected the SW872 and the A431 cell lines. These 
differences in the proliferation ratio could not only be 
due to GPR39 expression, but to the expression of 
diverse proteins that participate in the signalling 
mechanisms triggered by obestatin. Indeed, it has 
been established the GPR39-EGFR cross-talk in the 
signalling pathway of the obestatin/GPR39 system. 
EGFR is highly expressed in a variety of human 
tumours and is implicated in tumour development: 
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activation of the EGFR signalling network results in 
tumour growth, inhibition of apoptosis, cell migration 
and invasion, cellular differentiation, and 
transformation. Moreover, the heterodimerization of 
EGFR with HER2 (ErbB2) induces a more potent 
activation of the EGFR than does EGFR 
homodimerization. When tumour cells overexpress 
both EGFR and HER2, they exhibit aggressive tumour 
cell growth, owing to the increased potential for 
EGFR/HER2 heterodimerization and signalling.357 The 
results obtained in Chapter 3 supported this 
information. In fact, EGFR and ErbB2 resulted the most 
activated receptors after obestatin treatment. It has 
been also described that the rat tumour somatotroph 
cell line, GC, presented no proliferation upon 
obestatin treatment, possibly due to the low 
expression levels of EGFR.128 All cell lines tested 
expressed reasonable quantities of GPR39: PANC-1, 
the highest, and A431 the lowest; conversely, EGFR 
expression was low, except for PANC-1 and A431 
cells.323,324 With these data in mind, GPR39 knockdown 
abolished obestatin proliferative capabilities in PANC-
1 cells and, GPR39 overexpression caused a huge 
augment of the proliferation in the same conditions in 
A431 cells, together with effects on the cellular 
morphology of these cell lines, similarly as happened 
for the AGS cell line. 
In summary, these results involved the 
obestatin/GPR39 system in the proliferation and cell 
motility, probably by cytoskeletal modulation to 
facilitate cell migration and invasion, of these human 
cancer cell lines. Moreover, obestatin proliferative 




expression of key components of its signalling 
pathway: proteases and RTKs. However, the exact 
signalling mechanisms still need further 
investigations. 
The KATO III cell line deserves special mention. This 
cell line harbours a point mutation in E-cadherin that 
generates two subtypes of cells in culture, floating and 
adherent, with different characteristics during the 
metastatic process.358 Our results showed that 
obestatin treatment caused the conversion of floating 
spherical KATO III cells into adherent epithelial-like 
cells. This transformation might be related to the 
expression of the nm23‐H1 gen as changes in its 
expression are related to both populations in these 
cells; certainly, a diminution in its expression has been 
observed for the adherent culture. Additionally, 
nm23‐H1 is considered a metastasis-associated gene, 
and reductions in its expression have been 
significantly associated with aggressive behaviour in 
melanoma, breast, colon, and gastric carcinomas. 
Expression of nm23-H1 is inversely proportional to the 
metastasis of these carcinomas.359 The relationship 
between the obestatin/GPR39 system and the 
expression of nm23 is an attractive field for future 
projects. 
Several groups have designated Zn+2 as a ligand for 
GPR3955 and some others considered that GPR39 is 
the Zn+2-sensing receptor (ZnR). They reported that 
GPR39, activated by Zn+2, has a role in promoting 
proliferation81 and enhanced survival of colonocytes82 
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361 Wang Y, Zhang S, Li SJ. Zn(2+) induces apoptosis in human highly 
metastatic SHG-44 glioma cells, through inhibiting activity of the voltage-
and cancer prostate cells.83  However, Zn+2 has also 
been described as an apoptotic agent in several 
human cancer cells: melanoma,360  glioma,361 
bladder,362 prostate,363 and breast cancer cells.364  Our 
results showed that Zn+2 treatment caused cell 
apoptosis and cell viability reduction in KATO III and 
HT-29 cells. Besides the mitogenic and survival 
increase induced by obestatin in these cells, obestatin 
counteracted Zn+2 effects. These discrepancies might 
be attributed to the fact that colonocytes and prostate 
cancer cells were short-term stimulated with Zn+2, as 
well as this ion involvement in the EGFR signalling 
pathways. Treatment with Zn+2 triggers the activation 
of MAPK and PI3K/Akt signalling pathways through 
EGFR activation in several cell types.147,148,149 These 
findings also suggest that there are specific marked 
differences to each cell type in the EGFR activation 
mechanism induced by Zn+2.148 These contradictory 
results added more questions to the intriguing 
relationship between Zn+2 and the GPR39 receptor. 
However, these data could imply Zn+2 in GPR39 
signalling, probably due to the activation of the MMP-
EGFR pathways, since obestatin needs EGFR 
transactivation and MMPs activity. 
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1. The structural features of human obestatin 
required for the interaction with its receptor 
comprises: 
Amidation at the C-terminus, essential to adopt an α-
helix structure and stabilize the GPR39 conformations 
necessary for the full range of receptor activities. 
Human (11-23)-obestatin is able to induce selective 
coupling to the β-arrestin-dependent signalling, 
representing the first example of an endogenous 
biased ligand for GPR39. 
Mouse and human obestatin exhibit clear 
conformational differences beyond their primary 
structure. This evidence supports the species-specific 
activity of obestatin. 
Obestatin-GPR39 interaction might involve an E/Z 
isomerization of the peptide and the posibility that 
GPR39 could be acting as a prolyl cis-trans isomerase. 
 
2. Regarding the activation/regulation mechanism of 
GPR39 receptor signalling triggered by obestatin: 
Obestatin increases GPR39 phosphorylation and 
induces receptor endocytosis. 
The RTKs and proteases expression profiles confirm 
the implication of EGFR and MMPs in the obestatin 
signalling pathway, and introduce other proteases 




3. The role of the obestatin/GPR39 system in human 
tissues includes: 
The obestatin/GPR39 system regulates pepsinogen 
secretion. 
This system also regulates proliferation, motility, 
EMT, and invasion of gastric cancer cells. More 
importantly, the GPR39 expression levels found in 
human gastric adenocarcinomas provide the 
rationale for including GPR39 as a prognostic marker 
of these tumours. 
The ubiquitous expression of GPR39 and its cancer-
associated overexpression, together with obestatin, 
provokes the proliferation and cell motillity of diverse 
human cancer cell lines. Moreover, these effects 
depend not only on GPR39, but also on the expression 











































A obestatina é un péptido descuberto no 2005 
mediante aproximacións bioinformáticas, que deriva 
da escisión post-traducional do xene da 
preproghrelina. Nun principio, foi identificada como 
un opoñente fisiolóxico á ghrelina na inxesta, non 
obstante, ao longo deste anos descartáronse as súas 
funcións anorexíxenas.  A obestatina humana está 
formada por 23 aminoácidos cun residuo Leu 
terminal susceptible de ser amidado. Esta amidación 
terminal parece, ademais, ser fundamental para a súa 
funcionalidade. O estómago é o principal produtor 
desta hormona, así e todo, tamén pode atoparse no 
resto do tracto gastrointestinal (duodeno, xexuno, 
íleo), así como no páncreas, próstata, tiroides, 
hipófise, leite materno ou plasma. No momento do 
seu descubrimento, a obestatina foi descrita coma o 
ligando endóxeno do receptor orfo acoplado a 
proteínas G, GPR39, agora ben, unha serie de 
traballos posteriores non foron capaces de demostrar 
binding específico entre ligando e receptor, nin a 
activación de rutas transdutoras de sinais, polo que o 
feito de que o GPR39 sexa o receptor da obestatina 
púxose en dúbida. Un artigo publicado sobre a 
calidade dos péptidos utilizados, así como numerosos 
traballos subseguintes mostrando que a obestatina 
pode actuar especificamente a través deste receptor, 
apuntan claramente a que a obestatina si é capaz de 
unirse ao GPR39 e ser funcionalmente activa. A pesar 
da falta de reproducibilidade das accións biolóxicas 
da obestatina na inxesta, durante este período, 
describíronse numerosas funcións adicionais para 
este péptido. A obestatina ten efectos metabólicos e 
mioxénicos, actúa sobre o tecido adiposo, 
cardiovascular ou renal e ten funcións a niveis do 
sistema nervioso central. Con todo, unha das súas 
primeiras funcionalidades descubertas, e unha das 
máis importantes, son as capacidades mitoxénicas do 
péptido. O feito de que a obestatina regule a 
proliferación de células de cancro gástrico, unha das 
principais fontes desta  hormona, suxire a implicación 
da mesma en diferentes procesos tales como a 
reparación de dano na mucosa gástrica, ou como 
combustible para a proliferación de células 
canceríxenas. Ademais, a obestatina únese ao grupo 
dos factores reguladores de MMPs, implicados en 
diferentes patoloxías humanas, tales como a 
inflamación ou o cancro. Parece bastante probable 
que a transactivación de EGFR por obestatina puidese 
ser un elemento chave polo que as MMPs regulan 
estes procesos. Tales mecanismos reflicten a 
importancia desta transactivación na sinalización 
intracelular da obestatina. Estes feitos levan  a 
postular que o sistema obestatina/GPR39 ten un 
papel no desenvolvemento e progresión do cancro, 
especialmente do cancro gástrico. Tendo en conta 
estas calidades proliferativas é necesario un estudo 
máis exhaustivo destas capacidades, así como da 
relación existente entre a obestatina e o receptor 
GPR39, o cal axudará ao deseño futuro de novos 
fármacos relacionados con estas patoloxías. 
Deste xeito, o principal obxectivo deste proxecto de 
tese foi o de establecer a relación entre a obestatina 
e o receptor GPR39 en eidos tanto sans como 
tumorais, dende o nivel estrutural ao tisular.  
Este obxectivo dividiuse nos seguintes puntos:  
Estudo dos requirimentos estruturais necesarios para 
a interacción da obestatina co seu receptor. 
Determinar os mecanismos detallados de 
activación/regulación da transactivación GPR39/RTKs 
accionados por obestatina.        
Análise e correlación do sistema obestatina/GPR39 
no desenvolvemento e malignidade de tumores. 
A procura de aplicacións terapéuticas para a 
obestatina implica, como primeiro paso, a 




relación entre esa estrutura e a súa actividade 
biolóxica. Partindo desa base, empregamos unha 
combinación de dicroísmo circular, espectroscopía de 
resonancia magnética nuclear, e técnicas de 
modelización 3D para determinar a estrutura en 
solución da obestatina humana (1), a obestatina 
humana non amidada (2), os fragmentos humanos (6-
23) (3), (11-23) (4), e (16-23) (5); e a obestatina de 
rato (6). Estes estudos foron realizados nunha 
solución micelar imitando a membrana plasmática 
(micelas de SDS). Os estudos de relación de 
actividade-estrutura foron efectuados avaliando as 
capacidades mitoxénicas in vitro destes péptidos na 
liña celular humana de epitelio pigmentario retiniano, 
ARPE-19, mediante a fosforilación de ERK1/2 e Akt, a 
expresión de Ki67, e a capacidade de proliferación 
celular mediante incorporación de BrdU. Os 
resultados obtidos concluíron que a amidación C-
terminal da obestatina humana (1) era esencial para 
adoptar unha estrutura de α-hélice. Esta α-hélice 
atópase entre os residuos Gly8-Lys11 e Ser20-Leu23. 
A presenza desta estrutura enlázase coa 
estabilización conformacional do GPR39 necesaria 
para a gama completa de actividades do receptor. 
Isto implica que o GPR39 é capaz de adoptar múltiples 
conformacións activas, que están relacionadas coa 
activación de mecanismos de rutas de sinalización 
que rematan coa subsecuente activación de ERK1/2 e 
Akt. Observamos ademais, que o fragmento humano 
(11-23) (4) era capaz de inducir selectivamente a ruta 
de sinalización dependente de β-arrestinas. Este 
resultado podería implicar que 4 estabiliza unha 
conformación do receptor distinta da inducida pola 
obestatina humana (1) e esta actividade específica 
estaría relacionada coa presenza do segmento α-
hélice entre os residuos Tyr16-Leu23. Este dato sobre 
o truncado (11-23) podería ademais, representar o 
primeiro exemplo dun ligando endóxeno parcial para 
o GPR39. Por último, os resultados amosaron que a 
obestatina de rato (6) e a obestatina humana (1) 
presentaban diferenzas conformacionais claras alén 
das súas diferenzas na estrutura primaria. O análogo 
murino adoptaba unha estrutura 3D distinta, que non 
era capaz de  activar o receptor GPR39 humano. Esta 
evidencia apoiaría a existencia dunha actividade 
especie-específica para a obestatina humana. 
Nas células, as proteínas interactúan especificamente 
con receptores, factores, co-ligandos e outros 
péptidos, xerando un entorno celular difícil de 
reproducir. Aproximacións biomiméticas na 
determinación estrutural como as micelas 
mencionadas anteriormente, proporcionan 
información moi valiosa sobre os distintos péptidos; 
agora ben,  a base estrutural exacta das funcións 
biolóxicas dunha determinada proteína require 
observacións en células vivas. Dende o 
descubrimento da obestatina, diversos estudos 
intentaron determinar cales son os requisitos 
estruturais mínimos necesarios para a súa actividade 
biolóxica. Até o momento, non hai datos dispoñibles 
sobre a conformación bioactiva da obestatina cando 
interacciona co GPR39. Un estudo adecuado sobre a 
relación estrutura-actividade debe basearse no 
coñecemento da conformación exacta da obestatina 
cando se une ao receptor. O carácter non invasivo e a 
capacidade para proporcionar datos en resolución 
atómica fan á espectroscopía de RMN heteronuclear 
multidimensional  axeitada para esta tarefa. Neste 
contexto, o seguinte obxectivo que nos plantexamos 
foi a determinación da conformación bioactiva da 
obestatina cando interactúa co seu receptor, GPR39, 
en condicións quasi-fisiolóxicas, en células vivas 
enriquecidas co receptor. Deste xeito, utilizamos 
técnicas de RMN para determinar a estrutura da 
obestatina humana (1) e os truncados humanos (6-
23) (3), (11- 23) (4), (16-23) (5) e (1-10) (7) en  H2O, 
PBS e células HEK293 wild type e transfectadas 




atopados nos truncados non mostraban diferenzas 
significativas na estrutura en células vivas. Ademais, 
semellaba que o equilibrio encontrábase desprazado 
cara conformacións desestruturadas en todos eles. 
Soamente os truncados 3 e 7 parecían presentar unha 
certa tendencia helicoidal en H2O. En canto á 
obestatina completa, os datos de RMN amosaron 
resultados notables. Os cambios nos CSPs, o patrón 
NOE e a análise do CSI sinalaron que en H2O e PBS a 
obestatina tendía a conformacións tipo random coil. 
En presenza de células vivas wild type, atopáronse  
CSP positivos que poderían implicar unha 
reorganización β pregada ou unha perda de estrutura 
helicoidal en células sen receptor. Sen embargo, en 
células tranfectadas co GPR39 observáronse 
diferencias moi significativas entre os CSPs dos 
residuos  Pro4 e His19. Esta diferenza en Pro4 en 
presenza de células sen e con receptor podería 
implicar unha isomerización E/Z e o feito de que o 
GPR39 estaría actuando como unha prolil cis/trans 
isomerase. Pese a isto, non se atoparon efectos SCE 
e/ou conxuntos de dobres sinais para a obestatina en 
presenza de células HEK-GPR39 no espectro TOCSY, o 
que indicaría a presenza de dous confórmeros en 
equilibrio. Ademais, o patrón NOE e a análise do CSI 
sinalaron que a obestatina tendía a conformacións 
non estruturadas, así como acontecía para os 
diversos truncados. Aínda así, tendo en conta a 
posibilidade dun cambio conformacional no residuo 
Pro4 e os datos NOE observados, calculamos as 
estruturas 3D da obestatina humana en presenza de 
células vivas. Esta estrutura 3D indicaba que a 
obestatina podería estar parcialmente estruturada na 
zona N-terminal en ámbalas dúas conformacións E e 
Z, non obstante, a maior parte dos residuos parecen 
non estruturados. Atopamos sinais adicionais nos 
espectros TOCSY en presenza de células enriquecidas 
co GPR39 que non puideron ser asignados a un 
determinado residuo á fin de confirmar a existencia 
de efectos SCE neste sistema. Estes datos, xunto cos 
CSPs específicos atopados para Pro4 e His19 en 
células enriquecidas co receptor poderían indicar 
unha isomerización cis/trans da prolina, e que, antes 
de unirse ao seu receptor, a obestatina (1) adoptaría 
unha conformación específica. 
Como se comentou anteriormente, a obestatina 
describiuse inicialmente coma o ligando endóxeno do 
GPR39. Non obstante, varios grupos cuestionaron 
este feito e incluso se propuxo o Zn+2 como agonista 
do GPR39, debido á súa capacidade de activar 
distintas vías de sinalización. En 2015, o grupo de 
Camiña usando experimentos de co-
inmunoprecipitación demostraron binding específico 
entre a obestatina e o GPR39. Os nosos resultados 
relativos ao sistema tamén apoiaban este dato. A 
controversia xerada en canto ao modo de interacción, 
ou máis importante, se existe interacción entre a 
obestatina e o GPR39, levounos a investigar os 
primeiros pasos na vía sinalización do sistema, a 
fosforilación e a internalización do GPR39 mediada 
por obestatina. Os resultados amosaron que a 
obestatina aumentaba a fosforilación do GPR39 
sobre o seu nivel basal. A elevada fosforilación basal 
podería representar unha alta actividade constitutiva 
do receptor, principalmente debido á importancia do 
seu dominio C‐tail. Ademais, esta adición esóxena de 
obestatina, inducía a internalización e endocitose do 
GPR39 en células enriquecidas co receptor. Os 
estudos cinéticos de endocitose do GPR39 amosaron 
que o complexo obestatina-GPR39 era internalizado 
de forma dependente no tempo, mostrando unha 
perda máxima de expresión do GPR39 en superficie 
sobre os 20 min despois da estimulación con 
obestatina. Ademais, os resultados de microscopía 
confocal suxeriron a hipótese de que o complexo 
podería ser reciclado por endosomas temperáns e 




necesario unha análise mais profunda para elucidar 
os sistemas exactos de internalización do receptor. 
En células de cancro gástrico, xa se demostrara que a 
obestatina ao unirse a o GPR39 activaba dúas rutas 
en paralelo: i) a activación secuencial de Gi, PI3K, 
PKCε, Src e a posterior fosforilación de ERK1/2; e ii) 
unha vía dependente de β-arrestinas que activaba Akt 
e as súas dianas. Deste xeito, Src actuaba como un 
interruptor que activaba MMPs para iniciar a 
liberación proteolítica de ligandos EGF-like na 
superficie da célula, que se unirían posteriormente ao 
EGFR. Esta rede de sinalización engadía un novo 
compoñente nas vías de sinalización intracelular 
reguladas por obestatina. Esta transactivación de 
EGFR podería implicar un mecanismo fundamental 
polo cal as MMPs regularían estas patoloxías. En 
apoio a esta hipótese, numerosos estudos 
demostraron que os cambios na expresión e/ou 
mutacións en membros da familia de receptores 
tirosina quinase EGFR/ErbB están presentes en 
tumores e liñas celulares derivadas de estes tumores, 
e estas modificacións poden contribuír á progresión 
do cancro. Neste sentido, a obestatina engadiríase ao 
grupo de factores reguladores de MMPs, implicados 
en diversas enfermidades humanas, tales como 
enfermidades inflamatorias ou cancro. En resumo, 
MMPs e RTKs son pezas clave na patoloxía do cancro. 
Asumindo mediante traballos publicados 
anteriormente, que o sistema obestatina/GPR39 está 
implicado en procesos mitoxénicos en cancro 
gástrico, o seguinte obxectivo que planeamos foi o 
estudo detallado do mecanismo de 
activación/regulación da transactivación de GPR39 e 
receptores tirosina quinase desencadeada por 
obestatina.  Ademais, tamén incluímos a 
identificación de distintas proteases activadas e o 
estudo das posibles repercusións no 
desenvolvemento do tumor. Como modelo 
escollemos as liñas celulares humanas de cancro 
gástrico KATO III e AGS. O nivel diferencial de 
fosforilación dos distintos RTKs e a expresión de 
proteases implicadas na vía de sinalización 
intracelular de obestatina foron estudadas mediante 
arrays de proteínas. Posteriormente, tamén 
estudamos estes perfís de activación/expresión de 
RTKs e proteases en catro mostras de tecido gástrico 
humano, unha mostra sa e tres adenocarcinomas con 
distinto grao de diferenciación. Os datos obtidos nas 
liñas celulares concluíron que a obestatina 
estimulaba a activación de diversos RTKs implicados 
en proliferación, supervivencia, diferenciación celular 
e diversos procesos oncoxénicos como a migración, a 
invasión e a anxioxénese. Os resultados tamén 
confirmaban o seu efecto sobre o metabolismo da 
glicosa e a insulina. En canto as proteases, a adición 
esóxena de obestatina aumentaba tanto a expresión 
como a secreción de proteases implicadas na 
degradación da matriz extracelular, así como en 
procesos de migración e invasión. Moitas delas, 
ademais, son consideradas biomarcadores de mala 
prognose en diversas patoloxías, entre elas, o cancro 
gástrico. Os perfís de expresión confirmaban tamén a 
implicación das MMPs na vía de sinalización 
obestatina e introducía outras proteases na 
transactivación de distintos RTKs mediada polo 
receptor GPR39. En resumo, os resultados que 
obtivemos sobre os mecanismos de sinalización do 
sistema amosaron que a obestatina era capaz de 
unirse activamente ao GPR39 e desencadear vías de 
sinalización implicadas en procesos oncoxénicos en 
cancro gástrico. Ademais, comprobamos que o cross‐
talk GPR39-RTK non se limitaba só ao EGFR, senón 
que dependía dos RTKs dispoñibles expresados nos 
distintos sistemas estudados; e que está colaboración 
regulaba a expresión de proteases implicadas en 
procesos e vías xa descritos para a obestatina. Todos 
estes datos, xunto co feito de que as mostras de 




GPR39, permitiunos formular a hipótese de que o 
sistema obestatina/GPR39 podería desempeñar un 
papel clave no desenvolvemento e progresión do 
cancro gástrico. 
Seguindo esta hipótese formulada, e dado  o estado 
de coñecemento da relación entre o sistema 
obestatina/GPR39 e progresión do cancro gástrico, 
no seguinte paso quixemos determinar os niveis de 
expresión do sistema en adenocarcinomas gástricos 
humanos e elucidar o seu papel potencial funcional. 
Para isto, vinte e oito pacientes con adenocarcinoma 
gástrico foron estudados retrospectivamente, tendo 
en conta os seus datos clínicos. O papel do sistema 
obestatina/GPR39 na progresión do cancro gástrico, 
foi estudada in vitro mediante a liña celular de 
adenocarcinoma gástrico humano AGS. Os resultados 
que obtivemos amosaron unha regulación 
autócrina/parácrina do sistema na proliferación 
celular, activando tamén a expresión Ki67. Ademais, 
este estudo demostrou que o sistema 
obestatina/GPR39 podería ser un regulador clave da 
transición epitelio-mesénquima. Esta conclusión 
baséase na observación de que obestatina inducía 
unha serie de cambios bioquímicos (aumento da 
expresión de β-catenina, N-cadherina e vimentina) e 
morfolóxicos (aumento da formación de 
lamellipodia), que son característicos deste proceso. 
Deste xeito, a reorganización do citoesqueleto 
inducida polo sistema obestatina/GPR39, cambiando 
o fenotipo epitelial por outro  pro-invasivo facilitaría 
a migración, invasión e metástase do tumor. Estes 
datos concordan con estudos recentes que implican 
aos complexos mTORC1 e mTORC2 como reguladores 
clave da transición epitelio-mesénquima, dado que o 
GPR39 activa a sinalización a través da ruta de mTOR, 
β-arrestina/MMP/EGFR/Akt. Os datos tamén 
amosaban que a obestatina aumentaba a expresión 
de VEGF e a isoforma do receptor VEGFR2 nas células 
AGS. Por outra banda, a expresión de PEDF víase 
diminuída. O sistema VEGF/VEGFR2 é o principal 
responsable dos procesos anxioxénicos en tecidos 
tanto sans como tumorais. Os datos observados 
suxiren que o VEGF, que é producido por células 
estimuladas con obestatina, ofrecería a necesaria 
vascularización do tumor en desenvolvemento. Esta 
premisa estaría apoiada pola regulación negativa do 
factor anti-anxioxénico PEDF. En canto ás mostras 
humanas de adenocarcinomas gástricos analizadas, 
puidemos comprobar que en mucosa sa, a obestatina 
soamente se expresaba nas células neuroendócrinas, 
mentres que a expresión de GPR39 se circunscribía ás 
células principais situadas no fondo das foveolas 
gástricas. Estes datos descartaban unha regulación 
autócrina da obestatina, apuntando a un mecanismo 
de tipo endócrino ligando-receptor para mediar as 
accións do sistema. O GPR39 tamén se expresaba de 
forma intensa e variable, na zona tumoral das 
mostras estudadas. Este resultado, xunto co feito de 
que se expresara tamén nas células principais da 
mucosa oxíntica, resulta particularmente interesante. 
Diversos estudos propuxeron unha correlación 
potencial entre as células principais e a orixe do 
cancro gástrico. En estados avanzados de gastrite 
crónica, unha perda de células parietais podería 
producir unha transdiferenciación de células 
principais xerando unha metaplasia de tipo SPEM, e 
posteriormente inclusive, unha metaplasia intestinal. 
Esta metaplasia sería un paso previo para unha 
posterior displasia e xeración dun cancro gástrico. 
Neste senso, de gran significado clínico resultaron os 
datos observados en canto á expresión GPR39 nos 
distintos adenocarcinomas. Canto peor era a 
prognose de tumor, maior expresión de GPR39 
presentaba; é dicir, a expresión do receptor  
correlacionábase coa dediferenciación do tumor. Esta 
correspondencia entre o tipo histolóxico e a 
expresión de receptor apoiaría a inclusión do GPR39 




conclusión, observamos que o sistema 
obestatina/GPR39 regulaba a motilidade, a transición 
epitelio-mesénquima, e a invasión en células 
humanas de cancro gástrico. Aínda máis, os niveis de 
expresión de GPR39 atopados neste tipo de tumores 
proporcionaron un fundamento lóxico para a 
inclusión do GPR39 como un marcador prognose en 
adenocarcinomas gástricos humanos. 
A expresión atopada para o GPR39 en células 
principais da mucosa en mostras sas de estómago 
humano, levounos a investigar a posible relación 
existente entre o sistema obestatina/GPR39 e a 
secreción de pepsinóxeno I. A expresión do receptor 
e de pepsinóxeno foi determinada mediante técnicas 
inmunohistoquímicas. A secreción de pepsinóxeno I 
trala adición de obestatina foi determinada mediante 
distintos métodos nun modelo in vitro que expresaba 
endóxenamente os tres compoñentes do estudo: 
obestatina, GPR39 e pepsinóxeno; a liña de 
adenocarcinoma gástrico AGS. Os resultados 
atopados ofrecen tres conclusións importantes 
relacionadas coa secreción de pepsinóxeno I en 
resposta a obestatina. En primeiro lugar, o GPR39 
presentaba unha expresión intensa nas células 
principais do estómago humano, que son as células 
secretoras de pepsinóxeno. O GPR39 colocalizaba con 
pepsinóxeno I nas células pre-zimoxénicas e células 
principais situadas entre o colo e a base das glándulas 
oxínticas. En segundo lugar, a obestatina esóxena 
aumentaba a secreción de pepsinóxeno I no noso 
modelo in vitro, as células AGS, que endóxenamente 
expresan GPR39. En terceiro lugar, este efecto 
estimulador estaba mediado polo receptor GPR39. 
Estes resultados propoñen funcionalidade para a 
obestatina en estómago san, xa que, a pesar das 
numerosas accións descritas para a obestatina, á 
excepción dos nosos traballos en cancro gástrico, 
ningún deles estaba relacionado co principal 
produtor do péptido. Agora ben, as vías de 
sinalización subxacentes a esta nova acción non están 
claras. Os mecanismos de regulación da secreción de 
pepsinóxeno non se coñecen totalmente. Dúas vías 
principais parece que están implicadas. A primeira vía 
activa AC, cun aumento de AMPc e a posterior 
activación de PKA. A segunda implica a activación de 
PLC, coa consecuente activación de CaMKII e PKC. A 
obestatina é capaz de aumentar a produción de 
AMPc, sendo esta vía un mecanismo plausible para 
este efecto secretor. Non obstante, está descrito que 
a obestatina non promove a mobilización de calcio 
intracelular, nin activa PKCs dependentes de calcio, 
descartando esta segunda vía como posible 
reguladora. PAR2 parece que tamén pode modular a 
secreción de pepsinóxeno. Os mecanismos de 
sinalización do sistema descritos anteriormente, 
amosaron que a obestatina estimulaba a secreción de 
KLKs. Estas KLKs poderían estar implicadas na 
activación de distintos receptores activados por 
proteinases presentes nas células AGS, PAR2 entre 
eles, e poderían ser unha alternativa, a través da cal 
se regularía a secreción de pepsinóxeno estimulada 
por obestatina. Non obstante, os mecanismos 
exactos de regulación do proceso precisarían 
investigacións máis detalladas. 
Tendo en conta os datos obtidos relativos ao sistema 
obestatina/GPR39 en cancro gástrico xa 
mencionados na presente memoria, o último 
obxectivo que planeamos foi o estudo do papel deste 
sistema noutros tipos de cancro. Avaliamos os efectos 
da obestatina sobre a proliferación, capacidade de 
invasión e reorganización do citoesqueleto via GPR39 
en nove liñas celulares canceríxenas humanas, para 
comprobar se o potencial mitoxénico e invasivo do 
sistema estaba restrinxido a células de 
adenocarcinoma gástrico. Os resultados amosaron 
que todas as liñas celulares expresaban 
endóxenamente tanto o ligando coma  o receptor, e 




Asemade, a obestatina aumentaba a proliferación en 
todas elas. Observamos un máximo efecto nas células 
PANC-1 e menos pronunciado nas liñas SW872 e 
A431. Este efecto mitoxénico podería estar 
influenciado polo cross‐talk existente entre GPR39 e 
EGFR e/ou outros RTKs dispoñibles nos distintos 
sistemas. Tendo en conta estes datos, silenciamos o 
receptor GPR39 en células PANC-1 e observamos que 
as capacidades proliferativas e pro-morfoxéncias da 
obestatina estaban claramente diminuídas. Polo 
contrario, a sobreexpresión do receptor causaba en 
células A431, que expresan gran cantidade de EGFR, 
un enorme aumento na proliferación, así como unha 
reestruturación do citoesqueleto de xeito semellante 
ao que se producía nas células AGS. Os datos obtidos 
na liña celular KATO III merecen unha mención 
especial. Observamos que o tratamento con 
obestatina causaba a conversión de células esféricas 
flotantes KATO III en células con morfoloxía epitelial 
de tipo adherente; inducindo a formación de 
estruturas tipo lamellipodio/filopodio e favorecendo 
un fenotipo invasivo. Esta transformación podería 
estar relacionada coa expresión do xene anti-
metastásico nm23‐H1 e o seu efecto en ámbalas dúas 
poboacións celulares.  En células KATO III e HT-29, así 
mesmo, a obestatina aumentaba a mitoxénese e a 
supervivencia celular. Nas dúas liñas celulares, a 
adición esóxena de Zn+2 actuaba como un promotor 
apoptótico reducindo a viabilidade. Este efecto era 
contrarrestado por obestatina. O Zn+2 foi descrito por 
algúns grupos como o agonista endóxeno do GPR39. 
O receptor, activado polo ión, aumentaba a   
proliferación e a supervivencia celular en distintas 
liñas celulares humanas. Sen embargo, as 
capacidades apoptóticas do Zn+2 tamén foron 
descritas en diferentes sistemas. Estes resultados, cos 
datos existentes sobre a implicación do ión na 
activación de EGFR, poderían suxerir que os efectos 
estimuladores do Zn+2 nas vías de sinalización 
mediadas polo GPR39, poderían ser debidos á 
activación de vías dependentes de MMP-EGFR; dado 
que a obestatina precisa da transactivación dos 
mesmos para exercer as súas funcións biolóxicas. En 
xeral, o conxunto de resultados implica ao sistema 
obestatina/GPR39 na proliferación e a motilidade 
celular, posiblemente mediante a modulación do 
citoesqueleto, para facilitar a migración e invasión 
celular en liñas celulares canceríxenas humanas. 
Ademais, a acción mitoxénica da obestatina 
dependería non só do GPR39, senón tamén da 
expresión de compoñentes clave na súa vía de 
sinalización: proteases e RTKs.  
En resumo,  as conclusións que se poden extraer da 
presente memoria son as seguintes. A amidación C-
terminal da obestatina semella ser fundamental para 
a estrutura e a bioactividade. Asemade, esta 
actividade é especie-específica no caso da obestatina 
humana. O truncado (11-23) pode representar, á súa 
vez, o primeiro exemplo de ligando parcial endóxeno 
do GPR39. O receptor, así mesmo, podería estar 
actuando como unha prolil cis/trans isomerase e 
provocando a formación de conformacións bioactivas 
específicas da obestatina. Por outra banda, a 
obestatina aumenta a fosforilación e induce a 
internalización e endocitose do GPR39. A implicación 
de EGFR e MMPs na vía de sinalización da obestatina 
viuse claramente confirmada, introducindo outras 
proteases e RTKs no proceso de transactivación do 
GPR39. Dende o punto de vista funcional, 
observamos que o sistema obestatina/GPR39 pode 
ser un regulador clave da transición epitelio-
mesénquima, facilitando así a migración, invasión e 
metástase en cancro gástrico. Neste senso, o GPR39 
podería ser incluído como un marcador prognose 
deste tipo de tumores. Este efecto potenciador da 
obestatina sobre a proliferación, capacidade de 
invasión e reorganización do citoesqueleto tamén se 




último, a presenza de GPR39 nas células principais da 
mucosa oxíntica, así  como o efecto estimulador da 
obestatina sobre a secreción de pepsinóxeno I 
proporcionaría a primeira función biolóxica coñecida 
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Figure S1.1. Far-UV CD spectra of the peptides in 25 mM PBS under 
identical conditions. The concentration was 40 µM in all samples. 
Color code: solid blue, human obestatin (1); dotted blue, non-
amidated obestatin (2); solid red, human (6-23)-obestatin (3); 






Figure S1.2. Far-UV CD spectra of the peptides in 2.8 mM SDS 
under identical conditions. The concentration was 40 µM in all 
samples. Color code: solid blue, human obestatin (1); dotted blue, 
non-amidated obestatin (2); solid red, human (6-23)-obestatin (3); 






Figure S1.3.Far-UV CD spectra of human obestatin (1) and mouse 
obestatin (6) in 25 mM PBS or 2.8 mM SDS under identical conditions. 
The concentration was 40 µM in all samples. Color code: solid red, 
human obestatin (1) in SDS; dotted red, human obestatin (1) in PBS; 
solid blue, mouse obestatin (6) in SDS; and dotted blue, mouse 
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Table S1.1. Quantification of obestatins secondary structure by CD. The following table describes the quantification of the CD spectra in two 
different environments. The quantification was performed using the DICHROWEB server and the data were fit using K2d and CONTINLL. The 
latter was paired with two different data sets for data ranging from 190 to 240 nm. The NRMSD refers to the quality of the curve fitting based 





Residue HN Hα Hβ Hγ Hδ others 
PHE 1  4.187 Hβ2/Hβ3 
 
 7.186  





ALA 3 8.152 4.192 1.172    












ASP 6 8.341 4.592 Hβ2/Hβ3 
2.736/2.478 
   
VAL 7 8.012 3.908 2.091 0.899   
GLY 8 8.341 
Hα2/Hα3 
3.858/3.789 
    
ILE 9 7.465 3.978 1.767 0.810 0.770 
Hγ12/Hγ13 
1.402/1.099 
LYS 10 7.915 4.256 1.752 1.358 1.577 2.855 






SER 12 8.334 4.266 Hβ2/Hβ3 
3.915/3.858 
   
GLY 13 8.192 3.952     
VAL 14 7.554 3.858 2.053 Hγ1/Hγ2 
0.926/0.829 
  











GLN 17 8.142 3.958 1.905 2.234  
Hε21/Hε22 
7.325/6.697 
GLN 18 7.913 4.022 1.870 2.210  
Hε21/Hε22 
7.286/6.692 







SER 20 8.012 4.158 Hβ2/Hβ3 
3.796/3.627 
   





ALA 22 7.923 4.166 1.318    






     





Residue HN Hα Hβ Hγ Hδ others 












ALA 3 8.158 4.221 1.210    














ASP 6 8.352 4.635 
Hβ2/Hβ3 
2.767/2.508 
   
VAL 7 8.030 3.926 2.126 0.934   
GLY 8 8.371 
Hα2/Hα3 
3.874/3.817 
    







LYS 10 7.928 4.271 1.792 1.398 1.602 
Hε 
2.893 




SER 12 7.978 4.271 
Hβ2/Hβ3 
3.931/3.879 
   
GLY 13 8.160 
Hα2/Hα3 
4.017/3.929 
    




































SER 20 8.025 4.288 
Hβ2/Hβ3 
3.782/3.694 
   






ALA 22 8.079 4.253 1.297    
LEU 23 7.689 4.085 1.495  Hδ1/Hδ2  






Residue HN Hα Hβ Hγ Hδ others 
ASP 6 8.341 4.595 
Hβ2/Hβ3 
2.736/2.478 
   
VAL 7 8.012 3.908 2.093 0.897   
GLY 8 8.341 3.862     
ILE 9 7.465 3.978 1.767 0.887 0.797 
Hγ12/Hγ13 
1.402/1.096 
LYS 10 7.915 4.256 1.752 1.358 1.582 2.856 
LEU 11 8.002 4.252 1.649  0.799  




   
GLY 13 8.192 3.952     










TYR 16 7.923 4.240 2.890  6.922 Hε 6.694 






GLN 18 7.913 4.022 1.870 2.210  
Hε21/Hε22 
7.325/6.692 







SER 20 8.012 4.158 
Hβ2/Hβ3 
3.775/3.627 
   






ALA 22 7.923 4.166 1.325    




     









Table S1.5. 1H chemical shifts (ppm) for human (11-23)-obestatin (4) in SDS-d25 micelles at 298K. 
Residue HN Hα Hβ Hγ Hδ others 
TYR 16  4.094 
Hβ2/Hβ3 
2.944/2.878 
 6.907 Hε 6.603 



















SER 20 8.053 4.191 
Hβ2/Hβ3 
3.670/3.728 
4.566   






ALA 22 7.916 4.067 1.191    







     
Table S1.6. 1H chemical shifts (ppm) for human (16-23)-obestatin (5) in SDS-d25 micelles at 298K. 
Residue HN Hα Hβ Hγ Hδ others 
LEU 11  3.954 1.645 1.575 0.782  






    










TYR 16 7.851 4.064 2.794  6.785 Hε 6.572 
GLN 17 8.048 3.764 1.837 2.185  
Hε21/Hε22 
7.185/6.570 
GLN 18 7.765 3.890 1.734 2.088  
Hε21/Hε22 
7.094/6.566 







SER 20 7.839 3.977 
Hβ2/Hβ3 
3.614/3.432 
   






ALA 22 7.748 4.048 1.224    











Residue HN Hα Hβ Hγ Hδ others 












ALA 3 8.141 4.189 1.177    














ASP 6 8.320 4.615 
Hβ2/Hβ3 
2.732/2.482 
   
VAL 7 7.991 3.915 2.095 0.898   
GLY 8 8.330 
Hα2/Hα3 
3.837/3.801 
    
ILE 9 7.474 3.978 1.766  0.808 
Hγ12/Hγ13 
1.396/1.093 
LYS 10 7.913 4.246 1.751 1.361 1.585 
Hε 2.865 
Hζ 7.175 




SER 12 8.006 4.281 
Hβ2/Hβ3 
3.897/3.825 
7.921   
GLY 13 8.211 3.916     
ALA 14 7.773 4.136 1.301    
GLN 15 8.221 4.176 1.909 2.143  
Hε21/Hε22 
7.299/6.656 


























GLY 20 8.191 3.814     







ALA 22 8.086 4.226 1.286    







     

























Residue HN Hα Hβ Hγ Hδ others 
TYR 16 8.25 4.01 2.84    
GLN 17 8.58 4.13 
Hβ/Hβ2 
1.55/1.64 
1.95   
GLN 18 8.64 4.03 
Hβ1/Hβ2 
1.61/1.70 
2.02   







SER 20 8.51 4.25 3.63    
GLN 21 8.63 4.14 
Hβ1/Hβ2 
1.64/1.78 
2.05   
ALA 22 8.42 4.11 0.99    




Table S2.1. 1H chemical shifts (ppm) for human (16-23)-obestatin (5) in H2O at 298K. 
Residue HN Hα Hβ Hγ Hδ others 
TYR 16  4.21 2.84    
GLN 17  4.36 
Hβ1/Hβ2 
1.91/1.99 
2.28   
GLN 18 8.58 4.27 
Hβ1/Hβ2 
1.97/2.05 
2.34   




SER 20 8.43  3.87    
GLN 21 8.58 4.37 
Hβ1/Hβ2 
2.00/2.14 
2.39   
ALA 22 8.36 4.33 0.99    
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Residue HN Hα Hβ Hγ Hδ others 
TYR 16  4.19 3.12    
GLN 17  4.30 1.94 2.3   
GLN 18  4.22 
Hβ1/Hβ2 
2.01/2.08 
2.39   




SER 20  4.42 3.89    
GLN 21  4.33 
Hβ1/Hβ2 
2.03/2.17 
2.43   
ALA 22  4.30 1.43    




Table S2.3. 1H chemical shifts (ppm) for human (16-23)-obestatin (5) in HEK293-WT cells at 298K. 
 
 













Residue HN Hα Hβ Hγ Hδ others 
TYR 16  4.18 3.09    
GLN 17  4.30 1.92 2.25   
GLN 18 8.70 4.22 
Hβ1/Hβ2 
1.98/2.13 
2.34   







SER 20 8.55 4.42 3.86    
GLN 21 8.69 4.33 
Hβ1/Hβ2 
1.99/2.12 
2.38   
ALA 22 8.47 4.29 1.38    







 PBS-H2O WT-PBS GPR39-WT 
Residue HN Hα Hβ Hγ Hδ HN Hα Hβ Hγ Hδ HN Hα Hβ Hγ Hδ 
TYR 16  0.2 0    -0.02 0.02    -0.01 0   
GLN 17  0.23 
Hβ1/Hβ2 
0.36/0.35 
0.33   -0.06 -0.01 0.02   0 0 0.05  
GLN 18 -0.06 0.24 
Hβ1/Hβ2 
0.36/0.35 
0.32   -0.05 
Hβ1/Hβ2 
0.04/0.03 




HIS 19            0 0   
SER 20 -0.08  0.24     0.02    0 -0.03   
GLN 21 -0.05 0.23 
Hβ1/Hβ2 
0.36/0.36 
0.34   -0.04 
Hβ1/Hβ2 
0.03/0.03 




ALA 22 -0.06 0.22 0.40    -0.03 0.04    -0.01 -0.05   
LEU 23 -0.04 0.23 0.40 0.39 
Hδ1/Hδ2 
0.48/0.54 
 -0.04 0.04 0 
Hδ1/Hδ2 
-0.02/-0.07 





Table S2.5. CSPs between (16-23)-obestatin (5) spectra. δ ≥ 0,1 ppm were considered significant differences and were marked in red. 
Residue CSI H2O CSI PBS CSI WT CSI GPR39 
TYR 16 -1 -1 -1 -1 
GLN 17 -1 0 0 0 
GLN 18 -1 0 -1 -1 
HIS 19 0  0 0 
SER 20 -1  0 0 
GLN 21 -1 0 0 0 
ALA 22 -1 0 0 0 
LEU 23 0 +1 +1 +1 
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Residue HN Hα Hβ Hγ Hδ others 
LEU 11  4.08 1.69  0.93  
SER 12 8.76  3.89    
GLY 13 8.55 4.02     




GLN 15 8.51 4.29 
Hβ1/Hβ2 
1.91/2.20 
2.27   
TYR 16 8.17 4.55 
Hβ1/Hβ2 
2.92/3.06 
   
GLN 17 8.21 4.27 
Hβ1/Hβ2 
1.92/2.02 
2.30   
GLN 18 8.38 4.23 
Hβ1/Hβ2 
1.96/2.03 
2.34   
HIS 19 8.59 4.75 
Hβ1/Hβ2 
3.19/3.30 
   
SER 20 8.40 4.44 3.87    
GLN 21 8.54 4.34 
Hβ1/Hβ2 
2.00/2.13 
2.39   
ALA 22 8.34 4.31 1.38    




Table S2.7. 1H chemical shifts (ppm) for human (11-23)-obestatin (4) in H2O at 298K.  
Residue HN Hα Hβ Hγ Hδ others 
LEU 11  4.05 1.68  0.92  
SER 12  4.57 3.89    
GLY 13 8.54 4.01     




GLN 15 8.49 4.29 
Hβ1/Hβ2 
1.91/2.18 
2.27   
TYR 16 8.16 4.55 
Hβ1/Hβ2 
2.92/3.05 
   
GLN 17 8.21 4.26 
Hβ1/Hβ2 
1.92/2.02 
2.28   
GLN 18 8.37 4.23 
Hβ1/Hβ2 
1.94/2.03 
2.31   
HIS 19       
SER 20  4.41 3.88    
GLN 21 8.50 4.33 
Hβ1/Hβ2 
1.99/2.13 
2.38   
ALA 22 8.28 4.30 1.38    
LEU 23 8.15 4.29 1.66 1.60 0.90  




Residue HN Hα Hβ Hγ Hδ others 
LEU 11  4.09 1.70  0.95  
SER 12  4.59 3.91    
GLY 13       




GLN 15  4.31 
Hβ1/Hβ2 
1.94/2.20 
2.29   
TYR 16  4.55 
Hβ1/Hβ2 
2.94/3.07 
   
GLN 17  4.27 
Hβ1/Hβ2 
1.93/2.03 
2.30   
GLN 18  4.23 
Hβ1/Hβ2 
1.97/2.06 
2.35   
HIS 19  4.72 3.17    
SER 20  4.43 3.86    
GLN 21  4.35 
Hβ1/Hβ2 
2.01/2.15 
2.39   
ALA 22  4.32 1.40    
LEU 23  4.31 
Hβ1/Hβ2 
1.59/1.69 
 0.92  
Table S2.9. 1H chemical shifts (ppm) for human (11-23)-obestatin (4) in HEK293-WT cells at 298K. 
Residue HN Hα Hβ Hγ Hδ others 
LEU 11  4.07 
Hβ1/Hβ2 
1.69/1.75 
 0.94  
SER 12  4.57 3.90    
GLY 13 8.700 4.01     




GLN 15 8.65 4.29 
Hβ1/Hβ2 
1.98/2.18 
2.27   
TYR 16 8.34 4.53 
Hβ1/Hβ2 
2.93/3.04 
   
GLN 17 8.32 4.25 
Hβ1/Hβ2 
1.91/2.02 
2.28   
GLN 18 8.52 4.21 
Hβ1/Hβ2 
1.96/2.05 
2.33   
HIS 19 8.62 4.70 
Hβ1/Hβ2 
3.15/3.24 
   
SER 20  4.43 3.87    
GLN 21  4.35 
Hβ1/Hβ2 
2.00/2.13 
2.38   
ALA 22  4.32 1.39    
LEU 23  4.31 
Hβ1/Hβ2 
1.59/1.67 
   
Table S2.10. 1H chemical shifts (ppm) for human (11-23)-obestatin (4) in HEK293-GPR39 cells at 298K. 
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 PBS-H2O WT-PBS GPR39-WT 
Residue HN Hα Hβ Hγ Hδ HN Hα Hβ Hγ Hδ HN Hα Hβ Hγ Hδ 
LEU 11  -0.03 -0.01  -0.01  0.04 0.02  0.03  -0.02 0.02  -0.01 
SER 12   0    0.04 0.02    -0.02 -0.01   
GLY 13 -0.01 -0.01     0.02 0.02        
VAL 14 -0.03 0 0.01 0    0.01 
Hγ1/Hγ2 
0.02/0.02 




GLN 15 -0.02 0 
Hβ1/Hβ2 
0/-0.02 
0   0.02 
Hβ1/Hβ2 
0.02/0.02 




TYR 16 -0.01 0 
Hβ1/Hβ2 
0/-0.01 
   0 
Hβ1/Hβ2 
0.02/0.02 




GLN 17 0 -0.01 0 -0.02   0.01 
Hβ1/Hβ2 
0.01/0.01 




GLN 18 -0.01 0 
Hβ1/Hβ2 
-0.02/0 
-0.03   0 
Hβ1/Hβ2 
0.03/0.03 




HIS 19            -0.02 0.02   
SER 20  0.03 0.01    0.02 -0.02    -0.01 0.01   
GLN 21 -0.04 -0.01 
Hβ1/Hβ2 
-0.01/0 
   0.02 
Hβ1/Hβ2 
0.02/0.02 




ALA 22 -0.06 -0.01 0 -0.01   0.02 0.02    -0.03 -0.01   




Table S2.11. CSPs between (11-23)-obestatin (4) spectra. δ ≥ 0,1 ppm were considered significant differences and were marked in red. 
Residue CSI H2O CSI PBS CSI WT CSI GPR39 
LEU 11 0 -1 0 -1 
SER 12  0 0 0 
GLY 13 0 0  0 
VAL 14 +1 +1 +1 0 
GLN 15 0 0 0 0 
TYR 16 0 0 0 0 
GLN 17 0 -1 0 -1 
GLN 18 -1 -1 -1 -1 
HIS 19 +1  0 0 
SER 20 0 0 0 0 
GLN 21 0 0 0 0 
ALA 22 0 0 0 0 
LEU 23 +1 +1 +1 +1 





Residue HN Hα Hβ Hγ Hδ others 
PHE 1 8.47 4.41 Hβ1/Hβ2 
2.77/2.90 
   
ASN 2 8.72 4.53 Hβ1/Hβ2 
2.31/2.44 
   
ALA 3 8.38 4.29 0.94    






PHE 5 8.15 4.41 2.81    
ASP 6 8.35 4.47 Hβ1/Hβ2 
2.38/2.54 
   
VAL 7 8.02 3.86 1.78 0.53   
GLY 8 8.46 3.71     









Table S2.13. 1H chemical shifts (ppm) for human (1-10)-obestatin (7) in H2O at 298K. 
Residue HN Hα Hβ Hγ Hδ others 
PHE 1 8.33 4.62 Hβ1/Hβ2 
3.05/3.24 
   
ASN 2 8.31 4.63 Hβ1/Hβ2 
2.55/2.65 
   
ALA 3 8.37 4.51 1.35    






PHE 5 8.06 4.61 Hβ1/Hβ2 
3.10/3.13 
   
ASP 6 8.19 4.63 Hβ1/Hβ2 
2.58/2.66 
   
VAL 7 8.04 4.14 2.19 0.98   
GLY 8 8.47 3.96     
ILE 9 7.92 4.19 1.89 Hγ1/Hγ2 
1.19/1.84 
0.93  
LYS 10 7.96 4.21 Hβ1/Hβ2 
1.72/1.83 
1.40 1.65  
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Residue HN Hα Hβ Hγ Hδ others 
PHE 1 8.47 4.61 Hβ1/Hβ2 
3.03/3.24 
   
ASN 2 8.43 4.62 Hβ1/Hβ2 
2.54/2.66 
   
ALA 3 8.55 4.50 1.37    






PHE 5 8.26 4.59 3.10    
ASP 6 8.30 4.62 Hβ1/Hβ2 
2.55/2.67 
   
VAL 7 8.18 4.13 2.19 0.98   
GLY 8 8.58 3.94     
ILE 9 8.06 4.19 1.89 1.18 0.92  
LYS 10 8.12 4.19 Hβ1/Hβ2 
1.72/1.83 
0.95 1.40  
Table S2.15. 1H chemical shifts (ppm) for human (1-10)-obestatin (7) in HEK293-WT cells at 298K. 
Residue HN Hα Hβ Hγ Hδ others 
PHE 1 8.47 4.61 Hβ1/Hβ2 
3.03/3.24 
   
ASN 2 8.43 4.63 Hβ1/Hβ2 
2.54/2.66 
   
ALA 3 8.55 4.50 1.37    






PHE 5 8.26 4.59 3.10    
ASP 6 8.30 4.62 Hβ1/Hβ2 
2.56/2.67 
   
VAL 7 8.18 4.13 2.20 0.98   
GLY 8 8.57 3.94     
ILE 9 8.06 4.19 1.89 1.18 0.93  
LYS 10 8.12 4.19 Hβ1/Hβ2 
1.72/1.83 
0.96 1.41  




 PBS-H2O WT-PBS GPR39-WT 
Residue HN Hα Hβ Hγ Hδ HN Hα Hβ Hγ Hδ HN Hα Hβ Hγ Hδ 
PHE 1 -0.14 0.21 
Hβ1/Hβ2 
0.28/0.34 
  0.14 -0.01 
Hβ1/Hβ2 
-0.02/0 
  0 0 0   
ASN 2 0.41 0.10 
Hβ1/Hβ2 
0.24/0.21 
  0.12 -0.01 
Hβ1/Hβ2 
-0.01/0.01 
  0 0.01 0   
ALA 3 -0.01 0.22 0.41   0.18 -0.01 0.02   0 0 0   












 0 0 0 0 
PHE 5 -0.09 0.20 0.29   0.20 -0.02 -0.01   0 0 0   
ASP 6 -0.16 0.16 
Hβ1/Hβ2 
0.20/0.12 
  0.11 -0.01 
Hβ1/Hβ2 
-0.03/0.01 




VAL 7 0.02 0.28 0.41 0.45  0.14 -0.01 0 0  0 0 0.01 0  
GLY 8 0.01 0.25    0.11 -0.02    -0.01 0    
ILE 9 -0.01 0.22 0.38 0.13 0.05 0.14 0 0 -0.01 -0.01 0 0 0 0 0.01 
LYS 10 -0.34 0.13 0.22 0.36 0.26 0.16 -0.02 0 -0.45 -0.25 0 0 0 0.01 0.01 
Table S2.17. CSPs between (1-10)-obestatin (7) spectra. δ ≥ 0,1 ppm were considered significant differences and were marked in red. 
Residue CSI H2O CSI PBS CSI WT CSI GPR39 
PHE 1 -1 0 0 0 
ASN 2 -1 -1 -1 -1 
ALA 3 0 +1 +1 +1 
PRO 4 -1 0 0 0 
PHE 5 -1 0 0 0 
ASP 6 -1 -1 -1 -1 
VAL 7 0 +1 +1 +1 
GLY 8 -1 0 0 0 
ILE 9 0 +1 +1 +1 
LYS 10 -1 -1 -1 -1 
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Residue HN Hα Hβ Hγ Hδ others 
ASP 6  4.35 
Hβ1/Hβ2 
2.76/2.87 
   
VAL 7 8.65 4.21 2.14 0.98   
GLY 8 8.48 3.94     



















SER 12 8.34 4.48 3.89    
GLY 13 8.46 4.03     










TYR 16 8.16 4.55 
Hβ1/Hβ2 
2.93/3.06 
   
GLN 17 8.20 3.27 
Hβ1/Hβ2 
1.93/2.03 
2.31   
GLN 18 8.37 4.24 
Hβ1/Hβ2 
1.96/2.04 
2.35   
HIS 19 8.60 4.76 
Hβ1/Hβ2 
3.21/3.31 
   
SER 20 8.41 4.45 
Hβ1/Hβ2 
3.86/3.90 
   
GLN 21 8.54 4.35 
Hβ1/Hβ2 
2.00/2.13 
2.39   
ALA 22 8.34 4.32 1.39    














Residue HN Hα Hβ Hγ Hδ others 
ASP 6 7.82 4.41 
Hβ1/Hβ2 
2.87/3.12 
   
VAL 7  4.21 2.16 0.99   
GLY 8 8.49 3.97     




LYS 10 8.45 4.40 
Hβ1/Hβ2 
1.75/1.86 
1.45   




SER 12 7.88 4.27 3.86    
GLY 13       




GLN 15       
TYR 16 8.12 4.49 
Hβ1/Hβ2 
3.09/3.25 
   
GLN 17       
GLN 18   
 
 
   
HIS 19 8.24 4.50 
Hβ1/Hβ2 
3.10/3.26 
   
SER 20 8.24 4.30 3.89    
GLN 21       
ALA 22 8.34 4.33 1.40    
LEU 23 8.29 4.32 1.69 1.61 0.93  
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Residue HN Hα Hβ Hγ Hδ others 
ASP 6  4.29 
Hβ1/Hβ2 
2.71/2.84 
   
VAL 7 8.77 4.20 2.15 0.99   
GLY 8 8.65 3.93     
ILE 9 8.21 4.16 1.84 1.19 0.90  
LYS 10 8.62 4.35 1.78 1.45 1.67  
LEU 11 8.57 4.40 1.64 1.53 0.90  
SER 12 8.51 4.47 3.89    
GLY 13 8.62 4.02     




GLN 15 8.67 4.30 
Hβ1/Hβ2 
1.97/2.19 
2.28   
TYR 16 8.37 4.53 
Hβ1/Hβ2 
2.93/3.05 
   
GLN 17 8.34 4.25 
Hβ1/Hβ2 
1.93/2.02 
2.30   
GLN 18 8.55 4.22 1.97 2.34   
HIS 19 8.63 4.70 
Hβ1/Hβ2 
3.16/3.23 
   
SER 20 8.55 4.41 3.88    
GLN 21 8.68 4.33 
Hβ1/Hβ2 
2.00/2.14 
2.40   
ALA 22 8.47 4.29 1.40    
LEU 23 8.38 4.29 1.69 1.58 0.93  





Residue HN Hα Hβ Hγ Hδ others 
ASP 6  4.31 
Hβ1/Hβ2 
2.71/2.83 
   
VAL 7 8.75 4.20 2.15 0.98   
GLY 8 8.62 3.94     
ILE 9 8.17 4.16 1.84 1.18 0.89  
LYS 10 8.59 4.35 1.78 1.40 1.45  
LEU 11 8.53 4.40 1.63 1.53 0.90  
SER 12 8.49 4.47 3.89    
GLY 13 8.59 4.01     




GLN 15 8.65 4.30 
Hβ1/Hβ2 
1.96/2.19 
2.29   
TYR 16 8.33 4.53 
Hβ1/Hβ2 
2.93/3.05 
   
GLN 17 8.32 4.25 
Hβ1/Hβ2 
1.92/2.03 
2.30   
GLN 18 8.51 4.22 1.95 2.33   
HIS 19 8.63 4.71 
Hβ1/Hβ2 
3.16/3.25 
   
SER 20 8.52 4.42 3.88    
GLN 21 8.67 4.33 
Hβ1/Hβ2 
2.00/2.3 
2.42   
ALA 22 8.45 4.30 1.40    
LEU 23 8.34 4.30 1.68 1.58 0.92  
Table S2.22. 1H chemical shifts (ppm) for human (6-23)-obestatin (3) in HEK293-GPR39 cells at 298K. 
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 PBS-H2O WT-PBS GPR39-WT 
Residue HN Hα Hβ Hγ Hδ HN Hα Hβ Hγ Hδ HN Hα Hβ Hγ Hδ 
ASP 6  0.06 
Hβ1/Hβ2 
0.11/0.25 
   -0.12 
Hβ1/Hβ2 
-0.16/-0.28 




VAL 7  0 0.02 0.01   -0.01 -0.01 0  -0.02 0 0 -0.01  
GLY 8 0.01 0.03    0.16 -0.04    -0.03 0.01    
ILE 9 -0.03 0.01 0 
Hγ1/Hγ2 
0.01/0.02 
0.01 0.22 -0.03 0 0.01 0 -0.04 0 0 -0.01 -0.01 
LYS 10 0.01 0.03 
Hβ1/Hβ2 
0.01/0.05 
0.04  0.17 -0.05 
Hβ1/Hβ2 
0.03/-0.19 
0  -0.03 0 0 -0.05 -0.22 
LEU 11 0.15 0.03 0.10 -0.01 
Hδ1/Hδ2 
0.04/0.04 
0.06 -0.03 -0.04 0.12 -0.02 -0.04 0 -0.01 0 0 
SER 12 -0.46 -0.21 -0.03   0.63 0.20 0.03   -0.02 0 0   
GLY 13           -0.03 0    
VAL 14 -0.15 0.04 -0.04 
Hγ1/Hγ2 
-0.04/-0.01 
 0.32 -0.07 0.04 
Hγ1/Hγ2 
0.04/0.03 
- -0.04 0 -0.01 -0.01  




TYR 16 -0.04 -0.06 
Hβ1/Hβ2 
0.16/0.19 
  0.25 0.04 
Hβ1/Hβ2 
-0.16/-0.20 
  -0.04 0 0   




GLN 18           -0.04 0 -0.02 -0.01  
HIS 19 -0.36 -0.26 
Hβ1/Hβ2 
-0.11/-0.05 
  0.39 0.20 
Hβ1/Hβ2 
0.06/-0.03 




SER 20 -0.17 -0.15 0.01   0.31 0.11 -0.01   -0.03 0.01 0   




ALA 22 0 0.01 0.01   0.13 -0.04 0   -0.02 0.01 0   
LEU 23 0.10 0.01 0.02 0.01 0.02 0.09 -0.03 0 -0.03 0 -0.04 0.01 -0.01 0 -0.01 












Residue CSI H2O CSI PBS CSI WT CSI GPR39 
ASP 6 -1 -1 -1 -1 
VAL 7 +1 +1 +1 +1 
GLY 8 0 0 0 0 
ILE 9 +1 +1 +1 +1 
LYS 10 0 0 0 0 
LEU 11 +1 +1 +1 +1 
SER 12 0 -1 0 0 
GLY 13 0  0 0 
VAL 14 +1 +1 0 0 
GLN 15 0  0 0 
TYR 16 0 0 0 0 
GLN 17 0  -1 -1 
GLN 18 -1  -1 -1 
HIS 19 +1 -1 0 0 
SER 20 0 -1 0 0 
GLN 21 0  0 0 
ALA 22 0 0 0 0 
LEU 23 +1 +1 +1 +1 
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Residue HN Hα Hβ Hγ Hδ others 
PHE 1       
ASN 2 8.65 4.71 Hβ1/Hβ2 
2.62/2.75 
   
ALA 3 8.36 4.50 1.35    






PHE 5 8.10 4.59 3.09    
ASP 6 8.23 4.62 Hβ1/Hβ2 
2.61/2.72 
   
VAL 7 8.02 4.09 2.16 0.96   
GLY 8 8.43 3.93     
ILE 9 7.86 4.14 1.84 1.16 0.88  
LYS 10 8.35 4.33 Hβ1/Hβ2 
1.75/1.82 
1.43 1.65  
LEU 11 8.29 4.39 1.62 1.54 Hδ1/Hδ2 
0.84/0.90 
 
SER 12 8.29 4.46 3.89    
GLY 13 8.43 4.03     
VAL 14 7.99 4.04 2.03 Hγ1/Hγ2 
0.86/0.91 
  





TYR 16 8.14 4.54 Hβ1Hβ2 
2.92/3.06 
   
GLN 17 8.18 4.26 Hβ1/Hβ2 
1.93/2.03 
2.30   
GLN 18 8.36 4.23 Hβ1/Hβ2 
1.94/2.04 
2.34   
HIS 19 8.58 4.74 Hβ1/Hβ2 
3.21/3.29 
   
SER 20 8.40 4.43 3.88    
GLN 21 8.53 4.34 Hβ1/Hβ2 
2/2.12 
2.39   
ALA 22 8.33 4.30 1.38    
LEU 23 8.18 4.30 Hβ1/Hβ2 
1.60/1.67 
1.60 0.92  





Residue HN Hα Hβ Hγ Hδ others 
PHE 1       
ASN 2       
ALA 3 8.35 4.51 1.34    






PHE 5 8.08 4.59 3.10    
ASP 6 8.19 4.61 Hβ1/Hβ2 
2.57/2.67 
   
VAL 7 8.04 4.11 2.19 0.97   
GLY 8 8.46 3.93     
ILE 9 7.86 4.14 1.85 1.17 0.88  
LYS 10 8.35 4.34 1.77 1.45  
Hε 
3.22 
LEU 11 8.29 4.39 1.64 1.54 0.86  
SER 12 8.29 4.47 3.89    
GLY 13 8.45 4.03     
VAL 14 7.98 4.06 2.03 Hγ1/Hγ2 
0.86/0.91 
  





TYR 16 8.16 4.55 Hβ1Hβ2 
2.92/3.07 
   
GLN 17 8.21 4.26 Hβ1/Hβ2 
1.93/2.04 
2.30   
GLN 18 8.37 4.23 Hβ1/Hβ2 
1.94/2.04 
2.32   
HIS 19       
SER 20       
GLN 21 8.51 4.34 Hβ1/Hβ2 
2.02/2.13 
2.39   
ALA 22 8.29 4.30 1.39    
LEU 23 8.15 4.30 1.68 1.60 0.90  
Table S2.26. 1H chemical shifts (ppm) for human obestatin (1) in PBS at 298K. 
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Residue HN Hα Hβ Hγ Hδ others 
PHE 1       
ASN 2       
ALA 3 8.55 4.50 1.37    
PRO 4  4.37 Hβ1/Hβ2 
2.15/2.43 
2.56 3.78  
PHE 5 8.29 4.58 3.09    
ASP 6 8.30 4.60 Hβ1/Hβ2 
2.55/2.66 
   
VAL 7 8.19 4.10 2.20 0.98   
GLY 8 8.57 4.01     
ILE 9 8.01 4.13 1.85 1.18 0.89  
LYS 10 8.51 4.34 1.77 1.40   
LEU 11 8.47 4.39 1.64 1.52 0.84  
SER 12 8.44 4.46 3.88    
GLY 13 8.57 3.93     
VAL 14 8.13 4.04 2.04 Hγ1/Hγ2 
0.84/0.92 
  





TYR 16 8.32 4.53 Hβ1Hβ2 
2.92/3.04 
   
GLN 17 8.31 4.25 Hβ1/Hβ2 
1.92/2.03 
2.30   
GLN 18 8.51 4.22 Hβ1/Hβ2 
1.96/2.05 
2.33   
HIS 19 8.61 4.59 2.96    
SER 20  4.40 3.87    
GLN 21  4.33 Hβ1/Hβ2 
2.00/2.12 
2.40   
ALA 22 8.43 4.29 1.39    
LEU 23 8.33 4.29 1.68 1.58 0.89  






Residue HN Hα Hβ Hγ Hδ others 
PHE 1       
ASN 2       
ALA 3 8.55 4.50 1.36    






PHE 5 8.29 4.58 3.09    
ASP 6 8.30 4.61 Hβ1/Hβ2 
2.56/2.66 
   
VAL 7 8.20 4.11 2.20 0.98   
GLY 8 8.57 3.93     
ILE 9 8.00 4.13 1.85 1.17 0.89  
LYS 10 8.52 4.34 1.77 Hγ1/Hγ2 
1.39/1.46 
1.65  
LEU 11 8.47 4.40 1.64 1.53 0.90  
SER 12 8.45 4.47 3.89    
GLY 13 8.58 4.00     
VAL 14 8.13 4.04 2.03 Hγ1/Hγ2 
0.85/0.92 
  





TYR 16 8.32 4.53 Hβ1Hβ2 
2.92/3.05 
   
GLN 17 8.31 4.25 Hβ1/Hβ2 
1.93/2.02 
2.30   
GLN 18 8.51 4.22 Hβ1/Hβ2 
1.96/2.01 
2.33   
HIS 19 8.58 4.69 Hβ1/Hβ2 
3.14/3.22 
   
SER 20 8.47 4.41 3.87    
GLN 21 8.64 4.33 Hβ1/Hβ2 
2.00/2.13 
2.40   
ALA 22 8.43 4.29 1.39    
LEU 23 8.33 4.29 1.68 1.58 0.93  
Table S2.28. 1H chemical shifts (ppm) for human obestatin (1) in HEK293-GPR39 cells at 298K. 
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 PBS-H2O WT-PBS GPR39-WT 
Residue HN Hα Hβ Hγ Hδ HN Hα Hβ Hγ Hδ HN Hα Hβ Hγ Hδ 
PHE 1                
ASN 2                
ALA 3 -0.01 0.01 -0.01   0.20 -0.01 0.03   0 0 -0.01   
PRO 4   
Hβ1/Hβ2 
0.01/0 




PHE 5 -0.02 0 0.01   0.21 -0.01 -0.01   0 0 0   
ASP 6 -0.04 -0.01 
Hβ1/Hβ2 
-0.04/-0.05 
  0.11 -0.01 
Hβ1/Hβ2 
-0.02/-0.01 




VAL 7 0.02 0.02 0.03 0.01  0.15 -0.01 0.01 0.01  0.01 0.01 0 0  
GLY 8 0.03 0    0.11 0.08    0 -0.08    
ILE 9 0 0 0.01 0.01 0 0.15 -0.01 0 0.01 0.01 -0.01 0 0 -0.01 0 
LYS 10 0 0.01 -0.02 0.02  0.16 0 0 -0.05  0.01 0 0 0.03  
LEU 11 0 0 0.02 0 -0.01 0.18 0 0 -0.02 -0.02 0 0.01 0 0.01 0.06 
SER 12 0 0.01 0   0.15 0.01 -0.01   0.01 0.01 0.01   
GLY 13 0.02 0    0.12 -0.10    0.01 0.07    
VAL 14 -0.01 0.02 0 0  0.15 -0.02 0.01 
Hγ1/Hγ2 
-0.02/0.01 
 0 0 -0.01 0.01  
GLN 15 0 0.01 
Hβ1/Hβ2 
0/0.01 
0.01  0.15 0 
Hβ1/Hβ2 
0.02/0 




TYR 16 0.02 0.01 
Hβ1/Hβ2 
0/0.01 
  0.16 -0.02 
Hβ1/Hβ2 
0/-0.03 




GLN 17 0.03 0 
Hβ1/Hβ2 
0/0.01 
0  0.10 -0.01 
Hβ1/Hβ2 
-0.01/-0.01 




GLN 18 0.01 0.01 
Hβ1/Hβ2 
0.02/0 
-0.02  0.14 -0.02 
Hβ1/Hβ2 
0/0.01 




HIS 19           -0.03 0.10 0.18   
SER 20            0.01 0   
GLN 21 -0.02 0 
Hβ1/Hβ2 
0.02/0.01 
0   -0.01 
Hβ1/Hβ2 
-0.02/-0.01 




ALA 22 -0.04 0 0.01   0.14 -0.01 0   0 0 0   
LEU 23 -0.03 0 0.05 0 -0.02 0.18 -0.01 0 -0.02 -0.01 0 0 0 0 0.04 










Residue CSI H2O CSI PBS CSI WT CSI GPR39 
PHE 1     
ASN 2 0    
ALA 3 +1 +1 +1 +1 
PRO 4 0  0 0 
PHE 5 0 0 0 0 
ASP 6 -1 -1 -1 -1 
VAL 7 +1 +1 +1 +1 
GLY 8 0 0 0 0 
ILE 9 +1 +1 +1 +1 
LYS 10 0 0 0 0 
LEU 11 +1 +1 +1 +1 
SER 12 0 0 0 0 
GLY 13 0 0 0 0 
VAL 14 0 +1 0 0 
GLN 15 0 0 0 0 
TYR 16 0 0 0 0 
GLN 17 -1 -1 -1 -1 
GLN 18 -1 -1 -1 -1 
HIS 19 +1  0 0 
SER 20 0  0 0 
GLN 21 0 0 0 0 
ALA 22 0 0 0 0 
LEU 23 +1 +1 +1 +1 





















Figure S2.2. Amide region of 2D TOCSY spectra for human obestatin (1) in HEK293-GPR39 cells. 
















Figure S2.4. Alpha region of 2D TOCSY spectra for human obestatin (1) in HEK293-GPR39 cells. 
 
 
 
 
